



(51) International Patent Classification:

C07D 471/08 (2006.01) A61P 25/16 (2006.01)

A61K 31/439 (2006.01) A61P 43/00 (2006.01)

(21) International Application Number:

PCT/KR2020/015864

(22) International Filing Date:

12 November 2020 (12.11.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2019-0146679 15 November 2019 (15.11.2019) KR

(71) Applicants: YUHAN CORPORATION [KR/KR]; 74, Noryangjin-ro, Dongjak-gu, Seoul 06927 (KR). GREEN CROSS CORPORATION [KR/KR]; 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924 (KR).

(72) Inventors: KIM, Dong-Hoon; 208-1401, 1400, Deogyong-daero, Yeongtong-gu, Suwon-si, Gyeonggi-do 16684 (KR). JOO, Jae-Eun; 20-5, Deogyong-daero 1967beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 17097 (KR). LEE, Eui-Chul; B-3604, 9, Giheungyeok-ro, Giheung-gu, Yongin-si, Gyeonggi-do 17065 (KR). HAN, Tae-Dong; 103-1601, 1842, Yonggu-daero, Giheung-gu, Yongin-si, Gyeonggi-do 17080 (KR). SHIN, Seung-Yub; 109-404, 615, Sumogwon-ro, Osan-si, Gyeonggi-do 18107 (KR). KWON, Sool-Ki; 104-1503, 16, Gomae-ro, Giheung-gu, Yongin-si, Gyeonggi-do 17086 (KR). KIM, Ji-Hye; 107-205, 15, Tapsil-ro, Giheung-gu, Yongin-si, Gyeonggi-do 17084 (KR).

(74) Agent: OH, Kook-Jin; 302, Doocon Bldg., 24, Beobwon-ro 3-gil, Seocho-gu, Seoul 06595 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

(57) Abstract: The present invention provides a novel compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.



Description

Title of Invention: NOVEL DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

Technical Field

- [1] The present invention relates to a novel compound having an inhibitory activity against glucosylceramide synthase (GCS), i.e., derivatives having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof.

Background Art

- [2] Lysosomal storage disorders (LSDs) are the metabolic disorders that result from genetic lack or deficiency of certain enzymes in lysosomes. LSDs exhibit various pathological symptoms throughout the body, as the non-metabolized or non-degraded substrates are accumulated. Currently, about 50 types of LSDs are known and are largely classified into the diseases such as mucopolysaccharidose, oligosaccharidosis, and sphingolipidoses, depending on the substances accumulated.
- [3] Among the diseases, sphingolipidoses, which are a class of glycolipid storage disorders relating to sphingolipid metabolism, show pathologies due to the accumulation of various membrane glycosphingolipids (GSLs), such as glucosylceramide, trihexocylceramide, etc. For example, when the enzymes related to sphingolipid metabolism, such as beta-glucosidase, alpha-galactosidase, etc., do not have normal activity, the substrates thereof (e.g., glucosylceramide, trihexocylceramide, etc.) are accumulated, thereby exhibiting various pathologies, such as Gaucher disease, Fabry disease, etc.
- [4] There are known two types of therapies for the LSDs. The first method is to replace or supplement the insufficient or deficient metabolic enzymes. Although such an enzyme replacement therapy (ERT) is safe and effective, periodic intravenous administrations of the related enzyme(s) are required; the dose thereof should be adjusted according to the enzyme reaction(s); and the costs thereof are relatively high. Especially, since it is difficult to distribute the enzyme(s) toward the nervous system, the ERT does not show satisfactory efficacy in the treatment of symptoms related to the nervous system. In addition, there is also the problem that autoantibodies against the

administered enzyme(s) are frequently generated.

- [5] The second method is a substrate reduction therapy (SRT) for inhibiting the syntheses of accumulated substrates. Glucosylceramide synthase (GCS) (also referred to as "UDP-glucose: ceramide glycosyltransferase", "UDP-glucose: N-acylsphingosine D-glucosyltransferase", or "EC 2.4.1.80"), which is an enzyme involved in sphingolipid metabolism, is involved in the reaction of ceramide with glucose to produce glucosylceramide. The resulting glucosylceramide is converted into various GSLs. Glucosylceramide synthase (GCS) inhibitors inhibit the activity of GCS, thereby reducing the production of glucosylceramide in the body and preventing abnormal accumulation of glycolipids, such as trihexocylceramide, GM1, and GM2, in cells or organs.
- [6] As such, GCS inhibitors inhibit the activity of GCS to prevent the accumulation of glycolipids and thus may be usefully applied to the treatment of lysosomal storage disorders, especially glycolipid storage disorders, such as GM1 gangliosidosis, Tay-Sachs disease, Sandhoff disease, Gaucher disease, Fabry disease, Niemann-Pick disease (types A and B), metachromatic leukodystrophy, Krabbe disease, etc. GCS inhibitors may be also used in the treatment of the secondary diseases associated with glycolipid storage, such as Niemann-Pick disease (type C), mucopolysaccharidosis, and mucopolipidosis type IV (see, Chen CS, et al., Abnormal transport along the lysosomal pathway in mucopolipidosis, type IV disease *Proc Natl Acad Sci U S A.* 1998 May 26;95(11):6373-8; and Goodman LA, et al., Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in alpha-mannosidosis, *Proc Natl Acad Sci U S A.* 1991 Dec 15;88(24):11330-4). In addition, it has been reported to be useful in the treatment of diseases associated with the accumulation of glycolipids, such as renal hypertrophy (e.g., diabetic kidney disease); hyperglycemia or hyperinsulinemia; cancers with abnormal glycolipid synthesis; infectious diseases caused by the organisms using cell-surface glycolipids as a receptor; infectious diseases where the synthesis of glucosylceramide is essential or important; diseases in which excessive glycolipid synthesis occurs (e.g., atherosclerosis, polycystic kidney disease, and renal hypertrophy); neurological disorders and/or damages associated with the replenishment and activity of macrophages (e.g., Alzheimer's disease, epilepsy, stroke, spinal cord diseases, Parkinson's disease, etc.); inflammatory diseases or disorders (e.g., rheumatoid arthritis, Crohn's disease, asthma, sepsis); and diabetes and obesity (see, WO 2006/053043). And, overexpression of GCS interferes with ceramide-induced apoptosis (see, Liu YY, et al., Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance, *J Biol Chem.* 2000 Mar 10;275(10):7138-43). Therefore, GCS inhibitors may be useful for treating proliferative diseases, such as cancer, by inducing apoptosis in diseased

cells.

- [7] Various studies have been conducted to develop GCS inhibitors. For example, various compounds having an inhibitory activity against GCS have been disclosed in WO 2005/068426, WO 2006/053043, WO 2008/150486, WO 2009/117150, WO 2010/014554, WO 2014/043068, etc.

Disclosure of Invention

Technical Problem

- [8] The present inventors have found that a derivative having a 5,6-fused bicyclic moiety, i.e., a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety, or pharmaceutically acceptable salt thereof has an excellent inhibitory activity against glucosylceramide synthase (GCS). Therefore, the derivative having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc..
- [9] Therefore, the present invention provides the above derivative having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof.

Solution to Problem

- [10] According to an aspect of the present invention, there is provided a derivative having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof.
- [11] According to another aspect of the present invention, there is provided a process for preparing said derivative having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof.
- [12] According to still another aspect of the present invention, there is provided a pharmaceutical composition comprising said derivative having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof as an active ingredient.
- [13] According to still another aspect of the present invention, there is provided a therapeutic method comprising administering said derivative having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof.
- [14] According to still another aspect of the present invention, there is provided a use of said derivative having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting glucosylceramide synthase.

Advantageous Effects of Invention

- [15] It has been found by the present invention that the derivative having a 5,6-fused bicyclic moiety, i.e., a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety, or pharmaceutically acceptable salt thereof has an excellent inhibitory activity against glucosylceramide synthase (GCS). Therefore, the compound or pharmaceutically acceptable salt thereof according to the present invention can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.

Best Mode for Carrying out the Invention

- [16] As used herein, the term "alkyl" refers to a straight or branched aliphatic hydrocarbon radical. For example, the C₁~C₆ alkyl means a straight or branched aliphatic hydrocarbon having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, *n*-butyl, *n*-pentyl, *n*-hexyl, isopropyl, isobutyl, *sec*-butyl, *tert*-butyl, neopentyl, and isopentyl.
- [17] The term "hydroxy" refers to the '-OH' group. The term "alkoxy" refers to a radical formed by substituting the hydrogen atom in the hydroxyl group with an alkyl. For example, the C₁~C₆ alkoxy includes methoxy, ethoxy, propoxy, *n*-butoxy, *n*-pentyloxy, isopropoxy, *sec*-butoxy, *tert*-butoxy, neopentyloxy, and isopentyloxy.
- [18] The term "halogen" refers to the fluoro, bromo, chloro, or iodo group.
- [19] The term "cycloalkyl" refers to a saturated aliphatic 3- to 10-membered ring, preferably 3- to 7-membered ring, unless otherwise defined. Typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like, but are not limited thereto.
- [20] The term "aryl" refers to an organic radical derived from an aromatic hydrocarbon, through removing one hydrogen atom therefrom, including mono or poly-fused ring systems such as 5- to 14-membered substituted or unsubstituted rings and a form in which a plurality of aryls are connected by a single bond. The "aryl" includes, for example, phenyl, naphthyl, biphenyl, terphenyl, anthryl, indenyl, fluorenyl, phenanthryl, triphenylenyl, pyrenyl, perylenyl, chrysenyl, naphthacenyl, fluoranthenyl, and the like, but are not limited thereto.
- [21] The term "heteroaryl" refers to a 5- to 12-membered aromatic radical having one to three heteroatoms selected from the group consisting of nitrogen (N) atom, oxygen (O) atom, and sulfur (S) atom, including a 5- or 6-membered monocyclic heteroaryl radical and a bicyclic heteroaryl radical formed by fusing the 5- or 6-membered monocyclic heteroaryl radical with a benzene or pyridine ring. And, the term "heterocycle" refers to a 3- to 12-membered mono- or poly-cyclic ring having one or more, preferably one to four, same or different heteroatoms selected from oxygen (O) atom, nitrogen (N) atom, and sulfur (S) atom, but not containing an aromatic ring. Non-limiting examples


of heteroaryl or heterocyclic rings include oxetane, pyrrolidine, pyrrole, tetrahydrofuran, furan, tetrahydrothiophene, thiophene, imidazolidine, imidazole, pyrazolidine, pyrazole, pyrrolizine, oxazolidine, oxazole, isoxazolidine, isoxazole, thiazolidine, thiazole, isothiazolidine, isothiazole, dioxolane, dithiolane, oxadiazole, thiadiazole, dithiazole, tetrazole, oxatetrazole, thiatetrazole, piperidine, pyridine, pyrimidine, tetrahydropyran, pyran, thiane, thiopyran, piperazine, diazine, morpholine, oxazine, dioxane, indole, indoline, benzodioxole, benzothiophene, benzofuran, benzimidazole, bezoxazole, benzisoxazole, benzothiazole, benzothiadiazole, benzotriazole, quinoline, isoquinoline, purine, furopyridine, mono- or di-azabicycles (such as quinuclidine, diazabicycloheptane, monoazabicyclooctane, diazaspirooundecane, etc.), hexahydropyrrolopyrrole, pyrrolopyrrole, pyrrolopyridine, imidazopyridazine, dihydrobenzodioxine, dihydrobenzofuran, and the like, but are not limited thereto.

[22] The term "amino" refers to the '-NH₂' group. The term "alkylamino" refers to an amino group substituted with mono- or di-alkyl. For example, the C₁~C₆ alkylamino group includes an amino group substituted with mono- or di-C₁~C₆ alkyl group.

[23] The term "alkylthio" refers to the '-SR' group, in which R is an alkyl. The term "cyano" refers to the '-CN'.

[24] The present invention provides a derivative having a 5,6-fused bicyclic moiety, i.e., a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, that is a compound of Formula 1 or pharmaceutically acceptable salt thereof:

[25] <Formula 1>



[27] wherein,

[28] L is -O-, -CO-, -CR₁R₂-, or -NR₃-,

[29] Y and Z are, independently each other, -CR₁R₂-, -NR₃-, -O-, or -S-,

[30] R₁ and R₂ are, independently each other, hydrogen; halogen; C₁~C₆ alkyl; C₁~C₆ alkyl having a nitrogen, oxygen, or sulfur atom; C₃~C₁₀ cycloalkyl; 3- to 12-membered heterocyclic; or C₁~C₆ alkoxy; or R₁ and R₂ form C₃~C₁₀ cycloalkyl together with the carbon atom to which they are attached,

[31] R₃ is hydrogen; C₁~C₆ alkyl; C₁~C₆ alkyl having a nitrogen, oxygen, or sulfur atom; C₃~C₁₀ cycloalkyl; 3- to 12-membered heterocyclic; or C₁~C₆ alkoxy,

[32] X is hydrogen; halogen; C₁~C₆ alkyl; C₁~C₆ alkyl substituted with 1 to 3 halogens; C

- $_1\sim C_6$ alkyl having a nitrogen, oxygen, or sulfur atom; $C_1\sim C_6$ alkoxy; or $C_1\sim C_6$ alkoxy substituted with 1 to 3 halogens,
- [33] W is a bond, $-CH_2-$, $-O-$, $-NH-$, $-CH_2CH_2-$, $-CH=CH-$, or $-C\equiv C-$,
- [34] A ring is 6- to 12-membered aryl; 5- to 12-membered heteroaryl; $C_3\sim C_{10}$ cycloalkyl; or 3- to 12-membered heterocyclic, and
- [35] X_1 , X_2 , X_3 , and X_4 are, independently each other, hydrogen; cyano; halogen; $C_1\sim C_6$ alkyl; $C_1\sim C_6$ alkoxy- $C_1\sim C_6$ alkyl; $C_1\sim C_6$ alkyl substituted with 1 to 3 halogens; $C_3\sim C_{10}$ cycloalkyl; 3- to 12-membered heterocyclic; $C_1\sim C_6$ alkoxy; $C_1\sim C_6$ alkoxy substituted with 1 to 3 halogens; $C_1\sim C_6$ alkoxy- $C_1\sim C_6$ alkoxy; morpholinyl- $C_1\sim C_6$ alkoxy; mono- or di- $C_1\sim C_6$ alkylamino- $C_1\sim C_6$ alkoxy; $C_3\sim C_{10}$ cycloalkyl- $C_1\sim C_6$ alkoxy; $C_1\sim C_6$ alkylthio; amino; mono- or di- $C_1\sim C_6$ alkylamino; $C_1\sim C_6$ alkylcarbonyl; hydroxy; or nitro.
- [36] In the compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention, L may be $-O-$.
- [37] In the compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention, Y and Z may be, independently each other, $-O-$ or $-CR_1R_2-$.
- [38] In the compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention, R_1 and R_2 may be, independently each other, hydrogen or $C_1\sim C_6$ alkyl; or may form $C_3\sim C_{10}$ cycloalkyl together with the carbon atom to which they are attached. In an embodiment, Y may be $-O-$; and Z may be $-CR_1R_2-$.
- [39] In the compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention, X may be hydrogen, halogen, or $C_1\sim C_6$ alkoxy.
- [40] In the compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention, W may be a bond (i.e., the A ring is directly bound to the 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety) or $-CH=CH-$.
- [41] In the compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention, the A ring may be 6- to 12-membered aryl; 5- to 12-membered heteroaryl; or 3- to 12-membered heterocyclic. In an embodiment, the 6- to 12-membered aryl may be is phenyl, naphthalenyl, or biphenyl. In another embodiment, the 5- to 12-membered heteroaryl may be benzodioxolyl, pyridinyl, thiophenyl, quinolinyl, isoquinolinyl, benzofuranyl, benzo[b]thiophenyl, quinoxalinyl, or furanyl. In still another embodiment, the 3- to 12-membered heterocyclic may be 2,3-dihydrobenzodioxinyl, 2,3-dihydrobenzofuranyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, chromanyl, or 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl.
- [42] In the compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention, X_1 , X_2 , X_3 , and X_4 may be, independently each other, hydrogen; cyano; halogen; $C_1\sim C_6$ alkyl; $C_1\sim C_6$ alkoxy- $C_1\sim C_6$ alkyl; $C_1\sim C_6$ alkyl sub-

stituted with 1 to 3 halogens; C₃~C₁₀ cycloalkyl; morpholinyl; C₁~C₆ alkoxy; C₁~C₆ alkoxy substituted with 1 to 3 halogens; C₁~C₆ alkoxy-C₁~C₆ alkoxy; morpholinyl-C₁~C₆ alkoxy; mono- or di-C₁~C₆ alkylamino-C₁~C₆ alkoxy; C₃~C₁₀ cycloalkyl-C₁~C₆ alkoxy; C₁~C₆ alkylthio; mono- or di-C₁~C₆ alkylamino; or C₁~C₆ alkylcarbonyl.

- [43] In a preferred embodiment of the present invention,
- [44] L is -O-,
- [45] Y and Z are, independently each other, -O- or -CR₁R₂-,
- [46] R₁ and R₂ are, independently each other, hydrogen or C₁~C₆ alkyl; or R₁ and R₂ form C₃~C₁₀ cycloalkyl together with the carbon atom to which they are attached,
- [47] X is hydrogen, halogen, or C₁~C₆ alkoxy,
- [48] W is a bond or -CH=CH-,
- [49] A ring is 6- to 12-membered aryl, 5- to 12-membered heteroaryl, or 3- to 12-membered heterocyclic, and
- [50] X₁, X₂, X₃, and X₄ are, independently each other, hydrogen; cyano; halogen; C₁~C₆ alkyl; C₁~C₆ alkoxy-C₁~C₆ alkyl; C₁~C₆ alkyl substituted with 1 to 3 halogens; C₃~C₁₀ cycloalkyl; morpholinyl; C₁~C₆ alkoxy; C₁~C₆ alkoxy substituted with 1 to 3 halogens; C₁~C₆ alkoxy-C₁~C₆ alkoxy; morpholinyl-C₁~C₆ alkoxy; mono- or di-C₁~C₆ alkylamino-C₁~C₆ alkoxy; C₃~C₁₀ cycloalkyl-C₁~C₆ alkoxy; C₁~C₆ alkylthio; mono- or di-C₁~C₆ alkylamino; or C₁~C₆ alkylcarbonyl.
- [51] In said embodiment, Y may be -O-; and Z is -CR₁R₂-.
- [52] In said embodiment, the A ring may be phenyl, naphthalenyl, or biphenyl.
- [53] In said embodiment, the A ring may be benzodioxolyl, pyridinyl, thiophenyl, quinolinyl, isoquinolinyl, benzofuranyl, benzo[b]thiophenyl, quinoxalinyl, or furanyl.
- [54] In said embodiment, the A ring may be 2,3-dihydrobenzodioxinyl, 2,3-dihydrobenzofuranyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, chromanyl, or 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl.
- [55] In the compound of Formula 1 or pharmaceutically acceptable salt, preferable compounds include a compound, including a pharmaceutically acceptable salt thereof, selected from the group consisting of:
- [56] (S)-quinuclidin-3-yl (5-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [57] (S)-quinuclidin-3-yl (5-(4-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [58] (S)-quinuclidin-3-yl (5-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [59] (S)-quinuclidin-3-yl (5-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [60] (S)-quinuclidin-3-yl (5-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [61] (S)-quinuclidin-3-yl (5-(3-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [62] (S)-quinuclidin-3-yl

- (5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[63] (S)-quinuclidin-3-yl
(5-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[64] (S)-quinuclidin-3-yl (5-(2-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[65] (S)-quinuclidin-3-yl (5-(2-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[66] (S)-quinuclidin-3-yl
(5-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[67] (S)-quinuclidin-3-yl
(5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[68] (S)-quinuclidin-3-yl (5-(*p*-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[69] (S)-quinuclidin-3-yl
(5-(4-(difluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[70] (S)-quinuclidin-3-yl (5-(3,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[71] (S)-quinuclidin-3-yl (5-(2,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[72] (S)-quinuclidin-3-yl (5-(2,3-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[73] (S)-quinuclidin-3-yl (5-(2,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[74] (S)-quinuclidin-3-yl (5-(3,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[75] (S)-quinuclidin-3-yl
(5-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[76] (S)-quinuclidin-3-yl
(5-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[77] (S)-quinuclidin-3-yl (5-(3,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[78] (S)-quinuclidin-3-yl (5-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[79] (S)-quinuclidin-3-yl (5-(2,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[80] (S)-quinuclidin-3-yl (6-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[81] (S)-quinuclidin-3-yl (6-(4-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[82] (S)-quinuclidin-3-yl
(6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[83] (S)-quinuclidin-3-yl
(6-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[84] (S)-quinuclidin-3-yl (6-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[85] (S)-quinuclidin-3-yl (6-(3-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[86] (S)-quinuclidin-3-yl
(6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[87] (S)-quinuclidin-3-yl
(6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[88] (S)-quinuclidin-3-yl (6-(2-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
[89] (S)-quinuclidin-3-yl (6-(2-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

- [90] (S)-quinuclidin-3-yl
(6-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [91] (S)-quinuclidin-3-yl
(6-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [92] (S)-quinuclidin-3-yl
(6-(4-(difluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [93] (S)-quinuclidin-3-yl (6-(*p*-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [94] (S)-quinuclidin-3-yl (6-(3,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [95] (S)-quinuclidin-3-yl (6-(3,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [96] (S)-quinuclidin-3-yl (6-(2,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [97] (S)-quinuclidin-3-yl (6-(2,3-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [98] (S)-quinuclidin-3-yl (6-(2,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [99] (S)-quinuclidin-3-yl
(6-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [100] (S)-quinuclidin-3-yl
(6-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [101] (S)-quinuclidin-3-yl (6-(2,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [102] (S)-quinuclidin-3-yl (6-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [103] (S)-quinuclidin-3-yl (6-(3,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [104] (S)-quinuclidin-3-yl
(6-(4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [105] (S)-quinuclidin-3-yl
(6-(4-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [106] (S)-quinuclidin-3-yl
(2,2-dimethyl-6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [107] (S)-quinuclidin-3-yl
(2,2-dimethyl-6-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [108] (S)-quinuclidin-3-yl
(6-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [109] (S)-quinuclidin-3-yl
(6-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [110] (S)-quinuclidin-3-yl
(2,2-dimethyl-6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [111] (S)-quinuclidin-3-yl
(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [112] (S)-quinuclidin-3-yl
(6-(2-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [113] (S)-quinuclidin-3-yl

- (6-(2-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [114] (S)-quinuclidin-3-yl
(2,2-dimethyl-6-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [115] (S)-quinuclidin-3-yl (2,2-dimethyl-6-(*p*-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [116] (S)-quinuclidin-3-yl
(6-(4-(difluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [117] (S)-quinuclidin-3-yl
(6-(3,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [118] (S)-quinuclidin-3-yl
(6-(2,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [119] (S)-quinuclidin-3-yl
(6-(2,3-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [120] (S)-quinuclidin-3-yl
(6-(2,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [121] (S)-quinuclidin-3-yl
(6-(3,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [122] (S)-quinuclidin-3-yl
(2,2-dimethyl-6-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [123] (S)-quinuclidin-3-yl
(2,2-dimethyl-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [124] (S)-quinuclidin-3-yl
(6-(3,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [125] (S)-quinuclidin-3-yl
(6-(3,4-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [126] (S)-quinuclidin-3-yl
(6-(2,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [127] (S)-quinuclidin-3-yl
(6-(4-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [128] (S)-quinuclidin-3-yl
(5-(4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [129] (S)-quinuclidin-3-yl
(5-(4-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [130] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [131] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [132] (S)-quinuclidin-3-yl
(5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

- [133] (S)-quinuclidin-3-yl
(5-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [134] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [135] (S)-quinuclidin-3-yl
(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [136] (S)-quinuclidin-3-yl
(5-(2-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [137] (S)-quinuclidin-3-yl
(5-(2-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [138] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [139] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [140] (S)-quinuclidin-3-yl (2,2-dimethyl-5-(*p*-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [141] (S)-quinuclidin-3-yl
(5-(4-(difluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [142] (S)-quinuclidin-3-yl
(5-(3,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [143] (S)-quinuclidin-3-yl
(5-(2,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [144] (S)-quinuclidin-3-yl
(5-(2,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [145] (S)-quinuclidin-3-yl
(5-(3,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [146] (S)-quinuclidin-3-yl
(5-(2,3-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [147] (S)-quinuclidin-3-yl
(5-(3,4-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [148] (S)-quinuclidin-3-yl
(5-(2,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [149] (S)-quinuclidin-3-yl
(5-(3,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [150] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [151] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [152] (S)-quinuclidin-3-yl

- (5-(4-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [153] (S)-quinuclidin-3-yl
(5-(3-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [154] (S)-quinuclidin-3-yl
(5-(2-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [155] (S)-quinuclidin-3-yl
(5-(4-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [156] (S)-quinuclidin-3-yl
(5-(3-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [157] (S)-quinuclidin-3-yl
(5-(2-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [158] (S)-quinuclidin-3-yl
(5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [159] (S)-quinuclidin-3-yl
(5-(3-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [160] (S)-quinuclidin-3-yl
(5-(3-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [161] (S)-quinuclidin-3-yl
(5-(3-(dimethylamino)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [162] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(3-(methylthio)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [163] (S)-quinuclidin-3-yl
(5-(3-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [164] (S)-quinuclidin-3-yl
(5-(3-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [165] (S)-quinuclidin-3-yl (5-(3-(*tert*-butyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [166] (S)-quinuclidin-3-yl
(5-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [167] (S)-quinuclidin-3-yl
(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [168] (S)-quinuclidin-3-yl
(5-(2,3-dihydrobenzofuran-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [169] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(3-(2-morpholinoethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

- [170] (S)-quinuclidin-3-yl
(5-(4-(2-fluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [171] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(4-(2,2,2-trifluoroethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [172] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(4-(2-morpholinoethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [173] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(2-(trifluoromethyl)pyridin-4-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [174] (S)-quinuclidin-3-yl
(5-(2,5-dichloropyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [175] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [176] (S)-quinuclidin-3-yl
(5-(2-chloro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [177] (S)-quinuclidin-3-yl
(5-(3-chloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [178] (S)-quinuclidin-3-yl
(5-(2-chloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [179] (S)-quinuclidin-3-yl
(5-(2-chloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [180] (S)-quinuclidin-3-yl
(5-(4-chloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [181] (S)-quinuclidin-3-yl
(5-(2,3-dichloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [182] (S)-quinuclidin-3-yl
(5-(3-chloro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [183] (S)-quinuclidin-3-yl
(5-(2-fluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [184] (S)-quinuclidin-3-yl
(5-(3-(dimethylamino)-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [185] (S)-quinuclidin-3-yl
(5-(chroman-6-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

- [186] (S)-quinuclidin-3-yl
(5-(4-cyclopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [187] (S)-quinuclidin-3-yl
(5-(4-(dimethylamino)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [188] (S)-quinuclidin-3-yl
(5-(4-ethoxy-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [189] (S)-quinuclidin-3-yl
(5-(4-methoxy-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [190] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [191] (S)-quinuclidin-3-yl
(5-(4-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [192] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(thiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [193] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(4-methylthiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [194] (S)-quinuclidin-3-yl
(5-(3-(2-(dimethylamino)ethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [195] (S)-quinuclidin-3-yl
(5-(isoquinolin-8-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [196] (S)-quinuclidin-3-yl
(5-(isoquinolin-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [197] (S)-quinuclidin-3-yl
(5-(isoquinolin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [198] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(quinolin-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [199] (S)-quinuclidin-3-yl
(5-(4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [200] (S)-quinuclidin-3-yl
(5-(2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [201] (S)-quinuclidin-3-yl (5-(4-(*tert*-butyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [202] (S)-quinuclidin-3-yl
(5-(4-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [203] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(4-morpholinophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

- [204] (S)-quinuclidin-3-yl
(5-(4-(methoxymethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [205] (S)-quinuclidin-3-yl
(5-(4-(2,2-difluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [206] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(3-methyl-4-morpholinophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate
;
- [207] (S)-quinuclidin-3-yl
(5-(3-fluoro-4-morpholinophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [208] (S)-quinuclidin-3-yl
(5-(3-chloro-4-morpholinophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
;
- [209] (S)-quinuclidin-3-yl
(5-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [210] (S)-quinuclidin-3-yl
(5-(3-(difluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [211] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(quinolin-8-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [212] (S)-quinuclidin-3-yl
(5-(benzofuran-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [213] (S)-quinuclidin-3-yl
(5-(benzofuran-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [214] (S)-quinuclidin-3-yl
(5-(4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [215] (S)-quinuclidin-3-yl
(5-(4-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [216] (S)-quinuclidin-3-yl
(5-(4-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [217] (S)-quinuclidin-3-yl
(5-(2,4-dichloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
e;
- [218] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [219] (S)-quinuclidin-3-yl
(5-(4-butylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [220] (S)-quinuclidin-3-yl
(5-(2,3-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

- [221] (S)-quinuclidin-3-yl
(5-(2,4-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [222] (S)-quinuclidin-3-yl
(5-(2,5-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [223] (S)-quinuclidin-3-yl
(5-(2,6-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [224] (S)-quinuclidin-3-yl
(5-(3,5-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [225] (S)-quinuclidin-3-yl
(5-(4-ethoxy-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [226] (S)-quinuclidin-3-yl
(5-(2,5-difluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [227] (S)-quinuclidin-3-yl
(5-(2-fluoro-5-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [228] (S)-quinuclidin-3-yl
(5-(3,5-dimethyl-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [229] (S)-quinuclidin-3-yl
(5-(4-ethoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [230] (S)-quinuclidin-3-yl
(5-(2-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [231] (S)-quinuclidin-3-yl
(5-(2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [232] (S)-quinuclidin-3-yl
(5-(2-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [233] (S)-quinuclidin-3-yl
(5-(2-chloro-5-(trifluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [234] (S)-quinuclidin-3-yl
(5-(4-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [235] (S)-quinuclidin-3-yl
(5-(4-methoxy-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [236] (S)-quinuclidin-3-yl (5-(4-(*tert*-butoxymethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [237] (S)-quinuclidin-3-yl
(5-(2-chloro-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

- mate;
- [238] (S)-quinuclidin-3-yl
(5-(2-chloro-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [239] (S)-quinuclidin-3-yl
(5-(2,6-dimethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [240] (S)-quinuclidin-3-yl
(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [241] (S)-quinuclidin-3-yl
(5-(benzo[b]thiophen-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [242] (S)-quinuclidin-3-yl (5-(2-(*tert*-butoxy)pyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [243] (S)-quinuclidin-3-yl
(5-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [244] (S)-quinuclidin-3-yl
(5-(6-methoxynaphthalen-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [245] (S)-quinuclidin-3-yl
(5-([1,1'-biphenyl]-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [246] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(quinoxalin-6-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [247] (S)-quinuclidin-3-yl
(5-(3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [248] (S)-quinuclidin-3-yl
(5-(furan-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [249] (S)-quinuclidin-3-yl
(5-(4-isopropoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [250] (S)-quinuclidin-3-yl
(5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [251] (S)-quinuclidin-3-yl
(5-(6-isopropoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [252] (S)-quinuclidin-3-yl
(5-(3-(2-fluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [253] (S)-quinuclidin-3-yl
(5-(2-ethoxy-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

- [254] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [255] (S)-quinuclidin-3-yl
(5-(2-methoxy-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [256] (S)-quinuclidin-3-yl
(5-(2-butoxy-5-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [257] (S)-quinuclidin-3-yl
(5-(4-butoxy-3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [258] (S)-quinuclidin-3-yl
(5-(2,4-dipropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [259] (S)-quinuclidin-3-yl
(5-(3-chloro-4-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [260] (S)-quinuclidin-3-yl
(5-(3-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [261] (S)-quinuclidin-3-yl
(5-(4-ethoxy-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [262] (S)-quinuclidin-3-yl
(5-(3-chloro-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [263] (S)-quinuclidin-3-yl
(5-(5-fluoro-2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [264] (S)-quinuclidin-3-yl
(5-(3-fluoro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [265] (S)-quinuclidin-3-yl
(5-(5-chloro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [266] (S)-quinuclidin-3-yl
(5-(2-fluoro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [267] (S)-quinuclidin-3-yl
(5-(5-chloro-2-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [268] (S)-quinuclidin-3-yl
(5-(5-fluoro-2-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [269] (S)-quinuclidin-3-yl
(5-(2-fluoro-6-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [270] (S)-quinuclidin-3-yl
(5-(3-fluoro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [271] (S)-quinuclidin-3-yl
(5-(3-fluoro-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [272] (S)-quinuclidin-3-yl
(5-(5-chloro-2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

- [273] (S)-quinuclidin-3-yl
(5-(3-butoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [274] (S)-quinuclidin-3-yl
(5-(3-fluoro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [275] (S)-quinuclidin-3-yl
(5-(5-fluoro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [276] (S)-quinuclidin-3-yl
(5-(2-chloro-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [277] (S)-quinuclidin-3-yl
(5-(3-fluoro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [278] (S)-quinuclidin-3-yl
(5-(2-chloro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [279] (S)-quinuclidin-3-yl
(5-(3-methoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [280] (S)-quinuclidin-3-yl
(5-(2-chloro-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [281] (S)-quinuclidin-3-yl
(5-(4-fluoro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [282] (S)-quinuclidin-3-yl
(5-(3,4-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [283] (S)-quinuclidin-3-yl
(5-(4-fluoro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [284] (S)-quinuclidin-3-yl
(5-(2-fluoro-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [285] (S)-quinuclidin-3-yl
(5-(2-fluoro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [286] (S)-quinuclidin-3-yl
(5-(2-fluoro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [287] (S)-quinuclidin-3-yl
(5-(5-isopropyl-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
;
- [288] (S)-quinuclidin-3-yl
(5-(2-fluoro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [289] (S)-quinuclidin-3-yl
(5-(5-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

- [290] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(5-methylfuran-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [291] (S)-quinuclidin-3-yl
(5-(3-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [292] (S)-quinuclidin-3-yl
(5-(2-chloro-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [293] (S)-quinuclidin-3-yl
(5-(benzo[b]thiophen-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [294] (S)-quinuclidin-3-yl
(5-(4-fluoro-2-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [295] (S)-quinuclidin-3-yl (5-(3-(*tert*-
butyl)-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [296] (S)-quinuclidin-3-yl
(5-(2-chloro-5-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [297] (S)-quinuclidin-3-yl
(5-(4-chloro-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [298] (S)-quinuclidin-3-yl
(5-(2-fluoro-3-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [299] (S)-quinuclidin-3-yl
(5-(5-cyano-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [300] (S)-quinuclidin-3-yl
(5-(3-ethoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [301] (S)-quinuclidin-3-yl
(5-(3-fluoro-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [302] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(3-methyl-4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [303] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(3-(methylthio)-5-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [304] (S)-quinuclidin-3-yl
(5-(3-fluoro-4-(trifluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [305] (S)-quinuclidin-3-yl
(5-(2-ethoxy-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

- [306] (S)-quinuclidin-3-yl
(5-(2-methoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [307] (S)-quinuclidin-3-yl
(5-(2,4-bis(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [308] (S)-quinuclidin-3-yl
(5-(3-chloro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [309] (S)-quinuclidin-3-yl
(5-(3-methoxy-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [310] (S)-quinuclidin-3-yl
(5-(4-fluoro-3-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [311] (S)-quinuclidin-3-yl
(5-(2-ethoxy-5-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [312] (S)-quinuclidin-3-yl
(5-(3-fluoro-5-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [313] (S)-quinuclidin-3-yl
(5-(3,5-bis(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [314] (S)-quinuclidin-3-yl
(5-(3-chloro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [315] (S)-quinuclidin-3-yl
(5-(2,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [316] (S)-quinuclidin-3-yl
(5-(3-chloro-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [317] (S)-quinuclidin-3-yl
(5-(6-ethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [318] (S)-quinuclidin-3-yl
(5-(2-ethoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [319] (S)-quinuclidin-3-yl
(5-(2-isopropoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [320] (S)-quinuclidin-3-yl
(2,2-dimethyl-5-(6-propoxypyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [321] (S)-quinuclidin-3-yl
(5-(6-butoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [322] (S)-quinuclidin-3-yl
(5-(6-(2-methoxyethoxy)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

- [323] (S)-quinuclidin-3-yl
(5-(6-isobutoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [324] (S)-quinuclidin-3-yl
(5-(3-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [325] (S)-quinuclidin-3-yl
(5-(4-butoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [326] (S)-quinuclidin-3-yl
(5-(2,4-dimethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [327] (S)-quinuclidin-3-yl
(5-(2-acetylthiophen-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [328] (S)-quinuclidin-3-yl
(5-((E)-3-fluorostyryl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [329] (S)-quinuclidin-3-yl
(5-((E)-4-ethylstyryl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [330] (S)-quinuclidin-3-yl
(5-((E)-2-cyclohexylvinyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [331] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [332] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(4-ethylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [333] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [334] (S)-quinuclidin-3-yl (5-(4-(*tert*-
butyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [335] (S)-quinuclidin-3-yl
(5-(4-butylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [336] (S)-quinuclidin-3-yl
(5-(4-cyclopropylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [337] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(4-isopropylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [338] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(4-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [339] (S)-quinuclidin-3-yl
(5-(4-ethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [340] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [341] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(4-isopropoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

- [342] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(4-isobutylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [343] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [344] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(3-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [345] (S)-quinuclidin-3-yl
(5-(3-ethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [346] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(3-isopropoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [347] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(3-ethylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [348] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(3-isopropylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [349] (S)-quinuclidin-3-yl (5-(3-(*tert*-
butyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [350] (S)-quinuclidin-3-yl
(5-(2,3-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [351] (S)-quinuclidin-3-yl
(5-(2,4-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [352] (S)-quinuclidin-3-yl
(5-(2,5-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [353] (S)-quinuclidin-3-yl
(5-(3,4-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [354] (S)-quinuclidin-3-yl
(5-(3,5-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [355] (S)-quinuclidin-3-yl
(5-(2,6-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [356] (S)-quinuclidin-3-yl
(5-(3-(difluoromethyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [357] (S)-quinuclidin-3-yl
(5-(3-(dimethylamino)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [358] (S)-quinuclidin-3-yl
(5-(4-ethoxy-3,5-dimethylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [359] (S)-quinuclidin-3-yl
(5-(3,5-dimethyl-4-propoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [360] (S)-quinuclidin-3-yl
(5-(4-butoxy-3,5-dimethylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

- [361] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(thiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [362] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(furan-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [363] (S)-quinuclidin-3-yl
(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [364] (S)-quinuclidin-3-yl
(5-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [365] (S)-quinuclidin-3-yl
(2,2-diethyl-5-(2-fluoro-4-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [366] (S)-quinuclidin-3-yl
(5-(3-chloro-4-isopropoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [367] (S)-quinuclidin-3-yl
(5-(4-ethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [368] (S)-quinuclidin-3-yl
(6-methoxy-2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [369] (S)-quinuclidin-3-yl
(5-(4-isopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
;
- [370] (S)-quinuclidin-3-yl
(5-(4-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [371] (S)-quinuclidin-3-yl (5-(4-(*tert*-
butyl)phenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [372] (S)-quinuclidin-3-yl
(5-(4-cyclopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [373] (S)-quinuclidin-3-yl
(5-(4-ethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [374] (S)-quinuclidin-3-yl
(6-methoxy-2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [375] (S)-quinuclidin-3-yl
(5-(4-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [376] (S)-quinuclidin-3-yl
(5-(3,5-dimethyl-4-propoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

- [377] (S)-quinuclidin-3-yl
(5-(3-chloro-4-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
- [378] (S)-quinuclidin-3-yl
(5-(2-fluoro-4-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)ca
rbamate;
- [379] (S)-quinuclidin-3-yl
(5-(4-butoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [380] (S)-quinuclidin-3-yl
(5-(4-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [381] (S)-quinuclidin-3-yl
(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-ind
en-1-yl)carbamate;
- [382] (S)-quinuclidin-3-yl
(5-(5-chloro-2-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)c
arbamate;
- [383] (S)-quinuclidin-3-yl
(5-(4-butylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [384] (S)-quinuclidin-3-yl
(6-methoxy-5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-
yl)carbamate;
- [385] (S)-quinuclidin-3-yl
(5-(4-ethoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl
)carbamate;
- [386] (S)-quinuclidin-3-yl
(5-(4-butoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl
)carbamate;
- [387] (S)-quinuclidin-3-yl
(6-methoxy-5-(2-methoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carba
mate;
- [388] (S)-quinuclidin-3-yl
(5-(3-fluorophenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [389] (S)-quinuclidin-3-yl
(5-(3-ethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [390] (S)-quinuclidin-3-yl
(5-(3-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [391] (S)-quinuclidin-3-yl
(5-(3-isopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

- ;
- [392] (S)-quinuclidin-3-yl (5-(3-(*tert*-butyl)phenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [393] (S)-quinuclidin-3-yl (6-methoxy-5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [394] (S)-quinuclidin-3-yl (5-(3-ethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [395] (S)-quinuclidin-3-yl (6-methoxy-2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [396] (S)-quinuclidin-3-yl (5-(3-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [397] (S)-quinuclidin-3-yl (5-(3-butoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [398] (S)-quinuclidin-3-yl (5-(3-isobutoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- ;
- [399] (S)-quinuclidin-3-yl (5-(2,5-dimethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [400] (S)-quinuclidin-3-yl (5-(3,5-dimethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [401] (S)-quinuclidin-3-yl (5-(2-chloro-4-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [402] (S)-quinuclidin-3-yl (5-(4-ethoxy-3-fluorophenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [403] (S)-quinuclidin-3-yl (5-(4-isopropoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [404] (S)-quinuclidin-3-yl (5-(4-ethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [405] (S)-quinuclidin-3-yl (6-fluoro-2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [406] (S)-quinuclidin-3-yl (6-fluoro-5-(4-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

- [407] (S)-quinuclidin-3-yl
(6-fluoro-5-(4-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [408] (S)-quinuclidin-3-yl (5-(4-(*tert*-
butyl)phenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [409] (S)-quinuclidin-3-yl
(5-(4-cyclopropylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
;
- [410] (S)-quinuclidin-3-yl
(6-fluoro-5-(4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [411] (S)-quinuclidin-3-yl
(5-(4-ethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [412] (S)-quinuclidin-3-yl
(6-fluoro-2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [413] (S)-quinuclidin-3-yl
(6-fluoro-5-(4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [414] (S)-quinuclidin-3-yl
(5-(3-chloro-4-isopropoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)ca
rbamate;
- [415] (S)-quinuclidin-3-yl
(6-fluoro-5-(2-fluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carb
amate;
- [416] (S)-quinuclidin-3-yl
(5-(4-butoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [417] (S)-quinuclidin-3-yl
(6-fluoro-5-(4-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [418] (S)-quinuclidin-3-yl
(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-
1-yl)carbamate;
- [419] (S)-quinuclidin-3-yl
(5-(5-chloro-2-methoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carb
amate;
- [420] (S)-quinuclidin-3-yl
(5-(4-butylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [421] (S)-quinuclidin-3-yl
(6-fluoro-5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
- [422] (S)-quinuclidin-3-yl
(5-(4-ethoxy-3,5-dimethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)ca

- rbamate;
- [423] (S)-quinuclidin-3-yl
(5-(4-butoxy-3,5-dimethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [424] (S)-quinuclidin-3-yl
(6-fluoro-5-(2-methoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [425] (S)-quinuclidin-3-yl
(6-fluoro-5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [426] (S)-quinuclidin-3-yl
(5-(3-ethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [427] (S)-quinuclidin-3-yl
(6-fluoro-5-(3-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [428] (S)-quinuclidin-3-yl
(6-fluoro-5-(3-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [429] (S)-quinuclidin-3-yl (5-(3-(*tert*-butyl)phenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [430] (S)-quinuclidin-3-yl
(6-fluoro-5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [431] (S)-quinuclidin-3-yl
(5-(3-ethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [432] (S)-quinuclidin-3-yl
(6-fluoro-2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [433] (S)-quinuclidin-3-yl
(6-fluoro-5-(3-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [434] (S)-quinuclidin-3-yl
(5-(3-butoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [435] (S)-quinuclidin-3-yl
(6-fluoro-5-(3-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [436] (S)-quinuclidin-3-yl
(5-(2,4-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [437] (S)-quinuclidin-3-yl
(5-(2,5-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [438] (S)-quinuclidin-3-yl
(5-(2,6-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

- [439] (S)-quinuclidin-3-yl
(5-(3,5-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [440] (S)-quinuclidin-3-yl
(5-(3,4-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [441] (S)-quinuclidin-3-yl
(5-(2-chloro-4-methoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [442] (S)-quinuclidin-3-yl
(5-(4-ethoxy-3-fluorophenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [443] (S)-quinuclidin-3-yl
(6-fluoro-5-(4-isopropoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [444] (S)-quinuclidin-3-yl
(5'-(4-fluorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
- [445] (S)-quinuclidin-3-yl
(5'-(4-chlorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
- [446] (S)-quinuclidin-3-yl
(5'-(4-(trifluoromethyl)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
- [447] (S)-quinuclidin-3-yl
(5'-(4-(trifluoromethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
- [448] (S)-quinuclidin-3-yl
(5'-(3-chlorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
- [449] (S)-quinuclidin-3-yl
(5'-(3-(trifluoromethyl)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
- [450] (S)-quinuclidin-3-yl
(5'-(4-(2-methoxyethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
- [451] (S)-quinuclidin-3-yl
(5'-(3-(2-methoxyethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
- [452] (S)-quinuclidin-3-yl
(5'-(4-(methoxymethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;

- bamate;
- [453] (S)-quinuclidin-3-yl
(5'-(3-(methoxymethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
- bamate;
- [454] (S)-quinuclidin-3-yl
(5-(3-chlorophenyl)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [455] (S)-quinuclidin-3-yl
(5-(2-chlorophenyl)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
- [456] (S)-quinuclidin-3-yl
(3,3-dimethyl-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [457] (S)-quinuclidin-3-yl
(3,3-dimethyl-5-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [458] (S)-quinuclidin-3-yl
(3,3-dimethyl-5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
- [459] (S)-quinuclidin-3-yl
(6-(3-(trifluoromethyl)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate;
- [460] (S)-quinuclidin-3-yl
(6-(3-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate;
- [461] (S)-quinuclidin-3-yl
(5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate;
- [462] (S)-quinuclidin-3-yl
(6-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate;
- [463] (S)-quinuclidin-3-yl
(6-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate;
- [464] (S)-quinuclidin-3-yl
(2,2-dimethyl-6-(3-(trifluoromethyl)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate;
- [465] (S)-quinuclidin-3-yl
(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate;
- and
- [466] (S)-quinuclidin-3-yl
(6-(3-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate.
- [467] The compound of Formula 1 or pharmaceutically acceptable salt thereof may be in the form of cis- or trans- geometrical isomer. The compound of Formula 1 or its pharmaceutically acceptable salt comprises both cis- and trans- geometrical isomers, unless otherwise indicated. The compound of Formula 1 or pharmaceutically acceptable salt thereof may also have substituents containing asymmetric atom and therefore be in the form of racemic mixture (RS) or in the form of an optical isomer, such as (R) or (S) isomer. The compound of Formula 1 or pharmaceutically acceptable salt thereof

comprises both the racemic mixture (RS) and each optical isomer such as (R) or (S) isomer, unless otherwise indicated. In addition, the compound of Formula 1 or pharmaceutically acceptable salt thereof may have two or more chiral centers and therefore be in the form of one or more diastereomers or in the form of the mixture thereof. The compound of Formula 1 or pharmaceutically acceptable salt thereof comprises both each diastereomer and the mixture thereof, unless otherwise indicated.


[468] The compound of Formula 1 of the present invention may be in a pharmaceutically acceptable salt form. The salt may be a conventional acid addition salt form, which includes e.g., salts derived from an inorganic acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, or hydrobromic acid; and salts derived from an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, benzoic acid, citric acid, maleic acid, malonic acid, malic acid, tartaric acid, gluconic acid, lactic acid, gentisic acid, fumaric acid, lactobionic acid, salicylic acid, phthalic acid, embonic acid, aspartic acid, glutamic acid, or acetylsalicylic acid. And, the salt also includes, e.g., salts derived from an amino acid such as glycine, alanine, valine, isoleucine, serine, cysteine, cystine, aspartic acid, glutamine, lysine, arginine, tyrosine, or proline. In addition, the salt includes, e.g., salts derived from a sulfonic acid such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, or toluenesulfonic acid.

[469] The compound of Formula 1 or pharmaceutically acceptable salt thereof according to the present invention may be prepared according to various methods.

[470] For example, the compound of Formula 1a or pharmaceutically acceptable salt thereof according to the present invention may be prepared by a process which comprises reacting a compound of Formula 2 or salt thereof with ethyl chloroformate to obtain a compound of Formula 3; coupling the compound of Formula 3 with a compound of Formula 4 to obtain a compound of Formula 5; reacting the compound of Formula 5 with a A-W-boronic acid substituted with X₁, X₂, X₃, or X₄ to obtain a compound of Formula 1a; and optionally converting the compound of Formula 1a to a pharmaceutically acceptable salt thereof, as shown in the following Reaction Scheme 1.

[471] <Reaction Scheme 1>

[472]



[473] In the Reaction Scheme 1, X, Y, Z, W, A ring, X₁, X₂, X₃, and X₄ are the same as defined in the above.

[474] The compound of Formula 2, which is commercially available or a known compound, may be synthesized according to literatures. The reaction between the compound of Formula 2 or salt thereof and ethyl chloroformate may be carried out in the presence of an organic base such as triethylamine, *N,N*-diisopropylethylamine, etc. or an inorganic base such as potassium carbonate, etc. The base may be used in an amount ranging from 1 to 1.5 equivalents based on 1 equivalent of the compound of Formula 2 or in an amount ranging from 3 to 5 equivalents based on 1 equivalent of the salt of the compound of Formula 2 (e.g., hydrochloride). The reaction may be carried out in a solvent such as dichloromethane or tetrahydrofuran preferably at 0°C to room temperature.

[475] The coupling between the compound of Formula 3 and the compound of Formula 4 (i.e., quinuclidinol) may be carried out through a condensation reaction including the removal of ethanol. The reaction may be carried out preferably in the presence of a base such as sodium hydride. In addition, the reaction may be carried out in a non-polar organic solvent such as toluene at 120°C to 140°C.

[476] The reaction between the compound of Formula 5 and the A-W-boronic acid substituted with X₁, X₂, X₃, or X₄ may be carried out according to the Suzuki reaction. Said Suzuki reaction may be carried out using a palladium catalyst, such as tetrakis(triphenylphosphine)palladium(0) (Pd(PPh₃)₄), palladium(II) acetate (Pd(OAc)₂), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl₂), etc. In


addition, said Suzuki reaction may be carried out in the presence of an inorganic base such as cesium carbonate (Cs_2CO_3), sodium carbonate (Na_2CO_3), potassium carbonate (K_2CO_3), potassium phosphate (K_3PO_4), etc. Said Suzuki reaction may be carried out in a non-polar organic solvent such as toluene or a polar organic solvent such as 1,4-dioxane, tetrahydrofuran, acetonitrile, 1,2-dimethoxyethane, or *N,N*-dimethylformamide, at 50°C to 150°C, preferably 80°C to 120°C. Other reaction conditions including a reaction time may be determined according to known methods for the Suzuki reaction.

[477] The conversion of the compound of Formula 1a to a pharmaceutically acceptable salt thereof may be carried out according to conventional methods. For example, a pharmaceutically acceptable salt of the compound of Formula 1a may be prepared by dissolving the compound of Formula 1a in a water-miscible solvent such as methanol, ethanol, acetone or 1,4-dioxane and then added a free acid or a free base thereto for the crystallization thereof.

[478] In addition, the compound of Formula 1a or pharmaceutically acceptable salt thereof according the present invention may be prepared by a process which comprises reacting a compound of Formula 4 with bis(4-nitrophenyl) carbonate to obtain a compound of Formula 7; reacting the compound of Formula 7 with a compound of Formula 2 to obtain a compound of Formula 5; reacting the compound of Formula 5 with a A-W-boronic acid substituted with X_1 , X_2 , X_3 , or X_4 to obtain a compound of Formula 1a; and optionally converting the compound of Formula 1a to a pharmaceutically acceptable salt thereof, as shown in the following Reaction Scheme 2.

[479] <Reaction Scheme 2>

[480]



[481] In the Reaction Scheme 2, X , Y , Z , W , A ring, X_1 , X_2 , X_3 , and X_4 are the same as defined in the above.

- [482] The reaction between the compound of Formula 4 (i.e., quinuclidinol) and bis(4-nitrophenyl) carbonate may be carried out in a polar solvent such as *N,N*-dimethylformamide preferably at 0°C to 25°C. The compound of Formula 7 may be also prepared by reacting the compound of Formula 4 with 4-nitrophenyl chloroformate, in the presence of a base such as triethylamine, in a solvent such as dichloromethane, acetonitrile, etc.
- [483] The reaction between the compound of Formula 7 and the compound of Formula 2 may be carried out in a solvent such as *N,N*-dimethylformamide, tetrahydrofuran or acetonitrile, in the presence of a base such as *N,N*-diisopropylethylamine or triethylamine, at 0°C to 25°C.
- [484] The reaction between the compound of Formula 5 and the A-W-boronic acid substituted with X₁, X₂, X₃, or X₄ may be carried out according to the Suzuki reaction, as described in the above. In addition, the conversion of the compound of Formula 1a to a pharmaceutically acceptable salt thereof may be carried out according to conventional methods, as described in the above.
- [485] The compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety according to the present invention, i.e., the compound of Formula 1 or pharmaceutically acceptable salt thereof has an excellent inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS.
- [486] Therefore, the present invention includes, within its scope, a pharmaceutical composition for inhibiting glucosylceramide synthase (GCS), comprising a therapeutically effective amount of the compound of Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. In an embodiment, the present invention provides a pharmaceutical composition for preventing or treating the diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc., comprising a therapeutically effective amount of the compound of Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient.
- [487] The pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier, such as diluents, disintegrants, sweeteners, lubricants, or flavoring agents. The pharmaceutical composition may be formulated to an oral dosage form such as tablets, capsules, powders, granules, suspensions, emulsions, or syrups; or a parenteral dosage form such as solutions for external use, suspensions for external use, emulsions for external use, gels (e.g., ointment), inhalations, nebulizations, injections. The dosage form may be various forms, e.g., dosage forms for single administration or for multiple administrations.
- [488] The pharmaceutical composition of the present invention may comprise, for example, a diluent (e.g., lactose, corn starch, etc); a lubricant (e.g., magnesium stearate); an

emulsifying agent; a suspending agent; a stabilizer; and/or an isotonic agent. If necessary, the composition further comprises sweeteners and/or flavoring agents.

[489] The composition of the present invention may be administered orally or parenterally, including inhalant, intravenous, intraperitoneal, subcutaneous, rectal and topical routes of administration. Therefore, the composition of the present invention may be formulated into various forms such as tablets, capsules, aqueous solutions or suspensions. In the case of tablets for oral administration, carriers such as lactose, corn starch, and lubricating agents, e.g. magnesium stearate, are conventionally used. In the case of capsules for oral administration, lactose and/or dried corn starch can be used as a diluent. When an aqueous suspension is required for oral administration, the active ingredient may be combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring agents may be used. For intramuscular, intraperitoneal, subcutaneous and intravenous administration, sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous administration, the total concentration of solutes should be controlled in order to render the preparation isotonic. The composition of the present invention may be in the form of an aqueous solution containing pharmaceutically acceptable carriers, e.g., saline having a pH level of 7.4. The solutions may be introduced into a patient's intramuscular blood-stream by local bolus injection.

[490] The compound of Formula 1 or pharmaceutically acceptable salt thereof may be administered in a therapeutically effective amount ranging from about 0.0001 mg/kg to about 100 mg/kg per day to a subject patient. Of course, the dosage may be changed according to the patient's age, weight, susceptibility, symptom, or activity of the compound.

[491] The present invention includes, within its scope, a method for inhibiting glucosylceramide synthase (GCS) in a mammal, comprising administering a therapeutically effective amount of the compound of Formula 1 or pharmaceutically acceptable salt thereof to the mammal in need thereof. In an embodiment, the present invention provides a method for treating the diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc., comprising administering a therapeutically effective amount of the compound of Formula 1 or pharmaceutically acceptable salt thereof to the mammal in need thereof.

[492] The present invention also provides a use of the compound of Formula 1 or pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting glucosylceramide synthase (GCS) in a mammal. In an embodiment, the present invention provides a use of the compound of Formula 1 or pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or treating the diseases

associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.

[493] The following examples and experimental examples are provided for illustration purposes only, and are not intended to limit the scope of the invention.

[494] In the following examples, brine refers to a saturated aqueous sodium chloride solution. Unless otherwise indicated, all temperatures are in degrees Celsius (°C). All reactions were carried out at room temperature unless otherwise indicated.

[495] The analyses of the compounds prepared in the following Preparations and Examples were carried out as follows: Nuclear magnetic resonance (NMR) spectrum analysis was carried out using Bruker 400 MHz spectrometer and chemical shifts thereof were analyzed in ppm. Column chromatography was carried out on silica gel (Merck, 70-230 mesh). Each starting material is a known compound which was synthesized according to literatures or purchased commercially. All reactions and chromatographic fractions were analyzed by thin layer chromatography (TLC) on a 250 nm silica gel plate and visualized with ultraviolet or iodine (I₂) staining.

[496]

[497] Preparation 1. (S)-quinuclidin-3-yl (5-bromo-2,3-dihydro-1H-inden-1-yl)carbamate

[498] Step 1. ethyl (5-bromo-2,3-dihydro-1H-inden-1-yl)carbamate

[499] 5-Bromo-2,3-dihydro-1H-inden-1-amine (2 g, 9.4 mmol) was dissolved in dichloromethane (50 ml) and then triethylamine (1.45 ml, 10.4 mmol) and ethyl chloroformate (1 ml, 10.4 mmol) were slowly added thereto. The reaction mixture was stirred at room temperature for 4 hours. Water was added to the reaction mixture, which was then extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and then filtered and concentrated under reduced pressure. The resulting residue in the pale yellow oil form (2.6 g) was used in subsequent reaction without further purification.

[500] Step 2. (S)-quinuclidin-3-yl (5-bromo-2,3-dihydro-1H-inden-1-yl)carbamate

[501] (S)-(+)-3-Quinuclidinol (3.5 g, 27.5 mmol) was dissolved in toluene (80 ml) and then sodium hydride (219.6 mg, 9.2 mmol) was added thereto at 0°C. The reaction mixture was stirred for 15 minutes and then ethyl (5-bromo-2,3-dihydro-1H-inden-1-yl)carbamate (2.6 g, 9.2 mmol) prepared in Step 1 was added thereto. The reaction mixture was refluxed under stirring at 140°C for 21 hours and then cooled to room temperature. Brine was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed with brine two times, dried over anhydrous magnesium sulfate, and then filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate/methanol/ammonia water = 1/1) = 9/1, v/v) to give the titled compound as a white solid. (1.3 g, Yield: 46%)

- [502] ¹H-NMR (400MHz, CDCl₃) δ 7.34(s, 1H), 7.30(m, 1H), 7.15(m, 1H), 5.50(br, 1H), 5.13(m, 1H), 4.75(m, 2H), 3.18(m, 2H), 2.82~2.68(m, 7H), 1.96(m, 1H), 1.80(m, 1H), 1.66(m, 1H), 1.55(m, 1H), 1.37(m, 1H)
- [503]
- [504] Preparation 2. (S)-quinuclidin-3-yl (6-bromo-2,3-dihydro-1H-inden-1-yl)carbamate
- [505] The titled compound was prepared in accordance with the same procedures as in Preparation 1, using 6-bromo-2,3-dihydro-1H-inden-1-amine as a starting material.
- [506] ¹H-NMR (400MHz, CDCl₃) δ 7.40(s, 1H), 7.30(m, 1H), 7.08(d, 1H), 5.51(br, 1H), 5.19(m, 1H), 4.75(m, 2H), 3.20(m, 2H), 2.82~2.69(m, 7H), 1.97(m, 1H), 1.80(m, 1H), 1.67(m, 1H), 1.55(m, 1H), 1.38(m, 1H)
- [507]
- [508] Preparation 3. (S)-quinuclidin-3-yl (6-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
- [509] The titled compound was prepared in accordance with the same procedures as in Preparation 1, using 6-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-amine as a starting material.
- [510] ¹H-NMR (400MHz, CDCl₃) δ 7.28(m, 2H), 7.00(d, 1H), 4.89(m, 1H), 4.73(m, 2H), 3.15(m, 1H), 2.81~2.70(m, 7H), 1.95(m, 1H), 1.80(br, 1H), 1.64(br, 1H), 1.53(br, 1H), 1.39(br, 1H), 0.85(d, 6H)
- [511]
- [512] Preparation 4. (S)-quinuclidin-3-yl (5-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
- [513] Step 1. 5-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-amine hydrochloride
- [514] 5-Bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-one (100 g, 418.2 mmol) was dissolved in methanol (500 ml) and isopropanol (500 ml) and then ammonium acetate (515.8 g, 6691.5 mmol) and sodium cyanoborohydride (157.7 g, 2509.3 mmol) were slowly added thereto at room temperature. The reaction mixture was stirred at room temperature for 4 hours and then refluxed under stirring at 80°C for 22 hours. The reaction mixture was cooled to room temperature, basified to pH>12 with a 1N sodium hydroxide solution, and then extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and then filtered and concentrated under reduced pressure. Ethyl acetate was added to the resulting residue and then a hydrochloric acid solution (4M) in 1,4-dioxane was added thereto. The mixture was stirred at room temperature for 1 hour. The resulting solid was filtered under reduced pressure, washed with ethyl acetate, and then dried to give the titled compound as a white solid. (100 g, Yield: 86.5%)
- [515] ¹H-NMR (400MHz, CD₃OD) δ 7.50(m, 2H), 7.39(d, 1H), 4.28(s, 1H), 3.02~2.82(m, 2H), 1.24(s, 3H), 1.20(s, 3H)

[516] Step 2. (S)-quinuclidin-3-yl

(5-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[517] A solution of (S)-(+)-3-quinuclidinol (38.6 g, 303.7 mmol) and bis(4-nitrophenyl) carbonate (92.4 g, 303.7 mmol) in *N,N*-dimethylformamide (700 ml) was stirred at room temperature for 8 hours. 5-Bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-amine hydrochloride (70 g, 253.1 mmol) prepared in Step 1 and diisopropylethylamine (132.3 ml, 759.2 mmol) were added to the solution, which was then stirred at room temperature overnight. The reaction mixture was diluted with water (500 ml), acidified to pH 1-2 with a 1N aqueous hydrochloric acid solution, and then extracted with diisopropyl ether (300 ml X 2). The aqueous layer was basified to pH 12 with ammonia and then extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and then filtered and concentrated under reduced pressure. The resulting residue was dissolved in isopropyl acetate and then heptane was added thereto. The mixture was stirred at room temperature overnight. The resulting solid was filtered under reduced pressure, washed with heptane, and dried to give the titled compound as a white solid. (56 g, Yield: 56.3%)

[518] ¹H-NMR (400MHz, CDCl₃) δ 7.32(m, 2H), 7.09(m, 1H), 4.89(m, 1H), 4.86(m, 1H), 4.77(m, 1H), 3.25(m, 1H), 2.87~2.75(m, 2H), 2.74~2.69(m, 5H), 2.07(m, 1H), 1.83(br, 1H), 1.69(br, 1H), 1.57(br, 1H), 1.41(br, 1H), 1.27(s, 3H), 0.92(s, 3H)

[519]

[520] Preparation 5. (S)-quinuclidin-3-yl

(5-bromo-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[521] Step 1. 5-bromo-2,2-diethyl-2,3-dihydro-1H-inden-1-one

[522] 5-Bromo-1-indanone (20 g, 94.8 mmol) was dissolved in tetrahydrofuran (100 ml) and then 60% sodium hydride (19 g, 473.8 mmol) was added thereto at 0°C. The reaction mixture was stirred for 15 minutes and then iodoethane (19.1 ml, 236.9 mmol) was slowly added thereto at the same temperature. The reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (*n*-hexane/ethyl acetate = 10/1, v/v) to give the titled compound as a white solid. (17g, Yield: 67%)

[523] ¹H-NMR (400MHz, CDCl₃) δ 7.61(s, 1H), 7.58(m, 1H), 7.51(m, 1H), 2.97(s, 2H), 1.65(m, 2H), 1.62(m, 2H), 0.77(t, 6H)

[524] Step 2. 5-bromo-2,2-diethyl-2,3-dihydro-1H-inden-1-amine hydrochloride

[525] The titled compound was prepared in accordance with the same procedures as in Step 1 of Preparation 4, using 5-bromo-2,2-diethyl-2,3-dihydro-1H-inden-1-one prepared in Step 1.

- [526] ^1H -NMR (400MHz, MeOD) δ 7.49(s, 1H), 7.45(m, 2H), 4.38(s, 1H), 3.07(m, 1H), 2.83(m, 1H), 1.70(m, 2H), 1.40(m, 2H), 1.09(t, 3H), 0.88(t, 3H)
- [527] Step 3. (S)-quinuclidin-3-yl
(5-bromo-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate
- [528] The titled compound was prepared in accordance with the same procedures as in Step 2 of Preparation 4, using 5-bromo-2,2-diethyl-2,3-dihydro-1H-inden-1-amine hydrochloride prepared in Step 2.
- [529] ^1H -NMR (400MHz, CDCl_3) δ 7.32(m, 2H), 7.09(m, 1H), 5.01(m, 1H), 4.85(m, 1H), 4.76(m, 1H), 3.25(m, 1H), 2.89~2.70(m, 7H), 2.10(br, 1H), 1.80(br, 1H), 1.69(br, 1H), 1.55(m, 3H), 1.49(m, 2H), 1.40(br, 1H), 0.95(m, 3H), 0.81(m, 3H)
- [530]
- [531] Preparation 6. (S)-quinuclidin-3-yl
(5-bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
- [532] Step 1. 5-bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one
- [533] 5-Bromo-6-methoxy-2,3-dihydro-1H-inden-1-one (10 g, 43.7 mmol) was dissolved in tetrahydrofuran (50 ml) and then 60% sodium hydride (8.7 g, 218.3 mmol) was added thereto at 0°C. The reaction mixture was stirred for 15 minutes and then iodomethane (10.9 ml, 174.6 mmol) was slowly added thereto at the same temperature. The reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer dried over anhydrous magnesium sulfate and then filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (*n*-hexane/ethyl acetate = 10/1, v/v) to give the titled compound as a white solid. (10g, Yield: 89%)
- [534] ^1H -NMR (400MHz, CDCl_3) δ 7.66(s, 1H), 7.21(s, 1H), 3.94(s, 3H), 2.93(s, 2H), 1.24(s, 6H)
- [535] Step 2. 5-bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-amine hydrochloride
- [536] The titled compound was prepared in accordance with the same procedures as in Step 1 of Preparation 4, using
5-bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one prepared in Step 1.
- [537] ^1H -NMR (400MHz, MeOD) δ 7.47(s, 1H), 7.23(s, 1H), 4.29(s, 1H), 4.11(s, 3H), 2.95~2.92(m, 1H), 2.78~2.74(m, 1H), 1.29(m, 3H), 0.98(m, 3H)
- [538] Step 3. (S)-quinuclidin-3-yl
(5-bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
- [539] The titled compound was prepared in accordance with the same procedures as in Step 2 of Preparation 4, using
5-bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-amine hydrochloride

prepared in Step 2.

[540] ¹H-NMR (400MHz, CDCl₃) δ 7.34(s, 1H), 6.77(m, 1H), 4.87(s, 2H), 4.78(m, 1H), 3.85(m, 3H), 3.25(m, 1H), 2.78~2.61(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.57(br, 1H), 1.44(br, 1H), 1.21(m, 3H), 0.95(m, 3H)

[541]

[542] Preparation 7. (S)-quinuclidin-3-yl
(5-bromo-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[543] The titled compound was prepared in accordance with the same procedures as in Preparation 6, using 5-bromo-6-fluoro-2,3-dihydro-1H-inden-1-one as a starting material.

[544] ¹H-NMR (400MHz, CDCl₃) δ 7.34(d, 1H), 7.01(d, 1H), 4.91(m, 1H), 4.84(m, 1H), 4.69(m, 1H), 3.25(m, 1H), 2.93~2.72(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.40(br, 1H), 1.27(m, 3H), 0.92(m, 3H)

[545]

[546] Preparation 8. (S)-quinuclidin-3-yl
(5'-bromo-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate

[547] Step 1. 5'-bromospiro[cyclopropane-1,2'-inden]-1'(3'H)-one

[548] 5-Bromo-1-indanone (5 g, 23.7 mmol) was dissolved in *N,N*-dimethylformamide (100 ml) and then 60% sodium hydride (2.7 g, 35.5 mmol) was added thereto at 0°C. The reaction mixture was stirred for 15 minutes and then 1,2-dibromomethane (5.1 ml, 35.5 mmol) was slowly added thereto at the same temperature. The reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (*n* - hexane/ethyl acetate = 10/1, v/v) to give the titled compound as a white solid. (3.5 g, Yield: 62%)

[549] ¹H-NMR (400MHz, CDCl₃) δ 7.69(s, 1H), 7.65(m, 1H), 7.55(d, 1H), 3.15(s, 2H), 1.47(d, 2H), 1.19(d, 2H)

[550] Step 2. 5'-bromo-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-amine hydrochloride

[551] The titled compound was prepared in accordance with the same procedures as in Step 1 of Preparation 4, using 5'-bromospiro[cyclopropane-1,2'-inden]-1'(3'H)-one prepared in Step 1.

[552] ¹H-NMR (400MHz, MeOD) δ 7.56(s, 1H), 7.52(m, 1H), 7.45(m, 1H), 4.25(s, 1H), 3.45(m, 1H), 2.71(m, 1H), 1.15(m, 1H), 0.92(m, 2H), 0.82(m, 1H)

[553] Step 3. (S)-quinuclidin-3-yl
(5'-bromo-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate

[554] The titled compound was prepared in accordance with the same procedures as in

Preparation 1, using 5'-bromo-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-amine hydrochloride prepared in Step 2.

[555] ¹H-NMR (400MHz, CDCl₃) δ 7.36(m, 2H), 7.24(m, 1H), 4.92(m, 1H), 4.91(m, 1H), 4.74(m, 1H), 3.25(m, 1H), 3.00(m, 2H), 2.87~2.68(m, 5H), 1.97(br, 1H), 1.79(m, 1H), 1.67(br, 1H), 1.56(m, 1H), 1.41(br, 1H), 0.91(m, 2H), 0.81(m, 1H), 0.59(m, 1H)

[556]

[557] Preparation 9. (S)-quinuclidin-3-yl
(5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[558] Step 1. 6-bromo-1,1-dimethyl-2,3-dihydro-1H-indene

[559] A titanium(IV) chloride solution (1.0M) in dichloromethane (28.4 ml) was slowly added to dichloromethane (20 ml) at -30°C under nitrogen atmosphere. A dimethylzinc solution (2.0M) in toluene (16.6 ml) was slowly added at the same temperature to the mixture, which was then stirred at 30 minutes. A solution of 6-bromo-2,3-dihydro-1H-inden-1-one (2 g, 9.5 mmol) in dichloromethane (10 ml) was slowly added to the reaction mixture, which was then stirred at -10°C for 4 hours. The reaction was quenched by adding ice water to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and then filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (*n*-hexane/ethyl acetate = 5/1, v/v) to give the titled compound as a white solid. (2.1g, Yield: 99%)

[560] ¹H NMR (400 MHz, CDCl₃) δ 7.28(s, 1H), 7.20(d, 1H), 7.07(d, 1H), 2.85(t, 2H), 1.94(t, 2H), 1.26(s, 6H)

[561] Step 2. 5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-one

[562] 6-Bromo-1,1-dimethyl-2,3-dihydro-1H-indene (1.9 g, 8.4 mmol) prepared in Step 1 was dissolved in acetone (20 ml) and then a solution of anhydrous magnesium sulfate (2.5 g, 21.1 mmol) in water (10 ml) was slowly added thereto. Potassium permanganate (4 g, 25.3 mmol) was slowly added to the reaction mixture, which was then refluxed under stirring for 5 hours. The reaction mixture was cooled to room temperature and then filtered and concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate, washed with brine, dried over anhydrous magnesium sulfate, and then filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (*n*-hexane/ethyl acetate = 5/1, v/v) to give the titled compound as a white solid. (1.85g, Yield: 92%)

[563] ¹H NMR (400 MHz, CDCl₃) δ 7.65(s, 1H), 7.58~7.47(m, 2H), 2.58(s, 2H), 1.42(s, 6H)

[564] Step 3. 5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-amine hydrochloride

[565] The titled compound was prepared in accordance with the same procedures as in Step

1 of Preparation 4, using 5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-one prepared in Step 2. The product was used in subsequent reaction without further purification.

[566] Step 4. ethyl (5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[567] The titled compound was prepared in accordance with the same procedures as in Step 1 of Preparation 1, using 5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-aminehydrochloride prepared in Step 3.

[568] ¹H NMR (400 MHz, CDCl₃) δ 7.35(d, 1H), 7.30(s, 1H), 7.16(d, 1H), 5.24(q, 1H), 4.81(brd, 1H), 4.17(q, 2H), 2.46(m, 1H), 1.73~1.68(m, 1H), 1.37(s, 3H), 1.28(t, 3H), 1.22(s, 3H)

[569] Step 5. (S)-quinuclidin-3-yl (5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[570] The titled compound was prepared in accordance with the same procedures as in Step 2 of Preparation 1, using ethyl (5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate prepared in Step 4.

[571] ¹H NMR (400 MHz, MeOD) δ 7.38~7.33(m, 2H), 7.14(dd, 1H), 5.14(t, 1H), 4.80~4.75(m, 1H), 3.30~3.21(m, 1H), 2.90~2.69(m, 5H), 2.39~2.32(m, 1H), 2.11~2.04(m, 1H), 1.99~1.90(m, 1H), 1.84~1.74(m, 2H), 1.70~1.61(m, 1H), 1.55~1.45(m, 1H), 1.39(s, 3H), 1.22(s, 3H)

[572]

[573] Preparation 10. (S)-quinuclidin-3-yl (6-bromo-2,3-dihydrobenzofuran-3-yl)carbamate

[574] The titled compound was prepared in accordance with the same procedures as in Preparation 1, using 6-bromo-2,3-dihydrobenzofuran-3-amine a starting material.

[575] ¹H-NMR (400MHz, CDCl₃) δ 7.21(t, 1H), 7.08~7.06(m, 1H), 7.02(s, 1H), 5.35~5.31(m, 2H), 4.73~4.68(m, 2H), 4.41~4.37(m, 1H), 3.24~3.19(m, 1H), 2.82~2.66(m, 5H), 2.05~1.98(m, 1H), 1.75~1.66(m, 2H), 1.56~1.55(m, 1H), 1.40~1.38(m, 1H)

[576]

[577] Preparation 11. (S)-quinuclidin-3-yl (5-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate

[578] Step 1. 5-bromo-2,2-dimethylbenzofuran-3(2H)-one

[579] 5-Bromobenzofuran-3-one (2.75 g, 12.9 mmol) was dissolved in tetrahydrofuran (43 ml) and then 60% sodium hydride(2.07 g, 51.6 mmol) was added thereto at 0°C. The reaction mixture was stirred for 15 minutes and then iodomethane (9.15 g, 64.5 mmol) was slowly added thereto at the same temperature. The reaction mixture was stirred at room temperature overnight. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium

sulfate, and then filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography (*n*-hexane/ethyl acetate = 10/1, v/v) to give the titled compound as a white solid. (2.5g, Yield: 80%)

[580] ¹H-NMR (400MHz, CDCl₃) δ 7.81(s, 1H), 7.79(d, 1H), 6.98(d, 1H), 1.47(s, 6H)

[581] Step 2. 5-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-amine

[582] The titled compound was prepared in accordance with the same procedures as in Step 1 of Preparation 4, using 5-bromo-2,2-dimethylbenzofuran-3(2H)-one prepared in Step 1.

[583] ¹H-NMR (400MHz, CDCl₃) δ 7.40(s, 1H), 7.27(d, 1H), 6.63(d, 1H), 4.12(s, 1H), 1.41(d, 6H)

[584] Step 3. (S)-quinuclidin-3-yl

(5-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate

[585] The titled compound was prepared in accordance with the same procedures as in Preparation 1, using 5-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-amine prepared in Step 2.

[586] ¹H-NMR (400MHz, CDCl₃) δ 7.40(d, 1H), 7.31(d, 1H), 6.65(d, 1H), 5.36(t, 1H), 5.00(d, 1H), 4.78~4.69(m, 1H), 3.25~3.15(m, 1H), 2.89~2.59(m, 5H), 2.06~2.00(m, 1H), 1.83~1.74(m, 1H), 1.72~1.63(m, 1H), 1.60~1.51(m, 1H), 1.48(s, 3H), 1.41~1.36(m, 4H)

[587]

[588] Preparation 12. (S)-quinuclidin-3-yl

(6-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate

[589] Step 1. 6-bromo-2,2-dimethylbenzofuran-3(2H)-one

[590] The titled compound was prepared in accordance with the same procedures as in Step 1 of Preparation 11, using 6-bromobenzofuran-3(2H)-one as a starting material.

[591] ¹H-NMR (400MHz, CDCl₃) δ 7.53(d, 1H), 7.30~7.27(m, 1H), 7.21(dd, 1H), 1.47(s, 6H)

[592] Step 2. (S)-quinuclidin-3-yl

(6-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate

[593] The titled compound was prepared in accordance with the same procedures as in Preparation 4, using 6-bromo-2,2-dimethylbenzofuran-3(2H)-one prepared in Step 1.

[594] ¹H-NMR (400MHz, CDCl₃) δ 7.14(dd, 1H), 7.05~6.99(m, 1H), 6.91(s, 1H), 5.59~5.46(m, 1H), 4.94(d, 1H), 4.77~4.66(m, 1H), 3.27~3.14(m, 1H), 2.91~2.61(m, 5H), 2.12~2.01(m, 1H), 1.86~1.64(m, 2H), 1.61~1.52(m, 1H), 1.45(s, 3H), 1.43~1.32(m, 4H)

[595]

[596] **Example 1. (S)-quinuclidin-3-yl**

(5-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[597] To a mixture of (S)-quinuclidin-3-yl (5-bromo-2,3-dihydro-1H-inden-1-yl)carbamate (30 mg, 0.082 mmol) prepared in Preparation 1, 4-fluorophenylboronic acid (17.2 mg, 0.12 mmol), potassium phosphate (52.3 mg, 0.25 mmol), and tetrakis(triphenylphosphine)palladium(0) (9.4 mg, 10 mol%), were slowly added 1,4-dioxane (1 ml) and water (0.5 ml). The reaction mixture was refluxed under stirring at 120°C overnight and then cooled to room temperature. Water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then filtered and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate/(methanol/ammonia water = 1/1) = 9/1, v/v) to give the titled compound as a white solid. (19 mg, Yield: 64%)

[598] ¹H-NMR (400MHz, CDCl₃) δ 7.55(m, 2H), 7.42(m, 3H), 7.13(m, 2H), 5.29(m, 1H), 5.00(m, 1H), 4.81(br, 1H), 3.28(m, 1H), 3.05(m, 1H), 2.94(m, 3H), 2.82(m, 3H), 2.65(m, 1H), 2.06(m, 1H), 1.93~1.88(m, 2H), 1.71(m, 1H), 1.60(br, 1H), 1.42(br, 1H)

[599]

[600] **Examples 2 to 24**

[601] The titled compounds of Examples 2 to 24 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (5-bromo-2,3-dihydro-1H-inden-1-yl)carbamate prepared in Preparation 1; and the corresponding substituted-phenylboronic acids, respectively.

[602]

[603] **Example 2. (S)-quinuclidin-3-yl**

(5-(4-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[604] ¹H-NMR (400MHz, CDCl₃) δ 7.52(m, 2H), 7.42(m, 5H), 5.29(m, 1H), 5.01(m, 1H), 4.80(br, 1H), 3.28(m, 1H), 3.03(m, 1H), 2.85(m, 3H), 2.78~2.67(m, 4H), 2.09(m, 1H), 1.98(m, 1H), 1.87(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[605]

[606] **Example 3. (S)-quinuclidin-3-yl**

(5-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[607] ¹H-NMR (400MHz, CDCl₃) δ 7.69(s, 4H), 7.47(m, 3H), 5.31(m, 1H), 5.01(m, 1H), 4.81(br, 1H), 3.31(m, 1H), 3.04(m, 1H), 2.94(m, 3H), 2.78(m, 4H), 2.03(m, 2H), 1.91(m, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[608]

[609] **Example 4.(S)-quinuclidin-3-yl**

(5-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[610] ¹H-NMR (400MHz, CDCl₃) δ 7.58(d, 2H), 7.43(m, 3H), 7.29(d, 2H), 5.29(m, 1H), 4.99(m, 1H), 4.80(br, 1H), 3.31(m, 1H), 3.05(m, 1H), 2.95~2.75(m, 7H), 2.07(m, 1H), 1.84(m, 2H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[611]

[612] **Example 5. (S)-quinuclidin-3-yl**

(5-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[613] ¹H-NMR (400MHz, CDCl₃) δ 7.70(m, 1H), 7.45(m, 5H), 7.05(m, 1H), 5.28(m, 1H), 4.98(m, 1H), 4.80(br, 1H), 3.31(m, 1H), 2.94(m, 1H), 2.82~2.75(m, 7H), 2.09(m, 1H), 1.82(m, 2H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H)

[614]

[615] **Example 6.(S)-quinuclidin-3-yl**

(5-(3-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[616] ¹H-NMR (400MHz, CDCl₃) δ 7.57(s, 1H), 7.45(m, 4H), 7.34(m, 2H), 5.29(m, 1H), 4.98(m, 1H), 4.81(m, 1H), 3.30(m, 1H), 3.04(m, 1H), 2.95~2.66(m, 7H), 2.09(m, 1H), 1.82(m, 2H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H)

[617]

[618] **Example 7.(S)-quinuclidin-3-yl**

(5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[619] ¹H-NMR (400MHz, CDCl₃) δ 7.82(s, 1H), 7.76(d, 1H), 7.58(m, 2H), 7.47(m, 3H), 5.30(m, 1H), 4.98(m, 1H), 4.81(m, 1H), 3.30(m, 1H), 3.05(m, 1H), 3.05~2.68(m, 7H), 2.09(m, 1H), 1.91(br, 1H), 1.79(m, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.42(br, 1H)

[620]

[621] **Example 8. (S)-quinuclidin-3-yl**

(5-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[622] ¹H-NMR (400MHz, CDCl₃) δ 7.52~7.42(m, 6H), 7.21(m, 1H), 5.29(m, 1H), 5.01(m, 1H), 4.81(m, 1H), 3.31(m, 1H), 3.04(m, 1H), 2.95~2.75(m, 7H), 2.09(m, 1H), 1.92(m, 1H), 1.84(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[623]

[624] **Example 9.(S)-quinuclidin-3-yl**

(5-(2-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[625] ¹H-NMR (400MHz, CDCl₃) δ 7.42(m, 3H), 7.28~7.16(m, 4H), 5.29(m, 1H), 4.98(m, 1H), 4.81(m, 1H), 3.29(m, 1H), 2.95(m, 1H), 2.89~2.66(m, 7H), 2.06(m, 1H), 1.83(m, 1H), 1.74(m, 2H), 1.60(br, 1H), 1.41(br, 1H)

[626]

[627] **Example 10.(S)-quinuclidin-3-yl**

(5-(2-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[628] ¹H-NMR (400MHz, CDCl₃) δ 7.49(d, 1H), 7.41(d, 1H), 7.32(m, 5H), 5.32(m, 1H), 4.99(m, 1H), 4.81(br, 1H), 3.30(m, 1H), 3.03(m, 1H), 2.95~2.67(m, 7H), 2.06(m, 1H), 1.91(br, 1H), 1.83(br, 1H), 1.73(m, 1H), 1.61(br, 1H), 1.41(br, 1H)

[629]

[630] **Example 11.(S)-quinuclidin-3-yl**

(5-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[631] ¹H-NMR (400MHz, CDCl₃) δ 7.75(d, 1H), 7.54(m, 1H), 7.49(m, 1H), 7.36(m, 4H), 5.31(m, 1H), 5.12(m, 1H), 4.81(br, 1H), 3.29(m, 1H), 3.01(m, 1H), 2.93~2.66(m, 7H), 2.09(br, 1H), 1.95(m, 1H), 1.88(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[632]

Example 12. (S)-quinuclidin-3-yl**(5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[634] ¹H-NMR (400MHz, CDCl₃) δ 7.41(m, 6H), 7.26(m, 1H), 5.29(m, 1H), 5.04(m, 1H), 4.81(m, 1H), 3.31(m, 1H), 3.02(m, 1H), 2.94~2.76(m, 7H), 2.06(m, 1H), 1.84(m, 2H), 1.71(br, 1H), 1.61(br, 1H), 1.42(br, 1H)

[635]

Example 13.(S)-quinuclidin-3-yl (5-(p-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[637] ¹H-NMR (400MHz, CDCl₃) δ 7.46(m, 5H), 7.25(m, 2H), 5.29(m, 1H), 4.98(m, 1H), 4.80(m, 1H), 3.30(m, 1H), 3.04(m, 1H), 2.96~2.67(m, 7H), 2.40(s, 3H), 2.09(m, 1H), 1.85(m, 2H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H)

[638]

Example 14.(S)-quinuclidin-3-yl**(5-(4-(difluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[640] ¹H-NMR (400MHz, CDCl₃) δ 7.58(m, 2H), 7.41(m, 3H), 7.20(d, 2H), 6.75~6.38(t, 1H), 5.29(m, 1H), 4.98(m, 1H), 4.80(m, 1H), 3.30(m, 1H), 2.95~2.66(m, 7H), 2.08(m, 1H), 1.85(m, 2H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H)

[641]

Example 15.(S)-quinuclidin-3-yl**(5-(3,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[643] ¹H-NMR (400MHz, CDCl₃) δ 7.40(m, 4H), 7.23(m, 2H), 5.28(m, 1H), 5.00(m, 1H), 4.80(m, 1H), 3.30(m, 1H), 3.03(m, 1H), 2.94~2.66(m, 7H), 2.06(m, 1H), 1.87(m, 2H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[644]

Example 16.(S)-quinuclidin-3-yl**(5-(2,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[646] ¹H-NMR (400MHz, CDCl₃) δ 7.40(m, 4H), 6.96(m, 2H), 5.30(m, 1H), 5.00(m, 1H), 4.80(m, 1H), 3.28(m, 1H), 3.03(m, 1H), 2.95~2.66(m, 7H), 2.06(m, 1H), 1.82(m, 2H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[647]

Example 17.(S)-quinuclidin-3-yl**(5-(2,3-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[649] ¹H-NMR (400MHz, CDCl₃) δ 7.42(m, 3H), 7.16(m, 3H), 5.31(m, 1H), 5.00(m, 1H), 4.81(m, 1H), 3.27(m, 1H), 3.04(m, 1H), 2.95~2.67(m, 7H), 2.09(m, 1H), 1.86(m, 2H),

1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[650]

[651] **Example 18. (S)-quinuclidin-3-yl**

(5-(2,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[652] ¹H-NMR (400MHz, CDCl₃) δ 7.41(m, 3H), 7.12(m, 2H), 7.01(m, 1H), 5.30(m, 1H), 5.02(m, 1H), 4.81(m, 1H), 3.30(m, 1H), 3.03(m, 1H), 2.95~2.66(m, 7H), 2.09(m, 1H), 1.89(m, 2H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[653]

[654] **Example 19.(S)-quinuclidin-3-yl**

(5-(3,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[655] ¹H-NMR (400MHz, CDCl₃) δ 7.42(m, 3H), 7.09(d, 2H), 6.79(t, 1H), 5.29(m, 1H), 4.98(m, 1H), 4.81(m, 1H), 3.30(m, 1H), 3.04(m, 1H), 2.97~2.67(m, 7H), 2.09(m, 1H), 1.90(m, 1H), 1.82(m, 1H), 1.71(br, 1H), 1.61(br, 1H), 1.42(br, 1H)

[656]

[657] **Example 20.(S)-quinuclidin-3-yl**

(5-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[658] ¹H-NMR (400MHz, CDCl₃) δ 7.43(m, 1H), 7.37(m, 2H), 7.13(m, 1H), 7.04(m, 1H), 5.29(m, 1H), 5.02(m, 1H), 4.80(m, 1H), 3.28(m, 1H), 3.03(m, 1H), 2.97~2.67(m, 7H), 2.06(m, 1H), 1.91(m, 1H), 1.84(m, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H)

[659]

[660] **Example 21.(S)-quinuclidin-3-yl**

(5-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[661] ¹H-NMR (400MHz, CDCl₃) δ 7.45(d, 1H), 7.36(s, 2H), 7.21(m, 1H), 7.02(m, 1H), 5.30(m, 1H), 5.01(m, 1H), 4.81(m, 1H), 3.28(m, 1H), 3.04(m, 1H), 2.95~2.67(m, 7H), 2.09(m, 1H), 1.90(m, 2H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[662]

[663] **Example 22.(S)-quinuclidin-3-yl**

(5-(3,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[664] ¹H-NMR (400MHz, CDCl₃) δ 7.57(m, 1H), 7.49~7.42(m, 5H), 5.29(m, 1H), 5.00(m, 1H), 4.81(m, 1H), 3.28(m, 1H), 3.05(m, 1H), 2.89~2.67(m, 7H), 2.06(m, 1H), 1.83(m, 2H), 1.71(br, 1H), 1.61(br, 1H), 1.42(br, 1H)

[665]

[666] **Example 23.(S)-quinuclidin-3-yl**

(5-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[667] ¹H-NMR (400MHz, CDCl₃) δ 7.66(s, 1H), 7.52(m, 2H), 7.42(m, 4H), 5.30(m, 1H), 4.98(m, 1H), 4.81(m, 1H), 3.29(m, 1H), 3.05(m, 1H), 2.97~2.67(m, 7H), 2.06(m, 1H), 1.93(m, 1H), 1.80(m, 1H), 1.72(br, 1H), 1.61(br, 1H), 1.41(br, 1H)

[668]

[669] **Example 24. (S)-quinuclidin-3-yl**

(5-(2,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[670] ¹H-NMR (400MHz, CDCl₃) δ 7.42(m, 1H), 7.32(m, 2H), 7.28(m, 3H), 5.31(m, 1H), 5.07(m, 1H), 4.80(m, 1H), 3.28(m, 1H), 3.03(m, 1H), 2.94~2.66(m, 7H), 2.06(m, 1H), 1.94(m, 1H), 1.87(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[671]

[672] **Examples 25 to 48**

[673] The titled compounds of Examples 25 to 48 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (6-bromo-2,3-dihydro-1H-inden-1-yl)carbamate prepared in Preparation 2; and the corresponding substituted-phenylboronic acids, respectively.

[674]

[675] **Example 25.(S)-quinuclidin-3-yl**

(6-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[676] ¹H-NMR (400MHz, CDCl₃) δ 7.54(m, 3H), 7.42(m, 1H), 7.33(m, 1H), 7.13(t, 2H), 5.31(m, 1H), 5.00(m, 1H), 4.80(m, 1H), 3.28(m, 1H), 3.02(m, 1H), 3.00~2.72(m, 7H), 2.06(m, 2H), 1.93(m, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[677]

[678] **Example 26.(S)-quinuclidin-3-yl**

(6-(4-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[679] ¹H-NMR (400MHz, CDCl₃) δ 7.52(m, 3H), 7.40(m, 3H), 7.33(m, 1H), 5.31(m, 1H), 5.03(m, 1H), 4.80(br, 1H), 3.28(m, 1H), 3.00(m, 1H), 2.93~2.66(m, 7H), 1.91(m, 2H), 1.85(m, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.40(br, 1H)

[680]

[681] **Example 27.(S)-quinuclidin-3-yl**

(6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[682] ¹H-NMR (400MHz, CDCl₃) δ 7.69(s, 4H), 7.55(s, 1H), 7.49(d, 1H), 7.36(d, 1H), 5.33(m, 1H), 5.04(m, 1H), 4.81(br, 1H), 3.28(m, 1H), 3.02(m, 1H), 2.94~2.67(m, 7H), 1.93(m, 2H), 1.83(m, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[683]

[684] **Example 28.(S)-quinuclidin-3-yl**

(6-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[685] ¹H-NMR (400MHz, CDCl₃) δ 7.60(d, 2H), 7.58(s, 1H), 7.46(d, 1H), 7.34(d, 1H), 7.28(d, 2H), 5.32(m, 1H), 5.04(m, 1H), 4.80(br, 1H), 3.28(m, 1H), 3.09(m, 1H), 2.93~2.86(m, 3H), 2.76(m, 4H), 1.97(m, 1H), 1.90(m, 1H), 1.83(m, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.39(br, 1H)

[686]

[687] **Example 29.(S)-quinuclidin-3-yl**

(6-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[688] ¹H-NMR (400MHz, CDCl₃) δ 7.52(s, 1H), 7.46(d, 1H), 7.37(m, 3H), 7.28(m, 1H), 7.04(m, 1H), 5.31(m, 1H), 5.02(m, 1H), 4.81(br, 1H), 3.31(m, 1H), 3.04(m, 1H), 2.88(m, 3H), 2.77(m, 4H), 2.06(m, 1H), 1.93(m, 1H), 1.84(m, 1H), 1.68(m, 1H), 1.60(br, 1H), 1.41(br, 1H)

[689]

Example 30. (S)-quinuclidin-3-yl**(6-(3-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[691] ¹H-NMR (400MHz, CDCl₃) δ 7.56~7.45(m, 4H), 7.37~7.28(m, 3H), 5.32(m, 1H), 5.02(m, 1H), 4.81(br, 1H), 3.27(m, 1H), 3.03(m, 1H), 2.93(m, 3H), 2.77(m, 4H), 1.92(m, 1H), 1.86(m, 1H), 1.85(m, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[692]

Example 31. (S)-quinuclidin-3-yl**(6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[694] ¹H-NMR (400MHz, CDCl₃) δ 7.81(s, 1H), 7.77(m, 1H), 7.60~7.54(m, 3H), 7.50(m, 1H), 7.36(m, 1H), 5.33(m, 1H), 5.04(m, 1H), 4.80(br, 1H), 3.27(m, 1H), 3.03(m, 1H), 2.94(m, 3H), 2.76(m, 4H), 2.09(m, 1H), 1.96(m, 1H), 1.83(m, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[695]

Example 32. (S)-quinuclidin-3-yl**(6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[697] ¹H-NMR (400MHz, CDCl₃) δ 7.51(d, 2H), 7.46(m, 2H), 7.42(s, 1H), 7.35(d, 1H), 7.21(d, 1H), 5.30(m, 1H), 5.05(m, 1H), 4.80(br, 1H), 3.30(m, 1H), 3.02(m, 1H), 2.87(m, 3H), 2.70(m, 4H), 2.08(m, 1H), 2.00(m, 1H), 1.90(m, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H)

[698]

Example 33. (S)-quinuclidin-3-yl**(6-(2-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[700] ¹H-NMR (400MHz, CDCl₃) δ 7.49(s, 1H), 7.43(s, 2H), 7.33(m, 2H), 7.22(m, 1H), 7.18(m, 1H), 5.31(m, 1H), 5.05(m, 1H), 4.78(br, 1H), 3.27(m, 1H), 3.03(m, 1H), 2.91(m, 3H), 2.75(m, 4H), 1.95(m, 2H), 1.88(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.39(br, 1H)

[701]

Example 34. (S)-quinuclidin-3-yl**(6-(2-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[703] ¹H-NMR (400MHz, CDCl₃) δ 7.48(d, 1H), 7.39(s, 1H), 7.32(m, 5H), 5.31(m, 1H), 5.07(m, 1H), 4.77(br, 1H), 3.24(m, 1H), 3.04(m, 1H), 2.94~2.71(m, 7H), 1.99(m, 1H), 1.90(m, 1H), 1.81(br, 1H), 1.68(br, 1H), 1.57(br, 1H), 1.38(br, 1H)

[704]

[705] **Example 35. (S)-quinuclidin-3-yl**

(6-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[706] ¹H-NMR (400MHz, CDCl₃) δ 7.76(d, 1H), 7.56(m, 1H), 7.49(m, 1H), 7.34(m, 1H), 7.27(m, 2H), 7.22(m, 1H), 5.31(m, 1H), 5.06(m, 1H), 4.76(br, 1H), 3.25(m, 1H), 2.94(m, 1H), 2.84(m, 2H), 2.75~2.71(m, 5H), 1.93(m, 1H), 1.91(m, 1H), 1.81(m, 1H), 1.67(m, 1H), 1.56(br, 1H), 1.37(br, 1H)

[707]

[708] **Example 36. (S)-quinuclidin-3-yl**

(6-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[709] ¹H-NMR (400MHz, CDCl₃) δ 7.42(s, 2H), 7.36(m, 4H), 7.28(s, 1H), 5.32(m, 1H), 5.00(m, 1H), 4.78(br, 1H), 3.27(m, 1H), 3.04(m, 1H), 2.94(m, 3H), 2.72(m, 4H), 1.92(m, 2H), 1.82(m, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.39(br, 1H)

[710]

[711] **Example 37.(S)-quinuclidin-3-yl**

(6-(4-(difluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[712] ¹H-NMR (400MHz, CDCl₃) δ 7.58(d, 2H), 7.50(s, 1H), 7.45(d, 1H), 7.33(d, 1H), 7.21(d, 2H), 6.75~6.38(t, 1H), 5.31(m, 1H), 5.02(m, 1H), 4.79(br, 1H), 3.28(m, 1H), 3.01(m, 1H), 2.90(m, 3H), 2.72(m, 4H), 2.06(m, 1H), 1.93(br, 1H), 1.83(m, 1H), 1.70(m, 1H), 1.58(m, 1H), 1.40(br, 1H)

[713]

[714] **Example 38.(S)-quinuclidin-3-yl (6-(p-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[715] ¹H-NMR (400MHz, CDCl₃) δ 7.53(s, 1H), 7.48(m, 3H), 7.32(d, 1H), 7.25(m, 2H), 5.31(m, 1H), 5.01(m, 1H), 4.80(br, 1H), 3.28(m, 1H), 3.00(m, 1H), 2.76(m, 3H), 2.68(m, 4H), 2.41(s, 3H), 2.06(m, 1H), 1.92~1.82(m, 2H), 1.69(m, 1H), 1.59(br, 1H), 1.40(br, 1H)

[716]

[717] **Example 39.(S)-quinuclidin-3-yl**

(6-(3,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[718] ¹H-NMR (400MHz, CDCl₃) δ 7.47(s, 1H), 7.42(m, 2H), 7.37(m, 2H), 7.21(m, 1H), 5.31(m, 1H), 5.01(m, 1H), 4.80(br, 1H), 3.27(m, 1H), 3.02(m, 1H), 2.93(m, 3H), 2.76(m, 4H), 2.08(m, 1H), 1.93(m, 1H), 1.89(m, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(br, 1H)

[719]

[720] **Example 40.(S)-quinuclidin-3-yl**

(6-(3,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[721] ¹H-NMR (400MHz, CDCl₃) δ 7.50(s, 1H), 7.44(d, 1H), 7.32(d, 1H), 7.10(d, 2H), 6.79(m, 1H), 5.31(m, 1H), 5.03(m, 1H), 4.80(br, 1H), 3.28(m, 1H), 3.03(m, 1H),

2.93~2.67(m, 7H), 2.09(m, 1H), 1.92(m, 1H), 1.84(m, 1H), 1.70(m, 1H), 1.61(br, 1H), 1.40(br, 1H)

[722]

[723] **Example 41. (S)-quinuclidin-3-yl**

(6-(2,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[724] ¹H-NMR (400MHz, CDCl₃) δ 7.47(s, 1H), 7.42(d, 1H), 7.34(m, 1H), 7.10(m, 2H), 7.01(m, 1H), 5.30(m, 1H), 5.04(m, 1H), 4.79(m, 1H), 3.26(m, 1H), 3.04(m, 1H), 2.87~2.75(m, 7H), 2.06(s, 1H), 1.93(m, 1H), 1.88(br, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.40(br, 1H)

[725]

[726] **Example 42.(S)-quinuclidin-3-yl**

(6-(2,3-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[727] ¹H-NMR (400MHz, CDCl₃) δ 7.48(s, 1H), 7.43(m, 1H), 7.34(d, 1H), 7.15(m, 3H), 5.31(m, 1H), 5.04(m, 1H), 4.79(m, 1H), 3.26(m, 1H), 3.04(m, 1H), 2.94~2.67(m, 7H), 2.09(m, 1H), 1.93(m, 1H), 1.83(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.39(br, 1H)

[728]

[729] **Example 43. (S)-quinuclidin-3-yl**

(6-(2,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[730] ¹H-NMR (400MHz, CDCl₃) δ 7.44(s, 1H), 7.40(m, 2H), 7.32(m, 1H), 6.94(m, 2H), 5.31(m, 1H), 5.02(m, 1H), 4.78(m, 1H), 3.27(m, 1H), 3.03(m, 1H), 2.93~2.66(m, 7H), 2.06(m, 1H), 1.89(m, 1H), 1.83(br, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.40(br, 1H)

[731]

[732] **Example 44.(S)-quinuclidin-3-yl**

(6-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[733] ¹H-NMR (400MHz, CDCl₃) δ 7.43(s, 1H), 7.36(m, 2H), 7.23(m, 1H), 7.04(m, 1H), 5.31(m, 1H), 5.02(m, 1H), 4.79(m, 1H), 3.26(m, 1H), 3.02(m, 1H), 2.93~2.72(m, 7H), 2.06(m, 1H), 1.88(m, 1H), 1.83(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.41(br, 1H)

[734]

[735] **Example 45.(S)-quinuclidin-3-yl**

(6-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[736] ¹H-NMR (400MHz, CDCl₃) δ 7.44(s, 1H), 7.33(m, 2H), 7.13(m, 1H), 7.04(m, 1H), 5.31(m, 1H), 5.01(, 1H), 4.79(m, 1H), 3.29(m, 1H), 3.05(m, 1H), 2.96~2.67(m, 7H), 2.06(m, 1H), 1.88(m, 1H), 1.84(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.40(br, 1H)

[737]

[738] **Example 46.(S)-quinuclidin-3-yl**

(6-(2,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[739] ¹H-NMR (400MHz, CDCl₃) δ 7.49(m, 2H), 7.32(m, 3H), 7.25(m, 1H), 5.32(m, 1H), 5.01(m, 1H), 4.79(m, 1H), 3.27(m, 1H), 3.04(m, 1H), 2.97~2.68(m, 7H), 2.06(m, 1H),

1.93(br, 1H), 1.88(m, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.39(br, 1H)

[740]

[741] **Example 47.(S)-quinuclidin-3-yl**

(6-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[742] ¹H-NMR (400MHz, CDCl₃) δ 7.66(s, 1H), 7.52(m, 2H), 7.44(m, 2H), 7.34(m, 1H), 5.31(m, 1H), 4.99(m, 1H), 4.81(br, 1H), 3.28(m, 1H), 3.01(m, 1H), 2.88(m, 3H), 2.77(m, 4H), 2.08(m, 1H), 1.89(m, 1H), 1.81(m, 1H), 1.71(m, 1H), 1.61(m, 1H), 1.42(br, 1H)

[743]

[744] **Example 48. (S)-quinuclidin-3-yl**

(6-(3,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[745] ¹H-NMR (400MHz, CDCl₃) δ 7.48(m, 2H), 7.45(m, 2H), 7.34(m, 2H), 5.31(m, 1H), 5.00(m, 1H), 4.81(m, 1H), 3.30(m, 1H), 3.03(m, 1H), 2.95~2.68(m, 7H), 2.10(m, 1H), 1.91(m, 1H), 1.82(m, 1H), 1.70(m, 1H), 1.59(br, 1H), 1.41(br, 1H)

[746]

[747] **Examples 49 to 72**

[748] The titled compounds of Examples 49 to 72 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (6-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate prepared in Preparation 3; and the corresponding substituted-phenylboronic acids, respectively.

[749]

[750] **Example 49.(S)-quinuclidin-3-yl**

(6-(4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[751] ¹H-NMR (400MHz, CDCl₃) δ 7.54(m, 2H), 7.40(m, 2H), 7.24(t, 1H), 7.14(t, 2H), 5.01(m, 1H), 4.88(m, 1H), 4.81(m, 1H), 3.31(m, 1H), 2.81(m, 2H), 2.77(m, 5H), 2.10(m, 1H), 1.80(br, 1H), 1.75(br, 1H), 1.61(br, 1H), 1.43(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[752]

[753] **Example 50.(S)-quinuclidin-3-yl**

(6-(4-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[754] ¹H-NMR (400MHz, CDCl₃) δ 7.50(m, 2H), 7.42(m, 3H), 7.26(m, 2H), 5.02(m, 1H), 4.89(m, 1H), 4.81(m, 1H), 3.30(m, 1H), 2.89(m, 2H), 2.77(m, 5H), 2.14(m, 1H), 1.86(br, 1H), 1.73(br, 1H), 1.62(br, 1H), 1.43(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[755]

[756] **Example 51.(S)-quinuclidin-3-yl**

(2,2-dimethyl-6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[757] ¹H-NMR (400MHz, CDCl₃) δ 7.69(s, 4H), 7.45(m, 2H), 7.29(d, 1H), 5.04(m, 1H), 4.94(m, 1H), 4.80(m, 1H), 3.30(m, 1H), 2.91~2.66(m, 6H), 2.09(s, 1H), 2.00(br, 1H),

1.84(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.31(d, 3H), 0.99(d, 3H)

[758]

[759] **Example 52.(S)-quinuclidin-3-yl**

(2,2-dimethyl-6-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[760] ¹H-NMR (400MHz, CDCl₃) δ 7.60(m, 2H), 7.41(m, 2H), 7.29(m, 3H), 5.03(m, 1H), 4.95(m, 1H), 4.80(m, 1H), 3.29(m, 1H), 2.88~2.66(m, 6H), 2.09(s, 1H), 2.00(br, 1H), 1.85(br, 1H), 1.71(br, 1H), 1.59(br, 1H), 1.42(br, 1H), 1.34(d, 3H), 0.99(d, 3H)

[761]

[762] **Example 53.(S)-quinuclidin-3-yl**

(6-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[763] ¹H-NMR (400MHz, CDCl₃) δ 7.43(s, 2H), 7.39(m, 2H), 7.25(m, 2H), 7.04(t, 1H), 5.03(m, 1H), 4.89(m, 1H), 4.82(m, 1H), 3.30(m, 1H), 2.90(m, 2H), 2.78(m, 5H), 2.14(m, 1H), 1.85(br, 1H), 1.76(br, 1H), 1.61(br, 1H), 1.41(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[764]

[765] **Example 54. (S)-quinuclidin-3-yl**

(6-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[766] ¹H-NMR (400MHz, CDCl₃) δ 7.57(s, 1H), 7.43(m, 2H), 7.38(m, 1H), 7.33(t, 1H), 7.25(m, 2H), 5.03(m, 1H), 4.90(m, 1H), 4.83(m, 1H), 3.31(m, 1H), 2.83(m, 2H), 2.78(m, 5H), 2.14(m, 1H), 1.88(br, 1H), 1.75(br, 1H), 1.60(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[767]

[768] **Example 55. (S)-quinuclidin-3-yl**

(2,2-dimethyl-6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[769] ¹H-NMR (400MHz, CDCl₃) δ 7.82(s, 1H), 7.76(m, 1H), 7.58(m, 2H), 7.45(m, 2H), 7.30(m, 1H), 5.04(m, 1H), 4.91(m, 1H), 4.81(m, 1H), 3.29(m, 1H), 2.87(m, 2H), 2.79(m, 5H), 2.14(m, 1H), 1.85(br, 1H), 1.76(br, 1H), 1.61(br, 1H), 1.42(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[770]

[771] **Example 56.(S)-quinuclidin-3-yl**

(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[772] ¹H-NMR (400MHz, CDCl₃) δ 7.48(m, 5H), 7.21(m, 2H), 5.04(m, 1H), 4.90(m, 1H), 4.82(m, 1H), 3.30(m, 1H), 2.89(m, 2H), 2.78(m, 5H), 2.11(m, 1H), 1.86(br, 1H), 1.75(br, 1H), 1.61(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[773]

[774] **Example 57.(S)-quinuclidin-3-yl**

(6-(2-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[775] ¹H-NMR (400MHz, CDCl₃) δ 7.43(m, 2H), 7.31~7.16(m, 5H), 5.03(m, 1H), 4.91(m, 1H), 4.80(m, 1H), 3.30(m, 1H), 2.89(m, 2H), 2.78(m, 5H), 2.09(br, 1H), 1.85(br, 1H), 1.74(br, 1H), 1.59(br, 1H), 1.42(br, 1H), 1.31(d, 3H), 1.00(d, 3H)

[776]

Example 58.(S)-quinuclidin-3-yl**(6-(2-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[778] ¹H-NMR (400MHz, CDCl₃) δ 7.48(m, 1H), 7.30(m, 6H), 5.04(m, 1H), 4.91(m, 1H), 4.79(br, 1H), 3.30(m, 1H), 2.87~2.75(m, 7H), 2.08(br, 1H), 1.79(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.42(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[779]

Example 59. (S)-quinuclidin-3-yl**(2,2-dimethyl-6-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[781] ¹H-NMR (400MHz, CDCl₃) δ 7.76(d, 1H), 7.56(m, 1H), 7.49(m, 1H), 7.34(m, 1H), 7.20(m, 3H), 5.03(m, 1H), 4.89(m, 1H), 4.79(m, 1H), 3.26(m, 1H), 2.88~2.71(m, 7H), 2.09(m, 1H), 1.81(br, 1H), 1.71(br, 1H), 1.58(br, 1H), 1.41(br, 1H), 1.33(d, 3H), 0.99(d, 3H)

[782]

Example 60. (S)-quinuclidin-3-yl (2,2-dimethyl-6-(p - tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[784] ¹H-NMR (400MHz, CDCl₃) δ 7.44(m, 4H), 7.26(m, 3H), 5.02(m, 1H), 4.88(m, 1H), 4.82(m, 1H), 3.29(m, 1H), 2.89~2.77(m, 7H), 2.41(s, 3H), 2.08(br, 1H), 1.85(br, 1H), 1.75(br, 1H), 1.61(br, 1H), 1.43(br, 1H), 1.31(d, 3H), 0.99(d, 3H)

[785]

Example 61.(S)-quinuclidin-3-yl**(6-(4-(difluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[787] ¹H-NMR (400MHz, CDCl₃) δ 7.58(m, 2H), 7.50(m, 2H), 7.25(m, 1H), 7.20(m, 2H), 6.75~6.38(t, 1H), 5.03(m, 1H), 4.89(m, 1H), 4.81(m, 1H), 3.31(m, 1H), 2.90(m, 2H), 2.78(m, 5H), 2.11(m, 1H), 1.87(m, 1H), 1.71(br, 1H), 1.61(br, 1H), 1.43(br, 1H), 1.31(d, 3H), 1.00(d, 3H)

[788]

Example 62. (S)-quinuclidin-3-yl**(6-(3,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[790] ¹H-NMR (400MHz, CDCl₃) δ 7.69(m, 1H), 7.50(m, 1H), 7.38(m, 3H), 7.21(m, 1H), 5.02(m, 1H), 4.89(m, 1H), 4.83(m, 1H), 3.30(m, 1H), 2.86(m, 2H), 2.78(m, 5H), 2.14(m, 1H), 1.87(br, 1H), 1.73(br, 1H), 1.61(br, 1H), 1.43(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[791]

[792] **Example 63. (S)-quinuclidin-3-yl**

(6-(2,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[793] ¹H-NMR (400MHz, CDCl₃) δ 7.48(m, 3H), 7.28(m, 1H), 6.94(m, 2H), 5.03(m, 1H), 4.90(m, 1H), 4.81(m, 1H), 3.28(m, 1H), 2.88(m, 3H), 2.78(m, 4H), 2.14(m, 1H), 1.87(br, 1H), 1.75(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[794]

[795] **Example 64.(S)-quinuclidin-3-yl**

(6-(2,3-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[796] ¹H-NMR (400MHz, CDCl₃) δ 7.49(m, 1H), 7.39(m, 2H), 7.16(m, 3H), 5.04(m, 1H), 4.91(m, 1H), 4.88(m, 1H), 3.29(m, 1H), 2.86(m, 2H), 2.79(m, 5H), 2.10(m, 1H), 1.85(br, 1H), 1.73(br, 1H), 1.59(br, 1H), 1.43(br, 1H), 1.35(d, 3H), 0.99(d, 3H)

[797]

[798] **Example 65. (S)-quinuclidin-3-yl**

(6-(2,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[799] ¹H-NMR (400MHz, CDCl₃) δ 7.60(m, 1H), 7.39(m, 2H), 7.13(m, 2H), 7.02(m, 1H), 5.03(m, 1H), 4.91(m, 1H), 4.81(m, 1H), 3.31(m, 1H), 2.86(m, 2H), 2.78(m, 5H), 2.14(m, 1H), 1.87(br, 1H), 1.75(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[800]

[801] **Example 66.(S)-quinuclidin-3-yl**

(6-(3,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[802] ¹H-NMR (400MHz, CDCl₃) δ 7.69~7.49(m, 1H), 7.42(m, 2H), 7.09(m, 2H), 6.79(m, 1H), 5.03(m, 1H), 4.90(m, 1H), 4.82(m, 1H), 3.31(m, 1H), 2.95(m, 2H), 2.78(m, 5H), 2.14(m, 1H), 1.86(br, 1H), 1.73(br, 1H), 1.61(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[803]

[804] **Example 67.(S)-quinuclidin-3-yl**

(2,2-dimethyl-6-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[805] ¹H-NMR (400MHz, CDCl₃) δ 7.34(m, 1H), 7.28(m, 2H), 7.13(m, 1H), 7.07(m, 1H), 5.03(m, 1H), 4.91(m, 1H), 4.80(m, 1H), 3.29(m, 1H), 2.88(m, 2H), 2.79(m, 5H), 2.10(m, 1H), 1.85(br, 1H), 1.70(m, 1H), 1.61(br, 1H), 1.42(br, 1H), 1.31(d, 3H), 1.00(d, 3H)

[806]

[807] **Example 68.(S)-quinuclidin-3-yl**

(2,2-dimethyl-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[808] ¹H-NMR (400MHz, CDCl₃) δ 7.34(m, 2H), 7.28(m, 2H), 7.04(m, 1H), 5.03(m, 1H), 4.90(m, 1H), 4.80(m, 1H), 3.28(m, 1H), 2.98(m, 2H), 2.78(m, 5H), 2.10(m, 1H),

1.85(br, 1H), 1.73(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.32(d, 3H), 0.98(d, 3H)

[809]

[810] **Example 69. (S)-quinuclidin-3-yl**

(6-(3,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[811] ¹H-NMR (400MHz, CDCl₃) δ 7.71(m, 1H), 7.66(m, 1H), 7.50(m, 1H), 7.45(m, 1H), 7.40(m, 1H), 7.33(m, 1H), 5.03(m, 1H), 4.89(m, 1H), 4.82(m, 1H), 3.30(m, 1H), 2.91~2.74(m, 7H), 2.14(m, 1H), 1.88(br, 1H), 1.72(br, 1H), 1.67(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[812]

[813] **Example 70.(S)-quinuclidin-3-yl**

(6-(3,4-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[814] ¹H-NMR (400MHz, CDCl₃) δ 7.69(m, 2H), 7.50(m, 2H), 7.39(m, 2H), 5.02(m, 1H), 4.89(m, 1H), 4.82(m, 1H), 3.31(m, 1H), 2.90(m, 2H), 2.78(m, 5H), 2.14(m, 1H), 1.87(br, 1H), 1.74(br, 1H), 1.62(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[815]

[816] **Example 71. (S)-quinuclidin-3-yl**

(6-(2,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[817] ¹H-NMR (400MHz, CDCl₃) δ 7.41(m, 1H), 7.39(m, 1H), 7.28(m, 4H), 5.01(m, 1H), 4.92(m, 1H), 4.80(m, 1H), 3.27(m, 1H), 2.78(m, 7H), 2.09(m, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.41(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[818]

[819] **Example 72. (S)-quinuclidin-3-yl**

**(6-(4-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbama
te**

[820] ¹H-NMR (400MHz, CDCl₃) δ 7.51(m, 2H), 7.40(m, 2H), 7.21(d, 1H), 6.99(m, 2H), 4.98(m, 1H), 4.84(m, 1H), 4.80(br, 1H), 4.17(m, 2H), 3.78(m, 2H), 3.47(s, 3H), 3.25(m, 1H), 2.88~2.71(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[821]

[822] **Examples 73 to 275**

[823] The titled compounds of Examples 73 to 275 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (5-bromo-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate prepared in Preparation 4; and the corresponding substituted-phenylboronic acids, respectively.

[824]

[825] **Example 73.(S)-quinuclidin-3-yl**

(5-(4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[826] ¹H-NMR (400MHz, CDCl₃) δ 7.53(m, 2H), 7.40(m, 2H), 7.30(m, 1H), 7.13(t, 2H),

5.00(m, 1H), 4.88(m, 1H), 4.83(m, 1H), 3.29(m, 1H), 2.91~2.86(m, 2H), 2.82~2.75(m, 5H), 2.12(br, 1H), 1.82(br, 1H), 1.72(br, 1H), 1.61(br, 1H), 1.44(br, 1H), 1.31(d, 3H), 0.99(d, 3H)

[827]

[828] **Example 74.(S)-quinuclidin-3-yl**

(5-(4-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[829] ¹H-NMR (400MHz, CDCl₃) δ 7.51(d, 2H), 7.41(d, 2H), 7.36(m, 2H), 7.31(m, 1H), 5.00(m, 1H), 4.90(m, 1H), 4.81(br, 1H), 3.31(m, 1H), 2.91~2.87(m, 2H), 2.82~2.75(m, 5H), 2.12(br, 1H), 1.86(br, 1H), 1.72(br, 1H), 1.61(br, 1H), 1.44(br, 1H), 1.31(d, 3H), 0.99(d, 3H)

[830]

[831] **Example 75.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[832] ¹H-NMR (400MHz, CDCl₃) δ 7.67(s, 4H), 7.46~7.44(m, 1H), 7.42(s, 1H), 7.35~7.27(m, 1H), 5.02(m, 1H), 4.89(m, 1H), 4.82(m, 1H), 3.29(m, 1H), 2.90~2.85(m, 2H), 2.81~2.77(m, 5H), 2.13(br, 1H), 1.83(br, 1H), 1.72(br, 1H), 1.62(br, 1H), 1.46(br, 1H), 1.33(d, 3H), 1.01(d, 3H)

[833]

[834] **Example 76.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[835] ¹H-NMR (400MHz, CDCl₃) δ 7.58(d, 2H), 7.42~7.37(m, 2H), 7.29(m, 3H), 5.01(m, 1H), 4.89(m, 1H), 4.82(m, 1H), 3.29(m, 1H), 2.90~2.87(m, 2H), 2.83~2.77(m, 5H), 2.12(br, 1H), 1.83(br, 1H), 1.73(br, 1H), 1.61(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[836]

[837] **Example 77.(S)-quinuclidin-3-yl**

(5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[838] ¹H-NMR (400MHz, CDCl₃) δ 7.44~7.37(m, 3H), 7.34(m, 1H), 7.31(m, 2H), 7.04(t, 1H), 5.01(m, 1H), 4.90(m, 1H), 4.81(m, 1H), 3.29(m, 1H), 2.89~2.87(m, 2H), 2.83~2.75(m, 5H), 2.11(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.61(br, 1H), 1.43(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[839]

[840] **Example 78. (S)-quinuclidin-3-yl**

(5-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[841] ¹H-NMR (400MHz, CDCl₃) δ 7.56(s, 1H), 7.45(m, 2H), 7.40(m, 2H), 7.34(m, 1H), 7.30(m, 1H), 5.01(m, 1H), 4.96(m, 1H), 4.81(m, 1H), 3.28(m, 1H), 2.89~2.86(m, 2H), 2.82~2.75(m, 5H), 2.11(br, 1H), 1.86(br, 1H), 1.72(br, 1H), 1.61(br, 1H), 1.43(br, 1H),

1.32(d, 3H), 0.99(d, 3H)

[842]

[843] **Example 79.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[844] ¹H-NMR (400MHz, CDCl₃) δ 7.82(s, 1H), 7.75(d, 1H), 7.60~7.56(m, 2H), 7.43(m, 2H), 7.35(m, 1H), 5.03(m, 1H), 4.92(m, 1H), 4.81(br, 1H), 3.29(m, 1H), 2.89~2.84(m, 2H), 2.81~2.77(m, 5H), 2.12(br, 1H), 1.84(br, 1H), 1.72(br, 1H), 1.61(br, 1H), 1.44(br, 1H), 1.33(d, 3H), 1.00(d, 3H)

[845]

[846] **Example 80.(S)-quinuclidin-3-yl**

(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[847] ¹H-NMR (400MHz, CDCl₃) δ 7.52~7.45(m, 1H), 7.41(m, 4H), 7.32(m, 1H), 7.20(d, 1H), 5.02(m, 1H), 4.89(m, 1H), 4.82(m, 1H), 3.28(m, 1H), 2.90~2.84(m, 2H), 2.79~2.76(m, 5H), 2.12(br, 1H), 1.82(br, 1H), 1.70(br, 1H), 1.61(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[848]

[849] **Example 81.(S)-quinuclidin-3-yl**

(5-(2-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[850] ¹H-NMR (400MHz, CDCl₃) δ 7.43~7.37(m, 3H), 7.33~7.28(m, 2H), 7.23(m, 1H), 7.18(m, 1H), 5.01(m, 1H), 4.91(m, 1H), 4.81(br, 1H), 3.30(m, 1H), 2.89~2.87(m, 2H), 2.83~2.76(m, 5H), 2.12(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.61(br, 1H), 1.43(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[851]

[852] **Example 82.(S)-quinuclidin-3-yl**

(5-(2-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[853] ¹H-NMR (400MHz, CDCl₃) δ 7.47(d, 1H), 7.33~7.25(m, 6H), 5.02(m, 1H), 4.94(m, 1H), 4.82(br, 1H), 3.28(m, 1H), 2.89~2.87(m, 2H), 2.83~2.75(m, 5H), 2.13(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.61(br, 1H), 1.43(br, 1H), 1.34(d, 3H), 1.00(d, 3H)

[854]

[855] **Example 83.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[856] ¹H-NMR (400MHz, CDCl₃) δ 7.74(d, 1H), 7.55(m, 1H), 7.48(m, 1H), 7.33(d, 1H), 7.27(m, 1H), 7.17(m, 1H), 7.14(s, 1H), 5.03(m, 2H), 4.82(br, 1H), 3.31(m, 1H), 2.89~2.85(m, 2H), 2.82~2.73(m, 5H), 2.11(br, 1H), 1.85(br, 1H), 1.71(br, 1H), 1.61(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[857]

[858] **Example 84.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[859] ¹H-NMR (400MHz, CDCl₃) δ 7.42(m, 1H), 7.36(m, 3H), 7.27(m, 3H), 5.03(m, 1H), 4.94(m, 1H), 4.82(m, 1H), 3.28(m, 1H), 2.90~2.87(m 2H), 2.83~2.75(m, 5H), 2.12(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.62(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[860]

[861] **Example 85.(S)-quinuclidin-3-yl (2,2-dimethyl-5-(p - tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[862] ¹H-NMR (400MHz, CDCl₃) δ 7.49(d, 2H), 7.42(m, 2H), 7.26(m, 3H), 5.00(m, 1H), 4.89(m, 1H), 4.80(m, 1H), 3.29(m, 1H), 2.89~2.85(m, 2H), 2.82~2.75(m, 5H), 2.41(s, 3H), 2.11(br, 1H), 1.82(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.44(br, 1H), 1.31(d, 3H), 1.00(d, 3H)

[863]

[864] **Example 86.(S)-quinuclidin-3-yl (5-(4-(difluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[865] ¹H-NMR (400MHz, CDCl₃) δ 7.56(d, 2H), 7.37(m, 2H), 7.32(m, 1H), 7.19(d, 2H), 6.75~6.38(t, 1H), 4.99(m, 1H), 2.90(m, 1H), 4.82(br, 1H), 3.29(m, 1H), 2.90~2.87(m, 2H), 2.83~2.79(m, 5H), 2.11(br, 1H), 1.82(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.44(br, 1H), 1.32(s, 3H), 0.99(d, 3H)

[866]

[867] **Example 87.(S)-quinuclidin-3-yl (5-(3,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[868] ¹H-NMR (400MHz, CDCl₃) δ 7.37(m, 3H), 7.29(m, 2H), 7.23(m, 1H), 5.01(m, 1H), 4.90(m, 1H), 4.82(m, 1H), 3.32(m, 1H), 2.89~2.86(m, 2H), 2.82~2.75(m, 5H), 2.11(m, 1H), 1.90(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.34(d, 3H), 0.99(d, 3H)

[869]

[870] **Example 88.(S)-quinuclidin-3-yl (5-(2,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[871] ¹H-NMR (400MHz, CDCl₃) δ 7.36(m, 3H), 7.12(m, 2H), 6.99(m, 1H), 5.02(m, 1H), 4.90(m, 1H), 4.80(m, 1H), 3.29(m, 1H), 2.89~2.87(m, 2H), 2.83~2.75(m, 5H), 2.11(m, 1H), 1.86(br, 1H), 1.72(br, 1H), 1.61(br, 1H), 1.43(br, 1H), 1.32(d, 3H), 1.00(d, 3H)

[872]

[873] **Example 89.(S)-quinuclidin-3-yl (5-(2,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[874] ¹H-NMR (400MHz, CDCl₃) δ 7.40(m, 1H), 7.35(m, 3H), 6.95(m, 2H), 5.01(m, 1H), 4.91(m, 1H), 4.80(m, 1H), 3.29(m, 1H), 2.89~2.86(m, 2H), 2.83~2.75(m, 5H), 2.11(m, 1H), 1.85(br, 1H), 1.75(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[875]

[876] **Example 90.(S)-quinuclidin-3-yl**

(5-(3,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[877] ¹H-NMR (400MHz, CDCl₃) δ 7.50(m, 3H), 7.10(m, 2H), 6.78((m, 1H), 5.02(m, 1H), 4.89(m, 1H), 4.81(m, 1H), 3.30(m, 1H), 2.90~2.87(m, 2H), 2.83~2.75(m, 5H), 2.12(m, 1H), 1.86(br, 1H), 1.75(br, 1H), 1.61(br, 1H), 1.45(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[878]

[879] **Example 91.(S)-quinuclidin-3-yl**

(5-(2,3-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[880] ¹H-NMR (400MHz, CDCl₃) δ 7.38~7.28(m, 3H), 7.16(m, 3H), 5.02(m, 1H), 4.91(m, 1H), 4.82(m, 1H), 3.30(m, 1H), 2.88(m, 2H), 2.83~2.76(m, 5H), 2.12(m, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[881]

[882] **Example 92.(S)-quinuclidin-3-yl**

(5-(3,4-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[883] ¹H-NMR (400MHz, CDCl₃) δ 7.71(m, 2H), 7.56(m, 1H), 7.48(m, 2H), 7.39(m, 1H), 5.03(m, 1H), 4.86(m, 2H), 3.31(m, 1H), 2.91(m, 2H), 2.86~2.78(m, 5H), 2.13(m, 1H), 1.86(br, 1H), 1.75(br, 1H), 1.68(br, 1H), 1.46(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[884]

[885] **Example 93.(S)-quinuclidin-3-yl**

(5-(2,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[886] ¹H-NMR (400MHz, CDCl₃) δ 7.41(d, 1H), 7.33~7.23(m, 5H), 5.03(m, 1H), 4.94(m, 1H), 4.82(m, 1H), 3.28(m, 1H), 2.90~2.87(m, 2H), 2.83~2.75(m, 5H), 2.11(m, 1H), 1.85(br, 1H), 1.71(br, 1H), 1.61(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[887]

[888] **Example 94.(S)-quinuclidin-3-yl**

(5-(3,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[889] ¹H-NMR (400MHz, CDCl₃) δ 7.50(m, 1H), 7.45(m, 1H), 7.39(s, 2H), 7.35(d, 2H), 5.02(m, 1H), 4.87(m, 2H), 3.30(m, 1H), 2.90~2.82(m, 2H), 2.83~2.79(m, 5H), 2.13(br, 1H), 2.06(br, 1H), 1.88(br, 1H), 1.69(br, 1H), 1.48(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[890]

[891] **Example 95.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[892] ¹H-NMR (400MHz, CDCl₃) δ 7.31(m, 3H), 7.13(m, 1H), 7.06(m, 1H), 5.02(m, 1H), 4.90(m, 1H), 4.83(m, 1H), 3.30(m, 1H), 2.94~2.88(m, 2H), 2.83~2.76(m, 5H), 2.12(m, 1H), 1.87(br, 1H), 1.73(m, 1H), 1.61(br, 1H), 1.47(br, 1H), 1.31(d, 3H), 1.00(d, 3H)

[893]

[894] **Example 96.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[895] ¹H-NMR (400MHz, CDCl₃) δ 7.32(m, 3H), 7.23(m, 1H), 7.03(m, 1H), 5.02(m, 1H), 4.89(m, 1H), 4.81(m, 1H), 3.32(m, 1H), 2.91~2.87(m, 2H), 2.83~2.75(m, 5H), 2.11(m, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.61(br, 1H), 1.44(br, 1H), 1.32(d, 3H), 0.99(d, 3H)

[896]

Example 97.(S)-quinuclidin-3-yl**(5-(4-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[898] ¹H-NMR (400MHz, CDCl₃) δ 7.49(d, 2H), 7.39(m, 1H), 7.36(s, 1H), 7.27(m, 1H), 7.00(d, 2H), 4.98(m, 1H), 4.84(m, 1H), 4.80(br, 1H), 4.18(m, 2H), 3.78(m, 2H), 3.48(s, 3H), 3.25(m, 1H), 2.90~2.75(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[899]

Example 98. (S)-quinuclidin-3-yl**(5-(3-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[901] ¹H-NMR (400MHz, CDCl₃) δ 7.42(m, 1H), 7.36(s, 1H), 7.31~7.27(m, 2H), 7.18(m, 2H), 6.91(d, 1H), 4.99(m, 1H), 4.84~4.80(m, 2H), 4.18(m, 2H), 3.79(m, 2H), 3.48(s, 3H), 3.25(m, 1H), 2.90~2.75(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[902]

Example 99.(S)-quinuclidin-3-yl**(5-(2-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[904] ¹H-NMR (400MHz, CDCl₃) δ 7.40(m, 2H), 7.32~7.27(m, 3H), 7.04~7.98(m, 2H), 4.99(m, 1H), 4.84(m, 1H), 4.80(m, 1H), 4.10(m, 2H), 3.68(m, 2H), 3.38(s, 3H), 3.25(m, 1H), 2.90~2.75(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[905]

Example 100.(S)-quinuclidin-3-yl**(5-(4-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[907] ¹H-NMR (400MHz, CDCl₃) δ 7.51(d, 2H), 7.38(m, 1H), 7.35(s, 1H), 7.27(m, 1H), 7.10(d, 2H), 5.22(s, 2H), 4.99(m, 1H), 4.84(m, 1H), 4.80(m, 1H), 3.31(s, 3H), 3.25(m, 1H), 2.90~2.75(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[908]

Example 101.(S)-quinuclidin-3-yl

(5-(3-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[910] ¹H-NMR (400MHz, MeOD) δ 7.41(m, 2H), 7.28(m, 1H), 7.26(m, 1H), 7.05(d, 1H), 7.00(s, 1H), 6.75(d, 1H), 5.07(br, 1H), 4.87(s, 2H), 3.72(m, 1H), 3.67(s, 3H), 3.39(m, 2H), 3.39~3.29(m, 5H), 2.81(s, 2H), 2.45(m, 1H), 2.30(br, 1H), 2.10(br, 1H), 1.93(br, 1H), 1.24(d, 3H), 0.98(d, 3H)

[911]

[912] **Example 102.(S)-quinuclidin-3-yl**

(5-(2-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[913] ¹H-NMR (400MHz, CDCl₃) δ 7.39(m, 1H), 7.35(m, 4H), 7.21(m, 1H), 7.09(m, 1H), 5.12(s, 2H), 4.99(m, 1H), 4.84(m, 1H), 4.80(m, 1H), 3.41(s, 3H), 3.25(m, 1H), 2.90~2.75(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[914]

[915] **Example 103.(S)-quinuclidin-3-yl**

(5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[916] ¹H-NMR (400MHz, CDCl₃) δ 7.44(m, 1H), 7.39(s, 1H), 7.31~7.27(m, 2H), 7.15(d, 1H), 7.10(s, 1H), 6.89(d, 1H), 4.98(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 3.87(s, 3H), 3.25(m, 1H), 2.90~2.74(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[917]

[918] **Example 104.(S)-quinuclidin-3-yl**

(5-(3-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[919] ¹H-NMR (400MHz, CDCl₃) δ 7.44(m, 1H), 7.39(s, 1H), 7.31~7.27(m, 2H), 7.15(d, 1H), 7.10(s, 1H), 6.89(d, 1H), 4.98(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 4.11(m, 2H), 3.25(m, 1H), 2.90~2.74(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.45(t, 4H), 1.29(m, 3H), 0.98(m, 3H)

[920]

[921] **Example 105.(S)-quinuclidin-3-yl**

(5-(3-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[922] ¹H-NMR (400MHz, CDCl₃) δ 7.43(m, 1H), 7.39(s, 1H), 7.35~7.27(m, 2H), 7.14(d, 1H), 7.10(s, 1H), 6.88(d, 1H), 5.00(m, 1H), 4.85(m, 1H), 4.80(br, 1H), 4.62(m, 1H), 3.25(m, 1H), 2.90~2.74(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.38(d, 6H), 1.29(m, 3H), 0.98(m, 3H)

[923]

[924] **Example 106.(S)-quinuclidin-3-yl**

(5-(3-(dimethylamino)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[925] ¹H-NMR (400MHz, CDCl₃) δ 7.44(m, 1H), 7.40(s, 1H), 7.32~7.27(m, 2H), 6.91(m, 2H), 6.74(d, 1H), 4.99(m, 1H), 4.86(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 3.01(s, 6H), 2.92~2.75(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.97(m, 3H)

[926]

[927] **Example 107.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(3-(methylthio)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[928] ¹H-NMR (400MHz, CDCl₃) δ 7.45(s, 1H), 7.41~7.23(m, 6H), 4.99(m, 1H), 4.87(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.92~2.75(m, 7H), 2.54(s, 3H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.31(m, 3H), 0.98(m, 3H)

[929]

[930] **Example 108.(S)-quinuclidin-3-yl**

(5-(3-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[931] ¹H-NMR (400MHz, CDCl₃) δ 7.45(d, 1H), 7.42(s, 2H), 7.40~7.28(m, 3H), 7.19(d, 1H), 5.00(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.92~2.75(m, 7H), 2.70(m, 2H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.31(t, 3H), 1.29(m, 3H), 0.98(m, 3H)

[932]

[933] **Example 109.(S)-quinuclidin-3-yl**

(5-(3-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[934] ¹H-NMR (400MHz, CDCl₃) δ 7.43~7.34(m, 5H), 7.28(m, 1H), 7.22(d, 1H), 5.00(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.98(m, 1H), 2.92~2.75(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 9H), 0.98(m, 3H)

[935]

[936] **Example 110.(S)-quinuclidin-3-yl (5-(3-(tert -**

butyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[937] ¹H-NMR (400MHz, CDCl₃) δ 7.58(s, 1H), 7.44(d, 1H), 7.38(s, 4H), 7.28(m, 1H), 5.00(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 3.25(m, 1H), 2.92~2.75(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.38(s, 9H), 1.29(m, 3H), 0.98(m, 3H)

[938]

[939] **Example 111.(S)-quinuclidin-3-yl**

(5-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[940] ¹H-NMR (400MHz, CDCl₃) δ 7.34~7.27(m, 3H), 7.25(m, 2H), 7.10(d, 1H), 5.00(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 3.25(m, 1H), 2.92~2.75(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[941]

- [942] **Example 112.(S)-quinuclidin-3-yl**
(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate
- [943] ¹H-NMR (400MHz, CDCl₃) δ 7.38(m, 1H), 7.36(s, 1H), 7.25(m, 1H), 7.09(s, 1H), 7.05(d, 1H), 6.91(d, 1H), 4.98(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 4.29(s, 4H), 3.25(m, 1H), 2.92~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.29(m, 3H), 0.97(m, 3H)
- [944]
- [945] **Example 113.(S)-quinuclidin-3-yl**
(5-(2,3-dihydrobenzofuran-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
- [946] ¹H-NMR (400MHz, CDCl₃) δ 7.41(s, 1H), 7.36~7.30(m, 3H), 7.25(m, 1H), 6.84(d, 1H), 4.98(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 4.62(t, 2H), 3.25(m, 3H), 2.92~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.29(m, 3H), 0.97(m, 3H)
- [947]
- [948] **Example 114.(S)-quinuclidin-3-yl**
(2,2-dimethyl-5-(3-(2-morpholinoethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate
- [949] ¹H-NMR (400MHz, CDCl₃) δ 7.43(d, 1H), 7.39(s, 1H), 7.38~7.30(m, 2H), 7.17(d, 1H), 7.11(s, 1H), 6.89(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 4.19(t, 2H), 3.75(m, 4H), 3.25(m, 3H), 2.92~2.73(m, 9H), 2.60(m, 4H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)
- [950]
- [951] **Example 115.(S)-quinuclidin-3-yl**
(5-(4-(2-fluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
- [952] ¹H-NMR (400MHz, CDCl₃) δ 7.52(d, 2H), 7.35(m, 2H), 7.26(m, 1H), 7.00(d, 2H), 4.99(m, 1H), 4.87(m, 2H), 4.81(m, 1H), 4.71(br, 1H), 4.31~4.22(m, 2H), 3.25(m, 3H), 2.90~2.74(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.59(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)
- [953]
- [954] **Example 116.(S)-quinuclidin-3-yl**
(2,2-dimethyl-5-(4-(2,2,2-trifluoroethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate
- [955] ¹H-NMR (400MHz, CDCl₃) δ 7.43~7.36(m, 3H), 7.31~7.25(m, 2H), 7.15(s, 1H), 6.91(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 4.42(q, 2H), 3.25(m, 3H), 2.92~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[956]

[957] **Example 117.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(4-(2-morpholinoethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[958] ¹H-NMR (400MHz, CDCl₃) δ 7.50(d, 2H), 7.39(m, 2H), 7.24(m, 1H), 6.97(d, 2H), 4.98(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 4.16(t, 2H), 3.76(m, 4H), 3.25(m, 3H), 2.92~2.73(m, 9H), 2.60(m, 4H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[959]

[960] **Example 118.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(2-(trifluoromethyl)pyridin-4-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[961] ¹H-NMR (400MHz, CDCl₃) δ 8.76(d, 1H), 7.87(s, 1H), 7.67(d, 1H), 7.49(m, 2H), 7.37(m, 1H), 5.00(m, 1H), 4.93(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.92~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.31(m, 3H), 0.98(m, 3H)

[962]

[963] **Example 119.(S)-quinuclidin-3-yl**

(5-(2,5-dichloropyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[964] ¹H-NMR (400MHz, CDCl₃) δ 8.44(s, 1H), 7.30(m, 1H), 7.19(m, 3H), 4.96(m, 1H), 4.86(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.92~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.31(m, 3H), 0.98(m, 3H)

[965]

[966] **Example 120. (S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[967] ¹H-NMR (400MHz, CDCl₃) δ 7.39(m, 1H), 7.33(s, 1H), 7.25(m, 1H), 7.07(d, 1H), 7.03(s, 1H), 6.72(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 4.33(m, 2H), 3.29(m, 2H), 3.25(m, 1H), 2.92(s, 3H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[968]

[969] **Example 121.(S)-quinuclidin-3-yl**

(5-(2-chloro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.36(d, 1H), 7.28(m, 3H), 6.86(m, 1H), 6.81(m, 1H), 5.00(m, 2H), 4.80(br, 1H), 3.81(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.31(m, 3H), 0.99(m, 3H)

[970]

[971] **Example 122.(S)-quinuclidin-3-yl**

(5-(3-chloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
¹H-NMR (400MHz, CDCl₃) δ 7.59(d, 1H), 7.44(d, 1H), 7.37(m, 1H), 7.25(m, 1H), 6.98(d, 1H), 4.98(m, 2H), 4.80(br, 1H), 3.94(s, 3H), 3.25(m, 1H), 2.88~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.31(m, 3H), 0.98(m, 3H)

[972]

[973] **Example 123.(S)-quinuclidin-3-yl**

(5-(2-chloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
¹H-NMR (400MHz, CDCl₃) δ 7.24(m, 1H), 7.22(m, 3H), 7.01(s, 1H), 6.85(d, 1H), 4.99(s, 2H), 4.79(br, 1H), 3.84(s, 3H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.31(m, 3H), 0.97(m, 3H)

[974]

[975] **Example 124.(S)-quinuclidin-3-yl**

(5-(2-chloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
¹H-NMR (400MHz, CDCl₃) δ 7.31~7.22(m, 4H), 6.94(d, 2H), 4.99(s, 2H), 4.79(br, 1H), 3.95(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.31(m, 3H), 0.98(m, 3H)

[976]

[977] **Example 125.(S)-quinuclidin-3-yl**

(5-(4-chloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
¹H-NMR (400MHz, CDCl₃) δ 7.41~7.37(m, 3H), 7.27(m, 1H), 7.08(m, 2H), 5.00(m, 1H), 4.91(m, 1H), 4.80(br, 1H), 3.97(s, 3H), 3.25(m, 1H), 2.91~2.75(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[978]

[979] **Example 126.(S)-quinuclidin-3-yl**

(5-(2,3-dichloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[980] ¹H-NMR (400MHz, CDCl₃) δ 7.27(m, 1H), 7.21(m, 1H), 7.19(d, 2H), 6.90(d, 1H), 5.00(s, 2H), 4.80(br, 1H), 3.95(s, 3H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[981]

[982] **Example 127.(S)-quinuclidin-3-yl**

(5-(3-chloro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[983] ¹H-NMR (400MHz, CDCl₃) δ 7.59(s, 1H), 7.39(m, 2H), 7.33(s, 1H), 7.26(m, 1H), 7.00(d, 1H), 4.96(m, 2H), 4.79(br, 1H), 4.60(m, 1H), 3.25(m, 1H), 2.88~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.38(d, 6H), 1.30(m, 3H), 0.97(m, 3H)

[984]

[985] **Example 128.(S)-quinuclidin-3-yl**

(5-(2-fluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.35~7.27(m, 4H), 6.77(d, 1H), 6.69(d, 1H), 4.97(m, 2H), 4.80(br, 1H), 3.84(s, 3H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.38(d, 6H), 1.30(m, 3H), 0.98(m, 3H)

[986]

[987] **Example 129.(S)-quinuclidin-3-yl**

(5-(3-(dimethylamino)-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[988] ¹H-NMR (400MHz, CDCl₃) δ 7.39(m, 1H), 7.30(s, 1H), 7.25(m, 1H), 7.09(s, 1H), 7.04(m, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.90(s, 6H), 2.89~2.74(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.38(d, 6H), 1.30(m, 3H), 0.98(m, 3H)

[989]

[990] **Example 130.(S)-quinuclidin-3-yl**

(5-(chroman-6-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[991] ¹H-NMR (400MHz, CDCl₃) δ 7.37(m, 1H), 7.33(s, 1H), 7.25(m, 3H), 6.85(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 4.23(m, 2H), 3.25(m, 1H), 2.89~2.74(m, 9H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[992]

[993] **Example 131.(S)-quinuclidin-3-yl**

(5-(4-cyclopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[994] ¹H-NMR (400MHz, CDCl₃) δ 7.47(d, 2H), 7.42(m, 1H), 7.38(s, 1H), 7.25(m, 1H), 7.13(d, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.89~2.74(m, 7H), 2.10(br, 1H), 1.91(m, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 6H), 0.74(m, 2H)

[995]

[996] **Example 132.(S)-quinuclidin-3-yl**

(5-(4-(dimethylamino)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.48(d, 2H), 7.39(m, 1H), 7.36(s, 1H), 7.21(m, 2H), 6.80(d, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 3.00(s, 6H), 2.89~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[997]

[998] **Example 133.(S)-quinuclidin-3-yl**

(5-(4-ethoxy-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[999] ¹H-NMR (400MHz, CDCl₃) δ 7.38~7.32(m, 2H), 7.27(m, 3H), 6.99(t, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 4.15(m, 2H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.48(t, 3H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1000]

[1001] **Example 134.(S)-quinuclidin-3-yl**
(5-(4-methoxy-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1002] ¹H-NMR (400MHz, CDCl₃) δ 7.76(s, 1H), 7.69(d, 1H), 7.31(m, 2H), 7.27(m, 1H), 7.07(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 4.95(s, 3H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 0.98(m, 3H)

[1003]

[1004] **Example 135.(S)-quinuclidin-3-yl**
(2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1005] ¹H-NMR (400MHz, CDCl₃) δ 7.50(d, 2H), 7.38(m, 1H), 7.35(s, 1H), 7.26(m, 1H), 6.96(d, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 3.96(q, 2H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.84(m, 2H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 1.06(t, 3H), 0.98(m, 3H)

[1006]

[1007] **Example 136.(S)-quinuclidin-3-yl**
(5-(4-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1008] ¹H-NMR (400MHz, CDCl₃) δ 7.50(d, 2H), 7.39(m, 1H), 7.36(s, 1H), 7.26(m, 1H), 6.96(d, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 3.77(d, 2H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.10(m, 2H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 1.05(d, 6H), 0.98(m, 3H)

[1009]

[1010] **Example 137.(S)-quinuclidin-3-yl**
(2,2-dimethyl-5-(thiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1011] ¹H-NMR (400MHz, CDCl₃) δ 7.46~7.41(m, 3H), 7.38(m, 2H), 7.21(m, 1H), 4.98(m, 1H), 4.87(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 0.98(m, 3H)

[1012]

[1013] **Example 138.(S)-quinuclidin-3-yl**
(2,2-dimethyl-5-(4-methylthiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate¹H-NMR (400MHz, CDCl₃) δ 7.28~7.16(m, 4H), 7.02(s, 1H), 4.99(m, 1H), 4.87(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.26(s, 3H), 2.89~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 0.98(m, 3H)

[1014]

[1015] **Example 139.(S)-quinuclidin-3-yl**

(5-(3-(2-(dimethylamino)ethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate

[1016] ¹H-NMR (400MHz, CDCl₃) δ 7.28(m, 1H), 7.24(m, 4H), 6.94(m, 2H), 4.99(m, 1H), 4.87(m, 1H), 4.80(br, 1H), 4.07(m, 2H), 3.25(m, 1H), 2.89~2.73(m, 9H), 2.35(s, 6H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 0.98(m, 3H)

[1017]

[1018] **Example 140.(S)-quinuclidin-3-yl**

(5-(isoquinolin-8-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1019] ¹H-NMR (400MHz, CDCl₃) δ 9.31(s, 1H), 8.51(d, 1H), 7.82(d, 1H), 7.72(m, 2H), 7.52(d, 1H), 7.36(m, 3H), 5.24(m, 1H), 5.07(m, 1H), 4.81(m, 1H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.35(m, 3H), 0.98(m, 3H)

[1020]

[1021] **Example 141.(S)-quinuclidin-3-yl**

(5-(isoquinolin-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1022] ¹H-NMR (400MHz, CDCl₃) δ 9.31(s, 1H), 8.47(d, 1H), 7.99(d, 1H), 7.71(d, 1H), 7.65(m, 2H), 7.39~7.27(m, 3H), 5.05(m, 2H), 4.82(m, 1H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.34(m, 3H), 0.98(m, 3H)

[1023]

[1024] **Example 142.(S)-quinuclidin-3-yl**

(5-(isoquinolin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1025] ¹H-NMR (400MHz, CDCl₃) δ 9.25(s, 1H), 8.44(s, 1H), 8.04(d, 1H), 7.91(d, 1H), 7.65(m, 2H), 7.38(m, 3H), 5.09(m, 2H), 4.82(m, 1H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.35(m, 3H), 0.99(m, 3H)

[1026]

[1027] **Example 143.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(quinolin-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1028] ¹H-NMR (400MHz, CDCl₃) δ 9.16(s, 1H), 8.30(s, 1H), 8.14(d, 1H), 7.88(d, 1H), 7.72(m, 1H), 7.61~7.53(m, 3H), 7.39(m, 1H), 5.05~4.94(m, 2H), 4.82(m, 1H), 3.25(m, 1H), 2.91~2.77(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.34(m, 3H), 1.00(m, 3H)

[1029]

[1030] **Example 144.(S)-quinuclidin-3-yl**

(5-(4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1031] ¹H-NMR (400MHz, CDCl₃) δ 7.48(d, 1H), 7.37(m, 1H), 7.35(s, 1H), 7.25(m, 1H), 6.95(d, 2H), 4.98(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 4.61(m, 1H), 3.25(m, 1H), 2.89~2.74(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.36(d, 6H), 1.30(m, 3H), 0.98(m, 3H)

[1032]

Example 145.(S)-quinuclidin-3-yl**(5-(2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1034] ¹H-NMR (400MHz, CDCl₃) δ 7.42(m, 1H), 7.36(s, 1H), 7.30~7.21(m, 3H), 7.01(m, 2H), 4.98(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 4.42(m, 1H), 3.25(m, 1H), 2.91~2.72(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.29(m, 3H), 1.26(d, 6H), 0.98(m, 3H)

[1035]

Example 146.(S)-quinuclidin-3-yl (5-(4-(tert - butyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1037] ¹H-NMR (400MHz, CDCl₃) δ 7.53(m, 2H), 7.47(m, 2H), 7.26(m, 2H), 7.24(m, 1H), 4.98(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.91~2.72(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.36(s, 9H), 1.29(m, 3H), 0.98(m, 3H)

[1038]

Example 147.(S)-quinuclidin-3-yl**(5-(4-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1040] ¹H-NMR (400MHz, CDCl₃) δ 7.50(d, 2H), 7.43(m, 1H), 7.38(s, 1H), 7.27(m, 3H), 4.98(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.91~2.72(m, 7H), 2.69(m, 2H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 6H), 0.98(m, 3H)

[1041]

Example 148.(S)-quinuclidin-3-yl**(2,2-dimethyl-5-(4-morpholinophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[1043] ¹H-NMR (400MHz, CDCl₃) δ 7.51(d, 2H), 7.39(m, 1H), 7.36(s, 1H), 7.27(m, 1H), 6.97(d, 2H), 4.98(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 3.89(m, 4H), 3.25(m, 1H), 3.21(m, 4H), 2.91~2.72(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1044]

Example 149.(S)-quinuclidin-3-yl**(5-(4-(methoxymethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

¹H-NMR (400MHz, CDCl₃) δ 7.56(d, 2H), 7.42(m, 4H), 7.27(m, 1H), 4.98(m, 1H), 4.88(m, 1H), 4.80(br, 1H), 4.50(s, 2H), 3.42(s, 3H), 3.25(m, 1H), 2.89~2.74(m, 7H),

2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.29(m, 3H), 0.98(m, 3H)

[1046]

[1047] **Example 150.(S)-quinuclidin-3-yl**

(5-(4-(2,2-difluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1048] ¹H-NMR (400MHz, CDCl₃) δ 7.53(d, 2H), 7.39(m, 2H), 7.27(m, 1H), 6.99(d, 2H), 6.25~5.98(t, 1H), 4.98(m, 2H), 4.79(br, 1H), 4.21(m, 2H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.29(m, 3H), 0.97(m, 3H)

[1049]

[1050] **Example 151.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(3-methyl-4-morpholinophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1051] ¹H-NMR (400MHz, CDCl₃) δ 7.40~7.36(m, 4H), 7.24(m, 1H), 7.07(d, 1H), 4.95(m, 2H), 4.78(br, 1H), 3.89(m, 4H), 3.25(m, 1H), 2.95(m, 4H), 2.91~2.73(m, 7H), 2.38(s, 3H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1052]

[1053] **Example 152.(S)-quinuclidin-3-yl**

(5-(3-fluoro-4-morpholinophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1054] ¹H-NMR (400MHz, CDCl₃) δ 7.34(m, 2H), 7.26(m, 2H), 7.23(m, 1H), 6.98(t, 1H), 4.96(m, 1H), 4.91(br, 1H), 4.78(br, 1H), 3.90(m, 4H), 3.25(m, 1H), 3.14(m, 4H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1055]

[1056] **Example 153.(S)-quinuclidin-3-yl**

(5-(3-chloro-4-morpholinophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1057] ¹H-NMR (400MHz, CDCl₃) δ 7.60(s, 1H), 7.45(d, 1H), 7.36(m, 2H), 7.26(m, 1H), 7.10(d, 1H), 4.99(m, 1H), 4.91(br, 1H), 4.78(br, 1H), 3.90(m, 4H), 3.25(m, 1H), 3.09(m, 4H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1058]

[1059] **Example 154.(S)-quinuclidin-3-yl**

(5-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1060] ¹H-NMR (400MHz, CDCl₃) δ 7.37(m, 1H), 7.34(s, 1H), 7.24(m, 1H), 7.20(s, 1H), 7.15(d, 1H), 7.02(d, 1H), 4.99(m, 1H), 4.91(br, 1H), 4.78(br, 1H), 4.23(m, 4H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.22(m, 2H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.29(m, 3H), 0.97(m, 3H)

[1061]

[1062] **Example 155.(S)-quinuclidin-3-yl**

(5-(3-(difluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.71(m, 2H), 7.54(m, 2H), 7.41(m, 2H), 7.30(m, 1H), 6.85~6.57(t, 1H), 5.01(m, 1H), 4.92(br, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.29(m, 3H), 0.97(m, 3H)

[1063]

[1064] **Example 156.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(quinolin-8-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1065] ¹H-NMR (400MHz, CDCl₃) δ 8.96(m, 1H), 8.22(d, 1H), 7.84(d, 1H), 7.72(m, 1H), 7.62(d, 1H), 7.58(m, 1H), 7.50(s, 1H), 7.44(d, 1H), 7.35(d, 1H), 5.00(m, 1H), 4.92(br, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.28(m, 3H), 0.95(m, 3H)

[1066]

[1067] **Example 157.(S)-quinuclidin-3-yl**

(5-(benzofuran-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1068] ¹H-NMR (400MHz, CDCl₃) δ 7.84(d, 1H), 7.78(s, 1H), 7.55(d, 1H), 7.49(m, 1H), 7.45(s, 1H), 7.34(m, 3H), 5.02(m, 1H), 4.92(br, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.32(m, 3H), 0.97(m, 3H)

[1069]

[1070] **Example 158.(S)-quinuclidin-3-yl**

(5-(benzofuran-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1071] ¹H-NMR (400MHz, CDCl₃) δ 7.73(d, 1H), 7.71(s, 1H), 7.59(d, 1H), 7.53(d, 1H), 7.26(m, 3H), 5.02(m, 1H), 4.92(br, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 0.97(m, 3H)

[1072]

[1073] **Example 159.(S)-quinuclidin-3-yl**

(5-(4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1074] ¹H-NMR (400MHz, CDCl₃) δ 7.50(d, 2H), 7.38(m, 1H), 7.35(s, 1H), 7.26(m, 1H), 6.97(d, 2H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.85(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H),

1.30(m, 3H), 0.98(m, 3H)

[1075]

[1076] **Example 160.(S)-quinuclidin-3-yl**

(5-(4-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1077] ¹H-NMR (400MHz, CDCl₃) δ 7.50(d, 2H), 7.38(m, 1H), 7.35(s, 1H), 7.26(m, 1H), 6.95(d, 2H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 4.08(m, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.42(t, 3H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1078]

[1079] **Example 161.(S)-quinuclidin-3-yl**

(5-(4-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1080] ¹H-NMR (400MHz, CDCl₃) δ 7.50(d, 2H), 7.44(m, 1H), 7.39(s, 1H), 7.26(m, 1H), 7.20(d, 2H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.51(d, 2H), 2.10(br, 1H), 1.90(m, 1H), 1.87(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H), 0.93(d, 6H)

[1081]

[1082] **Example 162.(S)-quinuclidin-3-yl**

(5-(2,4-dichloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1083] ¹H-NMR (400MHz, CDCl₃) δ 7.34(d, 2H), 7.26(m, 2H), 7.20(s, 1H), 7.02(d, 1H), 4.99(m, 2H), 4.79(br, 1H), 3.94(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.87(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1084]

[1085] **Example 163.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1086] ¹H-NMR (400MHz, CDCl₃) δ 7.50(d, 2H), 7.42(m, 1H), 7.39(s, 1H), 7.25(m, 3H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.61(m, 2H), 2.10(br, 1H), 1.87(br, 1H), 1.67(m, 3H), 1.59(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 6H)

[1087]

[1088] **Example 164.(S)-quinuclidin-3-yl**

(5-(4-butylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1089] ¹H-NMR (400MHz, CDCl₃) δ 7.50(d, 2H), 7.42(m, 1H), 7.39(s, 1H), 7.25(m, 3H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.65(m, 2H), 2.10(br, 1H), 1.87(br, 1H), 1.70(br, 1H), 1.64(m, 3H), 1.40(m, 3H), 1.30(m, 3H), 0.98(m, 6H)

[1090]

[1091] **Example 165.(S)-quinuclidin-3-yl**

(5-(2,3-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1092] ¹H-NMR (400MHz, CDCl₃) δ 7.38(m, 1H), 7.36(s, 1H), 7.23(m, 1H), 7.10(m, 1H), 6.92(d, 2H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.91(s, 3H), 3.58(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.87(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1093]

Example 166.(S)-quinuclidin-3-yl**(5-(2,4-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1095] ¹H-NMR (400MHz, CDCl₃) δ 7.35(m, 1H), 7.33(s, 1H), 7.23(m, 1H), 7.20(d, 2H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.85(s, 3H), 3.80(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.87(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1096]

Example 167.(S)-quinuclidin-3-yl**(5-(2,5-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1098] ¹H-NMR (400MHz, CDCl₃) δ 7.39(m, 1H), 7.33(s, 1H), 7.26(m, 1H), 6.87(m, 3H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.81(s, 3H), 3.76(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.87(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1099]

Example 168.(S)-quinuclidin-3-yl**(5-(2,6-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1101] ¹H-NMR (400MHz, CDCl₃) δ 7.26(m, 2H), 7.19(m, 1H), 7.15(s, 1H), 6.65(d, 2H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.71(s, 6H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.87(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1102]

Example 169.(S)-quinuclidin-3-yl**(5-(3,5-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1104] ¹H-NMR (400MHz, CDCl₃) δ 7.43(m, 1H), 7.38(s, 1H), 7.26(m, 1H), 6.71(s, 2H), 6.46(s, 1H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.85(s, 6H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.87(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1105]

Example 170.(S)-quinuclidin-3-yl**(5-(4-ethoxy-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1107] ¹H-NMR (400MHz, CDCl₃) δ 7.75(s, 1H), 7.66(d, 1H), 7.34(m, 2H), 7.26(m, 1H),

7.04(d, 1H), 5.00(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 4.16(m, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.87(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.45(t, 3H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1108]

[1109] **Example 171.(S)-quinuclidin-3-yl**

(5-(2,5-difluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1110] ¹H-NMR (400MHz, CDCl₃) δ 7.32(m, 3H), 7.16(m, 1H), 6.78(m, 1H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.91(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.87(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1111]

[1112] **Example 172.(S)-quinuclidin-3-yl**

(5-(2-fluoro-5-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1113] ¹H-NMR (400MHz, CDCl₃) δ 7.37(m, 2H), 7.26(m, 1H), 7.04(t, 1H), 6.91(m, 1H), 6.80(m, 1H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 4.51(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.87(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.33(d, 6H), 1.30(m, 3H), 0.98(m, 3H)

[1114]

[1115] **Example 173.(S)-quinuclidin-3-yl**

(5-(3,5-dimethyl-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1116] ¹H-NMR (400MHz, CDCl₃) δ 7.39(m, 1H), 7.35(s, 1H), 7.25(m, 1H), 7.21(s, 2H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.78(t, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.34(s, 6H), 2.10(br, 1H), 1.85(m, 3H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 1.10(t, 3H), 0.98(m, 3H)

[1117]

[1118] **Example 174.(S)-quinuclidin-3-yl**

(5-(4-ethoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1119] ¹H-NMR (400MHz, CDCl₃) δ 7.39(m, 1H), 7.35(s, 1H), 7.25(m, 1H), 7.22(s, 2H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.91(q, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.34(s, 6H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.44(t, 3H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1120]

[1121] **Example 175.(S)-quinuclidin-3-yl**

(5-(2-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1122] ¹H-NMR (400MHz, CDCl₃) δ 7.31(d, 2H), 7.25(m, 2H), 7.18(m, 2H), 7.11(s, 1H),

4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 4.12(q, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 1.10(t, 3H), 0.98(m, 3H)

[1123]

[1124] **Example 176.(S)-quinuclidin-3-yl**

(5-(2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1125] ¹H-NMR (400MHz, CDCl₃) δ 7.39(m, 1H), 7.37~7.25(m, 4H), 7.04~6.78(m, 2H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.82(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1126]

[1127] **Example 177.(S)-quinuclidin-3-yl**

(5-(2-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1128] ¹H-NMR (400MHz, CDCl₃) δ 7.43(m, 1H), 7.35(s, 1H), 7.32~7.23(m, 3H), 7.03~6.96(m, 2H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 4.05(q, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.37(t, 3H), 1.30(m, 3H), 0.98(m, 3H)

[1129]

[1130] **Example 178.(S)-quinuclidin-3-yl**

(5-(2-chloro-5-(trifluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1131] ¹H-NMR (400MHz, CDCl₃) δ 7.48(d, 1H), 7.26(m, 2H), 7.21(d, 2H), 7.14(d, 1H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1132]

[1133] **Example 179.(S)-quinuclidin-3-yl**

(5-(4-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.27(m, 1H), 7.25(m, 3H), 6.70(m, 2H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.80(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1134]

[1135] **Example 180.(S)-quinuclidin-3-yl**

(5-(4-methoxy-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.26(m, 1H), 7.15(m, 3H), 6.77(m, 2H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 3.84(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.26(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1136]

- [1137] **Example 181.(S)-quinuclidin-3-yl (5-(4-(*tert*-butoxymethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**
- [1138] ¹H-NMR (400MHz, CDCl₃) δ 7.54(d, 2H), 7.40(m, 4H), 7.26(m, 1H), 4.99(m, 1H), 4.92(br, 1H), 4.79(br, 1H), 4.48(s, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.32(s, 9H), 1.30(m, 3H), 0.99(m, 3H)
- [1139]
- [1140] **Example 182.(S)-quinuclidin-3-yl (5-(2-chloro-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**
- [1141] ¹H-NMR (400MHz, CDCl₃) δ 7.72(d, 1H), 7.49(d, 1H), 7.40(m, 1H), 7.32(m, 1H), 7.22(m, 2H), 5.00(m, 2H), 4.79(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)
- [1142]
- [1143] **Example 183.(S)-quinuclidin-3-yl (5-(2-chloro-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**
- [1144] ¹H-NMR (400MHz, CDCl₃) δ 7.74(s, 1H), 7.57(d, 1H), 7.43(d, 1H), 7.33~7.23(m, 3H), 5.00(m, 2H), 4.79(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)
- [1145]
- [1146] **Example 184.(S)-quinuclidin-3-yl (5-(2,6-dimethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**
- [1147] ¹H-NMR (400MHz, CDCl₃) δ 7.56(d, 1H), 7.36(m, 1H), 7.49(m, 1H), 7.32(s, 1H), 6.38(d, 1H), 4.99(m, 1H), 4.86(br, 1H), 4.79(br, 1H), 3.97(s, 6H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)
- [1148] **Example 185.(S)-quinuclidin-3-yl (5-(6-(cyclopropylmethoxy)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**
- [1149] ¹H-NMR (400MHz, CDCl₃) δ 8.32(s, 1H), 7.78(d, 1H), 7.33(m, 3H), 6.83(d, 1H), 4.99(m, 1H), 4.86(br, 1H), 4.79(br, 1H), 4.15(d, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H), 0.63(m, 2H), 0.37(m, 2H)
- [1150]
- [1151] **Example 186.(S)-quinuclidin-3-yl (5-(benzo[b]thiophen-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

NMR (400MHz, CDCl₃) δ 7.67(m, 2H), 7.57(m, 3H), 7.48(m, 2H), 7.30(m, 1H), 4.99(m, 1H), 4.86(br, 1H), 4.79(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1152]

[1153] **Example 187.(S)-quinuclidin-3-yl (5-(2-(tert -**

butoxy)pyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 8.16(d, 1H), 7.45(m, 2H), 7.28(m, 1H), 7.03(d, 1H), 6.85(s, 1H), 5.00(m, 1H), 4.86(br, 1H), 4.79(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.61(s, 9H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1154]

[1155] **Example 188.(S)-quinuclidin-3-yl**

(5-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1156] ¹H-NMR (400MHz, CDCl₃) δ 8.50(s, 1H), 8.03(s, 1H), 7.33(m, 3H), 5.00(m, 1H), 4.86(br, 1H), 4.79(br, 1H), 4.09(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.61(s, 9H), 1.40(br, 1H), 1.30(m, 3H), 0.98(m, 3H)

[1157]

[1158] **Example 189.(S)-quinuclidin-3-yl**

(5-(6-methoxynaphthalen-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.96(s, 1H), 7.81(m, 2H), 7.70(m, 1H), 7.54(m, 2H), 7.32(m, 1H), 7.18(m, 2H), 5.02(m, 1H), 4.86(br, 1H), 4.79(br, 1H), 3.96(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.32(m, 3H), 1.00(m, 3H)

[1159]

[1160] **Example 190.(S)-quinuclidin-3-yl**

(5-([1,1'-biphenyl]-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1161] ¹H-NMR (400MHz, CDCl₃) δ 7.78(s, 1H), 7.66(m, 2H), 7.56(m, 1H), 7.50(m, 5H), 7.39(m, 2H), 7.33(m, 1H), 5.05(m, 1H), 4.92(br, 1H), 4.82(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.32(m, 3H), 1.00(m, 3H)

[1162]

[1163] **Example 191.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(quinoxalin-6-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1164] ¹H-NMR (400MHz, CDCl₃) δ 8.85(d, 2H), 8.28(s, 1H), 8.16(m, 1H), 8.04(m, 1H), 7.59(m, 2H), 7.33(m, 1H), 5.02(m, 2H), 4.79(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.32(m, 3H),

1.00(m, 3H)

[1165]

[1166] **Example 192.(S)-quinuclidin-3-yl**

(5-(3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1167] ¹H-NMR (400MHz, CDCl₃) δ 7.41(m, 2H), 7.26(m, 1H), 7.19(s, 2H), 6.99(s, 1H), 4.99(m, 1H), 4.81(br, 1H), 4.79(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.38(s, 6H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 0.99(m, 3H)

[1168]

[1169] **Example 193.(S)-quinuclidin-3-yl**

(5-(furan-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1170] ¹H-NMR (400MHz, CDCl₃) δ 7.54(m, 1H), 7.49(s, 1H), 7.45(s, 1H), 7.23(m, 1H), 6.63(m, 1H), 6.47(m, 1H), 4.99(m, 1H), 4.81(br, 1H), 4.79(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.38(s, 6H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 0.99(m, 3H)

[1171]

[1172] **Example 194.(S)-quinuclidin-3-yl**

(5-(4-isopropoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1173] ¹H-NMR (400MHz, CDCl₃) δ 7.40(m, 1H), 7.36(s, 1H), 7.25(m, 3H), 4.98(m, 1H), 4.81(br, 1H), 4.79(br, 1H), 4.13(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.33(s, 6H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.33(d, 6H), 1.31(m, 3H), 0.99(m, 3H)

[1174]

[1175] **Example 195.(S)-quinuclidin-3-yl**

(5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1176] ¹H-NMR (400MHz, CDCl₃) δ 7.39(m, 1H), 7.35(s, 1H), 7.27(m, 3H), 4.99(m, 1H), 4.81(br, 1H), 4.79(br, 1H), 3.76(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.35(s, 6H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.33(d, 6H), 1.31(m, 3H), 0.99(m, 3H)

[1177]

[1178] **Example 196.(S)-quinuclidin-3-yl**

(5-(6-isopropoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 8.34(s, 1H), 7.76(d, 1H), 7.30(m, 3H), 6.74(d, 1H), 5.35(m, 1H), 4.99(m, 1H), 4.81(br, 1H), 4.79(br, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.64(br, 1H), 1.40(br, 1H), 1.38(d, 6H), 1.31(m, 3H), 0.99(m, 3H)

[1179]

[1180] **Example 197.(S)-quinuclidin-3-yl**

(5-(3-(2-fluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 7.42(m, 1H), 7.34(m, 1H), 7.27(m, 1H), 7.19(d, 1H), 7.14(s, 1H), 6.91(d, 1H), 5.00(m, 1H), 4.96(m, 3H), 4.79(m, 1H), 4.33(m, 1H), 4.25(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 1.00(m, 3H)

[1181]

[1182] **Example 198.(S)-quinuclidin-3-yl**

(5-(2-ethoxy-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 7.41(m, 1H), 7.34(s, 1H), 7.22(m, 1H), 7.09(s, 1H), 7.07(d, 1H), 6.88(d, 1H), 4.99(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 4.00(m, 2H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.33(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 1.29(m, 3H), 1.00(m, 3H)

[1183]

[1184] **Example 199.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1185] ¹H-NMR (400MHz, CDCl₃) δ 7.44(m, 1H), 7.35(s, 1H), 7.31(m, 2H), 7.15(m, 1H), 7.11(s, 1H), 6.88(m, 1H), 5.00(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 4.01(t, 2H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(m, 3H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 1.06(t, 3H), 0.99(m, 3H)

[1186]

[1187] **Example 200.(S)-quinuclidin-3-yl**

(5-(2-methoxy-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 7.36(m, 1H), 7.31(s, 1H), 7.27(m, 1H), 7.10(m, 2H), 6.98(d, 1H), 4.98(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 3.79(s, 3H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.33(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1188]

[1189] **Example 201.(S)-quinuclidin-3-yl**

(5-(2-butoxy-5-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 7.36(m, 1H), 7.34(s, 1H), 7.25(m, 1H), 7.05(m, 1H), 6.95(m, 1H), 6.89(m, 1H), 4.98(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 3.90(t, 2H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(m, 3H), 1.60(br, 1H), 1.40(m, 3H), 1.30(m, 3H), 0.99(m, 3H), 0.91(t, 3H)

[1190]

[1191] **Example 202.(S)-quinuclidin-3-yl**

(5-(4-butoxy-3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

H-NMR (400MHz, CDCl₃) δ 7.59(s, 1H), 7.39(m, 2H), 7.33(s, 1H), 7.26(m, 1H), 6.97(d, 1H), 4.98(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 4.09(t, 2H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(m, 3H), 1.70(br, 1H), 1.60(m, 3H), 1.40(br, 3H), 1.30(m, 3H), 0.99(m, 3H), 0.97(t, 3H)

[1192]

[1193] **Example 203.(S)-quinuclidin-3-yl****(5-(2,4-dipropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1194] ¹H-NMR (400MHz, CDCl₃) δ 7.38(m, 1H), 7.33(s, 1H), 7.22(m, 2H), 6.55(s, 1H), 6.54(m, 1H), 4.98(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 3.95(m, 2H), 3.91(m, 2H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(m, 3H), 1.70(m, 3H), 1.60(br, 1H), 1.40(br, 3H), 1.30(m, 3H), 1.05(t, 3H), 0.99(m, 6H)

[1195]

[1196] **Example 204.(S)-quinuclidin-3-yl****(5-(3-chloro-4-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹**

H-NMR (400MHz, CDCl₃) δ 7.60(s, 1H), 7.41(m, 2H), 7.33(s, 1H), 7.26(m, 1H), 6.97(d, 1H), 4.99(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 4.15(m, 2H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.50(t, 3H), 1.40(br, 3H), 1.30(m, 3H), 0.99(m, 3H)

[1197]

[1198] **Example 205.(S)-quinuclidin-3-yl****(5-(3-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1199] ¹H-NMR (400MHz, CDCl₃) δ 7.44(m, 1H), 7.39(s, 1H), 7.31~7.26(m, 2H), 7.14(d, 1H), 7.11(s, 1H), 6.87(d, 1H), 4.99(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 3.78(d, 2H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(m, 2H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 3H), 1.30(m, 3H), 1.06(d, 6H), 0.99(m, 3H)

[1200]

[1201] **Example 206.(S)-quinuclidin-3-yl****(5-(4-ethoxy-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹**

H-NMR (400MHz, CDCl₃) δ 7.25(m, 1H), 7.14(m, 3H), 6.81(s, 1H), 6.76(d, 1H), 4.99(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 4.06(m, 2H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.24(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.43(m, 4H), 1.30(m, 3H), 1.00(m, 3H)

[1202]

[1203] **Example 207.(S)-quinuclidin-3-yl****(5-(3-chloro-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹**

¹H-NMR (400MHz, CDCl₃) δ 7.59(s, 1H), 7.38(m, 3H), 7.25(m, 1H), 6.97(d, 1H), 4.99(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 4.05(m, 2H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(m, 3H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H),

1.11(t, 3H), 0.99(m, 3H)

[1204]

[1205] **Example 208.(S)-quinuclidin-3-yl**

(5-(5-fluoro-2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1206] ¹H-NMR (400MHz, CDCl₃) δ 7.38(m, 1H), 7.34(s, 1H), 7.25(m, 1H), 7.02(d, 1H), 6.92(m, 2H), 4.99(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 4.24(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 1.20(d, 6H), 0.99(m, 3H)

[1207]

[1208] **Example 209.(S)-quinuclidin-3-yl**

(5-(3-fluoro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1209] ¹H-NMR (400MHz, CDCl₃) δ 7.38(m, 1H), 7.36(s, 1H), 7.32~7.24(m, 3H), 7.01(t, 1H), 6.92(m, 2H), 4.99(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 4.57(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.38(d, 6H), 1.30(m, 3H), 0.99(m, 3H)

[1210]

[1211] **Example 210.(S)-quinuclidin-3-yl**

(5-(5-chloro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.36(m, 1H), 7.27(m, 4H), 6.90(d, 1H), 4.99(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 3.80(s, 3H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1212]

[1213] **Example 211.(S)-quinuclidin-3-yl**

(5-(2-fluoro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.37(m, 2H), 7.29(m, 1H), 7.20(d, 1H), 7.07(m, 1H), 7.00(m, 1H), 4.99(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.36(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1214]

[1215] **Example 212.(S)-quinuclidin-3-yl**

(5-(5-chloro-2-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.38(m, 1H), 7.31~7.25(m, 3H), 7.21(m, 1H), 6.88(d, 1H), 4.99(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 4.00(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 6H), 0.99(m, 3H)

[1216]

[1217] **Example 213.(S)-quinuclidin-3-yl**

(5-(5-fluoro-2-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.37(m, 1H), 7.34(s, 1H), 7.25(m, 1H), 7.03(d, 1H), 6.93(m, 1H), 6.88(m, 1H), 5.00(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 3.88(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(m, 3H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 6H)

[1218]

[1219] **Example 214.(S)-quinuclidin-3-yl**

(5-(2-fluoro-6-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.25(m, 4H), 6.76(m, 2H), 5.00(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 3.91(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(m, 3H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H), 0.91(t, 3H)

[1220]

[1221] **Example 215.(S)-quinuclidin-3-yl**

(5-(3-fluoro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

H-NMR (400MHz, CDCl₃) δ 7.40(m, 1H), 7.36(s, 1H), 7.25(m, 4H), 5.00(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.31(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1222]

[1223] **Example 216.(S)-quinuclidin-3-yl**

(5-(3-fluoro-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.38(m, 1H), 7.33(s, 1H), 7.25(m, 3H), 7.01(t, 1H), 5.00(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 4.05(t, 2H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(m, 3H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 1.07(t, 3H), 0.99(m, 3H)

[1224]

[1225] **Example 217.(S)-quinuclidin-3-yl**

(5-(5-chloro-2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1226] ¹H-NMR (400MHz, CDCl₃) δ 7.38(m, 1H), 7.31(s, 1H), 7.28(m, 1H), 7.20(d, 2H), 6.89(d, 1H), 5.00(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 4.36(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 1.28(d, 6H), 0.99(m, 3H)

[1227]

[1228] **Example 218.(S)-quinuclidin-3-yl**

(5-(3-butoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1229] ¹H-NMR (400MHz, CDCl₃) δ 7.44(m, 1H), 7.34(s, 1H), 7.32(m, 2H), 7.15(d, 1H), 7.10(s, 1H), 6.87(m, 1H), 5.00(m, 1H), 4.96(m, 1H), 4.79(m, 1H), 4.03(t, 2H), 3.25(m,

1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(m, 3H), 1.70(br, 1H), 1.60(m, 3H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1230]

[1231] **Example 219.(S)-quinuclidin-3-yl**

(5-(3-fluoro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 7.41(m, 1H), 7.36(s, 1H), 7.27(m, 1H), 7.16(s, 1H), 7.05(d, 1H), 6.85(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.41(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1232]

[1233] **Example 220.(S)-quinuclidin-3-yl**

(5-(5-fluoro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 7.27(m, 1H), 7.25(m, 1H), 7.18(m, 1H), 7.13(s, 1H), 6.96(m, 1H), 6.92(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.21(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1234]

[1235] **Example 221.(S)-quinuclidin-3-yl**

(5-(2-chloro-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1236] ¹H-NMR (400MHz, CDCl₃) δ 7.65(m, 2H), 7.51(m, 1H), 7.26(m, 3H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1237]

[1238] **Example 222.(S)-quinuclidin-3-yl**

(5-(3-fluoro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 7.41(m, 1H), 7.36(s, 1H), 7.26(m, 1H), 6.89(m, 2H), 6.58(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.86(s, 3H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1239]

[1240] **Example 223.(S)-quinuclidin-3-yl**

(5-(2-chloro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 7.33(d, 1H), 7.26(m, 2H), 7.23(s, 1H), 7.14(s, 1H), 7.07(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.34(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1241]

- [1242] **Example 224.(S)-quinuclidin-3-yl**
(5-(3-methoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
- [1243] ¹H-NMR (400MHz, CDCl₃) δ 7.43(m, 3H), 7.28(m, 1H), 7.25(s, 1H), 7.10(s, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.91(s, 3H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.45(t, 3H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)
- [1244]
- [1245] **Example 225.(S)-quinuclidin-3-yl**
(5-(2-chloro-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹
H-NMR (400MHz, CDCl₃) δ 7.29(m, 2H), 2.22(m, 3H), 7.02(m, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.31(m, 3H), 0.99(m, 3H)
- [1246]
- [1247] **Example 226.(S)-quinuclidin-3-yl**
(5-(4-fluoro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹
¹H-NMR (400MHz, CDCl₃) δ 7.37(m, 2H), 7.28(m, 1H), 7.13(m, 2H), 7.08(m, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.96(s, 3H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)
- [1248]
- [1249] **Example 227.(S)-quinuclidin-3-yl**
(5-(3,4-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
- [1250] ¹H-NMR (400MHz, CDCl₃) δ 7.41(m, 1H), 7.38(m, 2H), 7.27(m, 2H), 7.19(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.33(s, 3H), 2.31(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)
- [1251]
- [1252] **Example 228.(S)-quinuclidin-3-yl**
(5-(4-fluoro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹
H-NMR (400MHz, CDCl₃) δ 7.25(m, 1H), 7.17~7.08(m, 3H), 6.98~6.90(m, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.25(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)
- [1253]
- [1254] **Example 229.(S)-quinuclidin-3-yl**
(5-(2-fluoro-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1255] ¹H-NMR (400MHz, CDCl₃) δ 7.54(m, 1H), 7.46(m, 1H), 7.41~7.36(m, 4H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1256]

[1257] **Example 230.(S)-quinuclidin-3-yl**

(5-(2-fluoro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.39~7.27(m, 3H), 7.04(t, 1H), 6.91(m, 1H), 6.83(m, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.83(s, 3H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1258]

[1259] **Example 231.(S)-quinuclidin-3-yl**

(5-(2-fluoro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.40~7.27(m, 3H), 7.12(t, 1H), 6.97(m, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.93(s, 3H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1260]

[1261] **Example 232.(S)-quinuclidin-3-yl**

(5-(5-isopropyl-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1262] ¹H-NMR (400MHz, CDCl₃) δ 7.40(m, 1H), 7.36(s, 1H), 7.27(m, 1H), 7.18(m, 2H), 6.91(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.80(s, 3H), 3.25(m, 1H), 2.91(m, 1H), 2.90~2.75(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 1.26(d, 6H), 0.99(m, 3H)

[1263]

[1264] **Example 233.(S)-quinuclidin-3-yl**

(5-(2-fluoro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.36~7.27(m, 4H), 6.98(m, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.39(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1265]

[1266] **Example 234.(S)-quinuclidin-3-yl**

(5-(5-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.37(m, 1H), 7.31(s, 1H), 7.27(m, 1H), 7.02(m, 1H), 6.97(m, 1H), 6.91(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.79(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1267]

[1268] **Example 235.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(5-methylfuran-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1269] ¹H-NMR (400MHz, CDCl₃) δ 7.47(m, 1H), 7.45(s, 1H), 7.19(m, 1H), 6.51(s, 1H), 6.04(s, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.31(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1270]

[1271] **Example 236.(S)-quinuclidin-3-yl**

(5-(3-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.36~7.26(m, 3H), 7.07(m, 3H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.73(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 6H)

[1272]

[1273] **Example 237.(S)-quinuclidin-3-yl**

(5-(2-chloro-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.30~7.23(m, 4H), 7.13(m, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 6H)

[1274]

[1275] **Example 238.(S)-quinuclidin-3-yl**

(5-(benzo[b]thiophen-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.92(m, 2H), 7.46~7.33(m, 6H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1276]

[1277] **Example 239.(S)-quinuclidin-3-yl**

(5-(4-fluoro-2-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.35(m, 1H), 7.30(s, 1H), 7.25(m, 2H), 6.70(m, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.91(t, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(m, 3H), 1.60(br, 1H), 1.40(br, 1H), 1.30(m, 3H), 0.99(m, 6H)

[1278]

[1279] **Example 240.(S)-quinuclidin-3-yl (5-(3-(tert -**

butyl)-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1280] ¹H-NMR (400MHz, CDCl₃) δ 7.44(m, 1H), 7.40(s, 2H), 7.26(m, 1H), 7.20(s, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.42(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(m, 3H), 1.60(br, 1H), 1.40(br, 1H), 1.37(s, 9H), 1.30(m, 3H), 0.99(m, 6H)

[1281]

[1282] **Example 241.(S)-quinuclidin-3-yl**

(5-(2-chloro-5-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 7.34(d, 1H), 7.28(d, 2H), 7.23(s, 1H), 6.85(s, 1H), 6.81(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 4.00(q, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(m, 3H), 1.60(br, 1H), 1.41(m, 4H), 1.30(m, 3H), 0.99(m, 6H)

[1283]

[1284] **Example 242.(S)-quinuclidin-3-yl**

(5-(4-chloro-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 7.44(m, 1H), 7.37(m, 3H), 7.28(m, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1285]

[1286] **Example 243.(S)-quinuclidin-3-yl**

(5-(2-fluoro-3-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 7.38(m, 2H), 7.35~7.23(m, 2H), 7.14(m, 1H), 7.08(t, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.34(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1287]

[1288] **Example 244.(S)-quinuclidin-3-yl**

(5-(5-cyano-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 7.64(d, 1H), 7.57(s, 1H), 7.31(m, 3H), 7.02(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.88(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1289]

[1290] **Example 245.(S)-quinuclidin-3-yl**

(5-(3-ethoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1291] ¹H-NMR (400MHz, CDCl₃) δ 7.43(d, 1H), 7.38(s, 2H), 7.30(m, 2H), 7.09(s, 1H),

4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 4.13(m, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(m, 3H), 1.30(m, 3H), 0.99(m, 3H)

[1292]

[1293] **Example 246.(S)-quinuclidin-3-yl**

(5-(3-fluoro-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)c

arbamate

[1294] ¹H-NMR (400MHz, CDCl₃) δ 7.61(s, 1H), 7.45(m, 2H), 7.32(s, 1H), 7.30~7.27(m, 2H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1295]

[1296] **Example 247.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(3-methyl-4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1297] ¹H-NMR (400MHz, CDCl₃) δ 7.43(s, 1H), 7.38(m, 3H), 7.26(m, 3H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.38(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1298]

[1299] **Example 248.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(3-(methylthio)-5-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1300] ¹H-NMR (400MHz, CDCl₃) δ 7.57(d, 2H), 7.38(m, 3H), 7.29(m, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.57(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1301]

[1302] **Example 249.(S)-quinuclidin-3-yl**

(5-(3-fluoro-4-(trifluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1303] ¹H-NMR (400MHz, CDCl₃) δ 7.41~7.27(m, 6H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1304]

[1305] **Example 250.(S)-quinuclidin-3-yl**

(5-(2-ethoxy-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1306] ¹H-NMR (400MHz, CDCl₃) δ 7.40(m, 2H), 7.33(s, 1H), 7.26(m, 2H), 7.17(s, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 4.10(m, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.60(br, 1H), 1.41(m, 4H), 1.30(m, 3H), 0.99(m, 3H)

[1307]

[1308] **Example 251.(S)-quinuclidin-3-yl**

(5-(2-methoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1309] ¹H-NMR (400MHz, CDCl₃) δ 7.57(d, 1H), 7.54(s, 1H), 7.37(m, 1H), 7.29(s, 2H),

7.02(d, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.86(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1310]

[1311] **Example 252.(S)-quinuclidin-3-yl**

(5-(2,4-bis(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1312] ¹H-NMR (400MHz, CDCl₃) δ 8.00(s, 1H), 7.81(d, 1H), 7.48(d, 1H), 7.26(m, 1H), 7.14(m, 1H), 7.12(s, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1313]

[1314] **Example 253.(S)-quinuclidin-3-yl**

(5-(3-chloro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1315] ¹H-NMR (400MHz, CDCl₃) δ 7.36(d, 1H), 7.26(m, 1H), 7.17~7.08(m, 4H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.25(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1316]

[1317] **Example 254.(S)-quinuclidin-3-yl**

(5-(3-methoxy-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.44(m, 1H), 7.40(s, 1H), 7.26(m, 1H), 7.18(d, 1H), 7.06(d, 1H), 7.02(s, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.90(s, 3H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1318]

[1319] **Example 255.(S)-quinuclidin-3-yl**

(5-(4-fluoro-3-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.38~7.29(m, 4H), 7.26(m, 1H), 7.03(t, 1H), 7.02(s, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.34(s, 3H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1320]

[1321] **Example 256.(S)-quinuclidin-3-yl**

(5-(2-ethoxy-5-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.40(m, 1H), 7.33(s, 1H), 7.25(m, 1H), 7.05(m, 1H), 6.95(m, 1H), 6.88(m, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.99(m, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.41(br, 1H), 1.30(m, 6H), 0.99(m, 3H)

[1322]

[1323] **Example 257.(S)-quinuclidin-3-yl**

(5-(3-fluoro-5-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.37(m, 1H), 7.35(s, 1H), 7.27(m, 1H), 7.02(t, 1H), 6.92(m, 1H), 6.81(m, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.93(m, 2H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(m, 3H), 1.70(br, 1H), 1.59(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 1.05(t, 3H), 0.99(m, 3H)

[1324]

[1325] **Example 258.(S)-quinuclidin-3-yl**

(5-(3,5-bis(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1326] ¹H-NMR (400MHz, CDCl₃) δ 7.99(s, 2H), 7.85(s, 1H), 7.44(m, 2H), 7.32(m, 1H), 4.99(m, 1H), 4.88(m, 1H), 4.80(m, 1H), 3.25(m, 1H), 2.91~2.74(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.41(br, 1H), 1.30(m, 3H), 0.99(m, 3H)

[1327]

[1328] **Example 259.(S)-quinuclidin-3-yl**

(5-(3-chloro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

H-NMR (400MHz, CDCl₃) δ 7.56(s, 1H), 7.36(m, 3H), 7.28(m, 2H), 4.96(s, 2H), 4.80(br, 1H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.39(s, 3H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(br, 1H), 1.40(br, 1H), 1.29(m, 3H), 0.98(m, 3H)

[1329]

[1330] **Example 260.(S)-quinuclidin-3-yl**

(5-(2,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1331] ¹H-NMR (400MHz, CDCl₃) δ 7.25(m, 1H), 7.16(t, 3H), 7.06(m, 2H), 4.96(s, 2H), 4.80(br, 1H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.34(s, 3H), 2.20(s, 3H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(br, 1H), 1.40(br, 1H), 1.29(m, 3H), 0.98(m, 3H)

[1332]

[1333] **Example 261.(S)-quinuclidin-3-yl**

(5-(3-chloro-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

H-NMR (400MHz, CDCl₃) δ 7.60(d, 1H), 7.42(m, 1H), 7.35(m, 3H), 7.19(t, 1H), 4.96(s, 2H), 4.80(br, 1H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(br, 1H), 1.40(br, 1H), 1.29(m, 3H), 0.98(m, 3H)

[1334]

[1335] **Example 262.(S)-quinuclidin-3-yl**

(5-(6-ethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1336] ¹H-NMR (400MHz, CDCl₃) δ 8.33(s, 1H), 7.76(d, 1H), 7.69(m, 1H), 7.51(m, 1H), 7.46(m, 1H), 7.36~7.27(m, 1H), 6.77(d, 1H), 4.96(s, 2H), 4.80(br, 1H), 4.37(m, 2H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(br, 1H),

1.39(m, 4H), 1.29(m, 3H), 0.98(m, 3H)

[1337]

[1338] **Example 263. (S)-quinuclidin-3-yl**

(5-(2-ethoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1339] ¹H-NMR (400MHz, CDCl₃) δ 8.17(d, 1H), 7.46(m, 2H), 7.30(m, 1H), 7.06(d, 1H), 6.91(s, 1H), 4.97(m, 2H), 4.80(br, 1H), 4.38(m, 2H), 3.24(m, 1H), 2.89~2.73(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(br, 1H), 1.40(m, 4H), 1.30(m, 3H), 0.96(m, 3H)

[1340]

[1341] **Example 264. (S)-quinuclidin-3-yl**

(5-(2-isopropoxyppyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1342] ¹H-NMR (400MHz, CDCl₃) δ 8.17(d, 1H), 7.44(m, 2H), 7.31(m, 1H), 7.04(d, 1H), 6.87(s, 1H), 5.34(m, 1H), 4.97(s, 2H), 4.80(br, 1H), 3.24(m, 1H), 2.89~2.73(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(br, 1H), 1.40(br, 1H), 1.36(d, 6H), 1.28(m, 3H), 0.97(m, 3H)

[1343]

[1344] **Example 265.(S)-quinuclidin-3-yl**

(2,2-dimethyl-5-(6-propoxyppyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1345] ¹H-NMR (400MHz, CDCl₃) δ 8.34(s, 1H), 7.76(d, 1H), 7.34~7.32(m, 3H), 6.79(d, 1H), 4.96(m, 2H), 4.80(br, 1H), 4.28(m, 2H), 3.25(m, 1H), 2.89~2.74(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.81(m, 2H), 1.68(br, 1H), 1.58(br, 1H), 1.40(br, 1H), 1.29(m, 3H), 1.06(t, 3H), 0.98(m, 3H)

[1346]

[1347] **Example 266.(S)-quinuclidin-3-yl**

(5-(6-butoxyppyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1348] ¹H-NMR (400MHz, CDCl₃) δ 8.33(s, 1H), 7.76(d, 1H), 7.34~7.31(m, 3H), 6.78(d, 1H), 4.96(s, 2H), 4.80(br, 1H), 4.31(m, 2H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.78(m, 2H), 1.68(br, 1H), 1.58(br, 1H), 1.48(m, 2H), 1.40(br, 1H), 1.29(m, 3H), 1.06(t, 3H), 0.98(m, 6H)

[1349]

[1350] **Example 267.(S)-quinuclidin-3-yl**

(5-(6-(2-methoxyethoxy)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1351] ¹H-NMR (400MHz, CDCl₃) δ 8.32(s, 1H), 7.76(d, 1H), 7.36~7.28(m, 3H), 6.86(d, 1H), 4.96(m, 2H), 4.80(br, 1H), 4.51(m, 2H), 3.78(m, 2H), 3.45(s, 3H), 3.25(m, 1H), 2.89~2.73(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(br, 1H), 1.40(br, 1H), 1.29(m, 3H), 0.98(m, 3H)

[1352]

[1353] **Example 268.(S)-quinuclidin-3-yl**

(5-(6-isobutoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1354] ¹H-NMR (400MHz, CDCl₃) δ 8.34(s, 1H), 7.76(d, 1H), 7.35~7.27(m, 3H), 6.80(d, 1H), 4.96(m, 2H), 4.78(br, 1H), 4.10(m, 2H), 3.27(m, 1H), 2.89~2.74(m, 7H), 2.08(br, 1H), 1.86(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.42(br, 1H), 1.29(m, 3H), 1.00(d, 6H), 0.98(m, 3H)

[1355]

[1356] **Example 269.(S)-quinuclidin-3-yl**

(5-(3-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1357] ¹H-NMR (400MHz, CDCl₃) δ 7.45~7.27(m, 6H), 7.12(d, 1H), 4.97(m, 2H), 4.80(br, 1H), 3.27(m, 1H), 2.89~2.74(m, 7H), 2.53(d, 2H), 2.08(br, 1H), 1.86(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.42(br, 1H), 1.29(m, 3H), 0.98(m, 3H), 0.93(d, 6H)

[1358]

[1359] **Example 270.(S)-quinuclidin-3-yl**

(5-(4-butoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1360] ¹H-NMR (400MHz, CDCl₃) δ 7.50(d, 2H), 7.39(m, 2H), 7.28(m, 1H), 6.96(d, 2H), 4.97(m, 2H), 4.80(br, 1H), 4.02(m, 1H), 3.27(m, 1H), 2.89~2.74(m, 7H), 2.53(d, 2H), 2.08(br, 1H), 1.86(br, 1H), 1.77(m, 2H), 1.69(br, 1H), 1.58(br, 1H), 1.52(m, 2H), 1.42(br, 1H), 1.29(m, 3H), 0.98(m, 6H)

[1361]

[1362] **Example 271. (S)-quinuclidin-3-yl**

(5-(2,4-dimethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1363] ¹H-NMR(400MHz, CDCl₃) δ 7.56(d, 1H), 7.38(m, 1H), 7.30(s, 1H), 7.28(m, 1H), 6.38(d, 1H), 4.97(m, 2H), 4.80(br, 1H), 3.96(s, 6H), 3.27(m, 1H), 2.89~2.74(m, 7H), 2.08(br, 1H), 1.86(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.42(br, 1H), 1.28(m, 3H), 0.97(m, 3H)

[1364]

[1365] **Example 272. (S)-quinuclidin-3-yl**

(5-(2-acetylthiophen-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1366] ¹H-NMR(400MHz, CDCl₃) δ 7.53(d, 1H), 7.30~7.19(m, 3H), 7.03(d, 1H), 5.02(m, 1H), 4.94(m, 1H), 4.79(br, 1H), 3.28(m, 1H), 2.89~2.72(m, 7H), 2.16(s, 3H), 2.08(br, 1H), 1.86(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.42(br, 1H), 1.30(m, 3H), 0.97(m, 3H)

[1367]

[1368] **Example 273. (S)-quinuclidin-3-yl**

(5-((E)-3-fluorostyryl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1369] ¹H-NMR (400MHz, CDCl₃) δ 7.35~7.19(m, 6H), 7.06(d, 2H), 6.97(m, 1H), 4.94(m, 2H), 4.79(br, 1H), 3.28(m, 1H), 2.89~2.71(m, 7H), 2.08(br, 1H), 1.86(br, 1H), 1.69(br,

1H), 1.58(br, 1H), 1.42(br, 1H), 1.29(m, 3H), 0.96(m, 3H)

[1370]

[1371] **Example 274.(S)-quinuclidin-3-yl**

(5-((E)-4-ethylstyryl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1372] ¹H-NMR(400MHz, CDCl₃) δ 7.44(d, 2H), 7.34(s, 1H), 7.21(m, 4H), 7.07(s, 2H), 4.94(m, 2H), 4.79(br, 1H), 3.28(m, 1H), 2.89~2.71(m, 7H), 2.63(m, 2H), 2.08(br, 1H), 1.86(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.42(br, 1H), 1.27(m, 6H), 0.94(m, 3H)

[1373]

[1374] **Example 275.(S)-quinuclidin-3-yl**

(5-((E)-2-cyclohexylvinyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1375] ¹H-NMR(400MHz, CDCl₃) δ 7.18~7.12(m, 3H), 6.35(m, 1H), 6.16(m, 1H), 4.94(m, 2H), 4.79(br, 1H), 3.28(m, 1H), 2.89~2.71(m, 7H), 2.08(br, 1H), 1.86(br, 1H), 1.76(m, 5H), 1.69(br, 2H), 1.58(br, 1H), 1.42(br, 1H), 1.27(m, 3H), 1.15(m, 3H), 0.94(m, 3H)

[1376]

[1377] **Examples 276 to 311**

[1378] The titled compounds of Examples 276 to 311 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (5-bromo-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate prepared in Preparation 5; and the corresponding substituted-boronic acids, respectively.

[1379]

[1380] **Example 276.(S)-quinuclidin-3-yl**

(2,2-diethyl-5-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1381] ¹H-NMR(400MHz, CDCl₃) δ 7.52(m, 2H), 7.50~7.27(m, 3H), 7.11(t, 2H), 5.13(m, 1H), 4.90(m, 1H), 4.78(m, 1H), 3.26(m, 1H), 2.87~2.73(m, 7H), 2.11(br, 1H), 1.88(br, 1H), 1.61(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.95(m, 3H), 0.85(m, 3H)

[1382]

[1383] **Example 277.(S)-quinuclidin-3-yl**

(2,2-diethyl-5-(4-ethylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1384] ¹H-NMR (400MHz, CDCl₃) δ 7.49(d, 2H), 7.40(m, 1H), 7.25(m, 3H), 5.12(m, 1H), 4.93(m, 1H), 4.78(m, 1H), 3.26(m, 1H), 2.87~2.69(m, 7H), 2.67(m, 2H), 2.11(br, 1H), 1.88(br, 1H), 1.61(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 1.26(t, 3H), 0.95(m, 3H), 0.86(m, 3H)

[1385]

[1386] **Example 278.(S)-quinuclidin-3-yl**

(2,2-diethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1387] ¹H-NMR (400MHz, CDCl₃) δ 7.48(d, 2H), 7.40(m, 1H), 7.27(m, 1H), 7.25(d, 2H), 5.11(m, 1H), 4.96(m, 1H), 4.78(m, 1H), 3.26(m, 1H), 2.87~2.72(m, 7H), 2.62(m, 2H), 2.11(br, 1H), 1.88(br, 1H), 1.69(m, 3H), 1.58(m, 3H), 1.37(br, 1H), 0.97(m, 6H),

0.85(m, 3H)

[1388]

[1389] **Example 279.(S)-quinuclidin-3-yl (5-(4-(tert -butyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1390] ¹H-NMR (400MHz, CDCl₃) δ 7.51(d, 2H), 7.45(d, 3H), 7.37(m, 1H), 7.27(m, 1H), 5.12(m, 1H), 4.94(m, 1H), 4.78(m, 1H), 3.26(m, 1H), 2.87~2.71(m, 7H), 2.11(br, 1H), 1.88(br, 1H), 1.69(br, 1H), 1.58(m, 3H), 1.38(br, 1H), 1.36(s, 9H), 0.97(m, 6H), 0.86(m, 3H)

[1391]

[1392] **Example 280.(S)-quinuclidin-3-yl (5-(4-butylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1393] ¹H-NMR (400MHz, CDCl₃) δ 7.48(d, 2H), 7.42(m, 2H), 7.30(m, 1H), 7.26(d, 2H), 5.11(m, 1H), 4.94(m, 1H), 4.78(m, 1H), 3.26(m, 1H), 2.87~2.71(m, 7H), 2.63(m, 2H), 2.11(br, 1H), 1.85(br, 1H), 1.69~1.57(m, 6H), 1.38(m, 3H), 0.94(m, 6H), 0.87(m, 3H)

[1394]

[1395] **Example 281.(S)-quinuclidin-3-yl (5-(4-cyclopropylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1396] ¹H-NMR (400MHz, CDCl₃) δ 7.46(d, 2H), 7.40(m, 1H), 7.30(m, 1H), 7.28(m, 1H), 7.14(d, 2H), 5.12(m, 1H), 4.94(m, 1H), 4.78(m, 1H), 3.26(m, 1H), 2.87~2.71(m, 7H), 2.11(br, 1H), 1.94(m, 1H), 1.85(br, 1H), 1.60(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.95(m, 5H), 0.87(m, 3H), 0.74(m, 2H)

[1397]

[1398] **Example 282.(S)-quinuclidin-3-yl (2,2-diethyl-5-(4-isopropylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[1399] ¹H-NMR (400MHz, CDCl₃) δ 7.50(d, 2H), 7.41(m, 1H), 7.30(m, 1H), 7.28(m, 3H), 5.11(m, 1H), 4.95(m, 1H), 4.78(m, 1H), 3.26(m, 1H), 2.94(m, 1H), 2.88~2.73(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 1.29(d, 6H), 0.98(m, 3H), 0.87(m, 3H)

[1400]

[1401] **Example 283.(S)-quinuclidin-3-yl (2,2-diethyl-5-(4-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[1402] ¹H-NMR (400MHz, CDCl₃) δ 7.50(d, 2H), 7.38(m, 1H), 7.30(m, 2H), 6.96(d, 2H), 5.12(m, 1H), 4.91(m, 1H), 4.88(m, 1H), 3.85(s, 3H), 3.26(m, 1H), 2.88~2.71(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.97(m, 3H), 0.87(m, 3H)

[1403]

[1404] **Example 284.(S)-quinuclidin-3-yl (5-(4-ethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1405] ¹H-NMR (400MHz, CDCl₃) δ 7.49(d, 2H), 7.35(m, 1H), 7.28(m, 2H), 6.95(d, 2H), 5.12(m, 1H), 4.91(m, 1H), 4.88(m, 1H), 4.10(m, 2H), 3.26(m, 1H), 2.88~2.71(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.41(t, 3H), 1.37(br, 1H), 0.97(m, 3H), 0.87(m, 3H)

[1406]

[1407] **Example 285.(S)-quinuclidin-3-yl**

(2,2-diethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1408] ¹H-NMR (400MHz, CDCl₃) δ 7.49(d, 2H), 7.35(m, 1H), 7.28(m, 2H), 6.96(d, 2H), 5.12(m, 1H), 4.91(m, 1H), 4.88(m, 1H), 3.98(t, 2H), 3.26(m, 1H), 2.88~2.71(m, 7H), 2.11(br, 1H), 1.85(m, 3H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 1.06(t, 3H), 0.97(m, 3H), 0.87(m, 3H)

[1409]

[1410] **Example 286.(S)-quinuclidin-3-yl**

(2,2-diethyl-5-(4-isopropoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1411] ¹H-NMR (400MHz, CDCl₃) δ 7.49(d, 2H), 7.35(m, 1H), 7.28(m, 2H), 6.96(d, 2H), 5.12(m, 1H), 4.91(m, 1H), 4.78(m, 1H), 4.77(m, 1H), 3.26(m, 1H), 2.88~2.71(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 1.36(d, 6H), 0.96(m, 3H), 0.87(m, 3H)

[1412]

[1413] **Example 287.(S)-quinuclidin-3-yl**

(2,2-diethyl-5-(4-isobutylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1414] ¹H-NMR (400MHz, CDCl₃) δ 7.48(d, 2H), 7.38(m, 1H), 7.28(m, 2H), 7.20(d, 2H), 5.13(m, 1H), 4.92(m, 1H), 4.78(m, 1H), 3.26(m, 1H), 2.88~2.73(m, 7H), 2.51(d, 2H), 2.11(br, 1H), 1.92(m, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.96(m, 3H), 0.93(d, 6H), 0.86(m, 3H)

[1415]

[1416] **Example 288.(S)-quinuclidin-3-yl**

(2,2-diethyl-5-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1417] ¹H-NMR (400MHz, CDCl₃) δ 7.41~7.02(m, 6H), 7.02(t, 1H), 5.14(m, 1H), 4.92(m, 1H), 4.79(m, 1H), 3.24(m, 1H), 2.88~2.74(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.96(m, 3H), 0.86(m, 3H)

[1418]

[1419] **Example 289.(S)-quinuclidin-3-yl**

(2,2-diethyl-5-(3-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1420] ¹H-NMR (400MHz, CDCl₃) δ 7.43(m, 1H), 7.37~7.27(m, 3H), 7.17(d, 1H), 7.15(s, 1H), 6.88(d, 1H), 5.13(m, 1H), 4.91(m, 1H), 4.79(m, 1H), 3.87(s, 3H), 3.25(m, 1H), 2.88~2.74(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.96(m, 3H), 0.86(m, 3H)

[1421]

[1422] **Example 290.(S)-quinuclidin-3-yl**

(5-(3-ethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1423] ¹H-NMR (400MHz, CDCl₃) δ 7.41(m, 1H), 7.38~7.27(m, 3H), 7.15(d, 1H), 7.13(s, 1H), 6.89(d, 1H), 5.13(m, 1H), 4.91(m, 1H), 4.79(m, 1H), 4.12(m, 2H), 3.25(m, 1H), 2.88~2.74(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.43(t, 3H), 1.37(br, 1H), 0.96(m, 3H), 0.87(m, 3H)

[1424]

[1425] **Example 291.(S)-quinuclidin-3-yl**

(2,2-diethyl-5-(3-isopropoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1426] ¹H-NMR (400MHz, CDCl₃) δ 7.41(m, 1H), 7.39~7.27(m, 3H), 7.12(d, 1H), 7.09(s, 1H), 6.88(d, 1H), 5.13(m, 1H), 4.91(m, 1H), 4.78(m, 1H), 4.62(m, 1H), 3.25(m, 1H), 2.88~2.73(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.29(br, 1H), 1.26(d, 6H), 0.97(m, 3H), 0.86(m, 3H)

[1427]

[1428] **Example 292.(S)-quinuclidin-3-yl**

(2,2-diethyl-5-(3-ethylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1429] ¹H-NMR (400MHz, CDCl₃) δ 7.44~7.27(m, 6H), 7.18(d, 1H), 5.13(m, 1H), 4.93(m, 1H), 4.78(m, 1H), 3.27(m, 1H), 2.85~2.71(m, 7H), 2.68(m, 2H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.39(br, 1H), 1.29(t, 3H), 0.97(m, 3H), 0.86(m, 3H)

[1430]

[1431] **Example 293.(S)-quinuclidin-3-yl**

(2,2-diethyl-5-(3-isopropylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1432] ¹H-NMR (400MHz, CDCl₃) δ 7.44~7.27(m, 6H), 7.21(d, 1H), 5.14(m, 1H), 4.92(m, 1H), 4.79(m, 1H), 3.27(m, 1H), 2.99(m, 1H), 2.85~2.71(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.39(br, 1H), 1.27(d, 6H), 0.98(m, 3H), 0.86(m, 3H)

[1433]

[1434] **Example 294. (S)-quinuclidin-3-yl (5-(3-(tert -**

butyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1435] ¹H-NMR (400MHz, CDCl₃) δ 7.58(s, 1H), 7.41~7.27(m, 6H), 5.11(m, 1H), 4.92(m, 1H), 4.79(m, 1H), 3.27(m, 1H), 2.86~2.75(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.39(br, 1H), 1.38(s, 9H), 0.96(m, 3H), 0.87(m, 3H)

[1436]

[1437] **Example 295.(S)-quinuclidin-3-yl**

(5-(2,3-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1438] ¹H-NMR (400MHz, CDCl₃) δ 7.37~7.26(m, 3H), 7.10(m, 1H), 6.92(d, 2H), 5.14(m, 1H), 4.92(m, 1H), 4.77(m, 1H), 3.91(s, 3H), 3.59(s, 3H), 3.25(m, 1H), 2.86~2.73(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.96(m, 3H),

0.85(m, 3H)

[1439]

[1440] **Example 296. (S)-quinuclidin-3-yl**

(5-(2,4-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1441] ¹H-NMR (400MHz, CDCl₃) δ 7.33(m, 1H), 7.28~7.21(m, 3H), 6.57(m, 2H), 5.11(m, 1H), 4.90(m, 1H), 4.85(m, 1H), 3.85(s, 3H), 3.80(s, 3H), 3.24(m, 1H), 2.86~2.71(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.95(m, 3H), 0.87(m, 3H)

[1442]

[1443] **Example 297. (S)-quinuclidin-3-yl**

(5-(2,5-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1444] ¹H-NMR (400MHz, CDCl₃) δ 7.35(m, 1H), 7.30~7.27(m, 2H), 6.92~6.83(m, 3H), 5.12(m, 1H), 4.90(m, 1H), 4.85(m, 1H), 3.80(s, 3H), 3.75(s, 3H), 3.24(m, 1H), 2.86~2.72(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.96(m, 3H), 0.87(m, 3H)

[1445]

[1446] **Example 298. (S)-quinuclidin-3-yl**

(5-(3,4-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1447] ¹H-NMR (400MHz, CDCl₃) δ 7.39(m, 1H), 7.31(s, 1H), 7.28(m, 1H), 7.13(d, 1H), 7.08(s, 1H), 6.93(d, 1H), 5.12(m, 1H), 4.91(m, 1H), 4.85(m, 1H), 3.95(s, 3H), 3.92(s, 3H), 3.24(m, 1H), 2.86~2.72(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.95(m, 3H), 0.86(m, 3H)

[1448]

[1449] **Example 299. (S)-quinuclidin-3-yl**

(5-(3,5-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1450] ¹H-NMR (400MHz, CDCl₃) δ 7.40(m, 1H), 7.39(s, 1H), 7.29(m, 1H), 6.70(s, 2H), 6.45(m, 1H), 5.13(m, 1H), 4.92(m, 1H), 4.85(brs, 1H), 3.85(s, 6H), 3.24(m, 1H), 2.86~2.73(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.96(m, 3H), 0.87(m, 3H)

[1451]

[1452] **Example 300. (S)-quinuclidin-3-yl**

(5-(2,6-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1453] ¹H-NMR (400MHz, CDCl₃) δ 7.30~7.26(m, 2H), 7.18(d, 1H), 7.14(s, 1H), 6.65(d, 2H), 5.12(m, 1H), 4.92(m, 1H), 4.77(m, 1H), 3.73(s, 6H), 3.24(m, 1H), 2.85~2.71(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.96(m, 3H), 0.88(m, 3H)

[1454]

[1455] **Example 301. (S)-quinuclidin-3-yl**

(5-(3-(difluoromethyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1456] ¹H-NMR (400MHz, CDCl₃) δ 7.70(m, 2H), 7.53~7.39(m, 4H), 7.31(m, 1H), 6.85~6.56(t, 1H), 5.15(m, 1H), 4.92(m, 1H), 4.79(m, 1H), 3.24(m, 1H), 2.85~2.74(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.96(m, 3H), 0.86(m, 3H)

[1457]

Example 302. (S)-quinuclidin-3-yl**(5-(3-(dimethylamino)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1459] ¹H-NMR (400MHz, CDCl₃) δ 7.43(m, 1H), 7.38(s, 1H), 7.27(m, 2H), 6.91(m, 2H), 6.73(d, 1H), 5.13(m, 1H), 4.88(m, 1H), 4.79(m, 1H), 3.24(m, 1H), 3.00(s, 6H), 2.85~2.74(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.96(m, 3H), 0.87(m, 3H)

[1460]

Example 303.(S)-quinuclidin-3-yl**(5-(4-ethoxy-3,5-dimethylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1462] ¹H-NMR (400MHz, CDCl₃) δ 7.38~7.33(m, 2H), 7.28(m, 1H), 7.21(s, 2H), 5.12(m, 1H), 4.88(m, 1H), 4.79(m, 1H), 3.89(q, 2H), 3.25(m, 1H), 2.85~2.74(m, 7H), 2.33(s, 6H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.41(t, 3H), 1.37(br, 1H), 0.95(m, 3H), 0.85(m, 3H)

[1463]

Example 304.(S)-quinuclidin-3-yl**(5-(3,5-dimethyl-4-propoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1465] ¹H-NMR(400MHz, CDCl₃) δ 7.38~7.30(m, 2H), 7.28(m, 1H), 7.20(s, 2H), 5.11(m, 1H), 4.93(m, 1H), 4.79(m, 1H), 3.77(t, 2H), 3.25(m, 1H), 2.85~2.74(m, 7H), 2.33(s, 6H), 2.05(br, 1H), 1.85(m, 3H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 1.09(t, 3H), 0.95(m, 3H), 0.85(m, 3H)

[1466]

Example 305.(S)-quinuclidin-3-yl**(5-(4-butoxy-3,5-dimethylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1468] ¹H-NMR (400MHz, CDCl₃) δ 7.38~7.30(m, 2H), 7.28(m, 1H), 7.20(s, 2H), 5.12(m, 1H), 4.91(m, 1H), 4.79(m, 1H), 3.78(t, 2H), 3.25(m, 1H), 2.85~2.74(m, 7H), 2.33(s, 6H), 2.05(br, 1H), 1.85(m, 3H), 1.68(br, 1H), 1.58(m, 5H), 1.37(br, 1H), 0.99(t, 3H), 0.95(m, 3H), 0.86(m, 3H)

[1469]

Example 306.(S)-quinuclidin-3-yl

(2,2-diethyl-5-(thiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1471] ¹H-NMR (400MHz, CDCl₃) δ 7.45~7.36(m, 5H), 7.26(m, 1H), 5.11(m, 1H), 4.88(m, 1H), 4.77(m, 1H), 3.25(m, 1H), 2.85~2.72(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.95(m, 3H), 0.85(m, 3H)

[1472]

Example 307.(S)-quinuclidin-3-yl**(2,2-diethyl-5-(furan-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[1474] ¹H-NMR (400MHz, CDCl₃) δ 7.70(s, 1H), 7.46(s, 1H), 7.30~7.20(m, 3H), 6.68(s, 1H), 5.10(m, 1H), 4.88(m, 1H), 4.78(m, 1H), 3.25(m, 1H), 2.85~2.69(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.94(m, 3H), 0.85(m, 3H)

[1475]

Example 308.(S)-quinuclidin-3-yl**(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1477] ¹H-NMR (400MHz, CDCl₃) δ 8.31(s, 1H), 7.77(d, 1H), 7.31(m, 3H), 6.82(d, 1H), 5.12(m, 1H), 4.93(m, 1H), 4.78(m, 1H), 4.16(m, 2H), 3.25(m, 1H), 2.85~2.72(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.94(m, 3H), 0.85(m, 3H), 0.63(m, 2H), 0.37(m, 2H)

[1478]

Example 309.(S)-quinuclidin-3-yl**(5-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1480] ¹H-NMR (400MHz, CDCl₃) δ 7.33~7.24(m, 5H), 7.10(m, 1H), 5.14(m, 1H), 4.91(m, 1H), 4.87(m, 1H), 3.25(m, 1H), 2.85~2.73(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.96(m, 3H), 0.86(m, 3H)

[1481]

Example 310.(S)-quinuclidin-3-yl**(2,2-diethyl-5-(2-fluoro-4-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate**

[1483] ¹H-NMR (400MHz, CDCl₃) δ 7.34~7.27(m, 4H), 6.74(m, 2H), 5.12(m, 1H), 4.94(m, 1H), 4.77(m, 1H), 3.83(s, 3H), 3.25(m, 1H), 2.85~2.72(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.96(m, 3H), 0.86(m, 3H)

[1484]

Example 311.(S)-quinuclidin-3-yl**(5-(3-chloro-4-isopropoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1486] ¹H-NMR (400MHz, CDCl₃) δ 7.59(s, 1H), 7.40~7.01(m, 4H), 7.00(d, 1H), 5.13(m, 1H), 4.94(m, 1H), 4.77(m, 1H), 3.83(s, 3H), 3.25(m, 1H), 2.85~2.72(m, 7H), 2.05(br, 1H), 1.85(br, 1H), 1.68(br, 1H), 1.58(m, 3H), 1.37(br, 1H), 0.96(m, 3H), 0.86(m, 3H)

[1487]

[1488] **Examples 312 to 348**

[1489] The titled compounds of Examples 312 to 348 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (5-bromo-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate prepared in Preparation 6; and the corresponding substituted-boronic acids, respectively.

[1490]

[1491] **Example 312.(S)-quinuclidin-3-yl**

(5-(4-ethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1492] ¹H-NMR (400MHz, CDCl₃) δ 7.42(d, 2H), 7.24(m, 3H), 6.85(d, 1H), 4.94(m, 1H), 4.82(m, 1H), 4.74(br, 1H), 3.79(d, 3H), 3.29(m, 1H), 2.91(m, 2H), 2.89~2.70(m, 5H), 2.69(m, 2H), 2.11(br, 1H), 1.88(br, 1H), 1.72(br, 1H), 1.61(br, 1H), 1.44(br, 1H), 1.30(m, 6H), 1.00(m, 3H)

[1493]

[1494] **Example 313.(S)-quinuclidin-3-yl**

(6-methoxy-2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1495] ¹H-NMR (400MHz, CDCl₃) δ 7.41(d, 2H), 7.22(d, 2H), 7.11(s, 1H), 6.85(d, 1H), 4.95(m, 1H), 4.82(m, 1H), 4.74(br, 1H), 3.79(d, 3H), 3.29(m, 1H), 2.90(m, 2H), 2.89~2.71(m, 5H), 2.62(m, 2H), 2.11(br, 1H), 1.88(br, 1H), 1.72~1.67(m, 3H), 1.61(br, 1H), 1.43(br, 1H), 1.32(m, 3H), 1.00(m, 6H)

[1496]

[1497] **Example 314. (S)-quinuclidin-3-yl**

(5-(4-isopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1498] ¹H-NMR (400MHz, CDCl₃) δ 7.43(d, 2H), 7.26(d, 2H), 7.11(s, 1H), 6.85(d, 1H), 4.95(m, 1H), 4.82(m, 1H), 4.74(br, 1H), 3.80(d, 3H), 3.29(m, 1H), 2.92(m, 3H), 2.89~2.71(m, 5H), 2.11(br, 1H), 1.88(br, 1H), 1.71(br, 1H), 1.62(br, 1H), 1.44(br, 1H), 1.30(m, 9H), 1.00(m, 3H)

[1499]

[1500] **Example 315.(S)-quinuclidin-3-yl**

(5-(4-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1501] ¹H-NMR (400MHz, CDCl₃) δ 7.41(d, 2H), 7.17(d, 2H), 7.11(s, 1H), 6.85(d, 1H), 4.95(m, 1H), 4.82(m, 1H), 4.74(br, 1H), 3.80(d, 3H), 3.29(m, 1H), 2.90~2.71(m, 7H), 2.50(d, 2H), 2.11(br, 1H), 1.92(m, 2H), 1.71(br, 1H), 1.62(br, 1H), 1.44(br, 1H), 1.30(m, 3H), 1.00(m, 3H), 0.99(d, 6H)

[1502]

- [1503] **Example 316. (S)-quinuclidin-3-yl (5-(4-(tert -**
butyl)phenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
- [1504] ¹H-NMR (400MHz, CDCl₃) δ 7.46(m, 4H), 7.12(s, 1H), 6.85(d, 1H), 4.95(m, 1H), 4.82(m, 1H), 4.74(br, 1H), 3.81(d, 3H), 3.29(m, 1H), 2.93~2.66(m, 7H), 2.50(d, 2H), 2.11(br, 1H), 1.88(br, 1H), 1.71(br, 1H), 1.62(br, 1H), 1.44(br, 1H), 1.40(s, 9H), 1.30(m, 3H), 1.00(m, 3H)
- [1505]
- [1506] **Example 317. (S)-quinuclidin-3-yl**
(5-(4-cyclopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
- [1507] ¹H-NMR (400MHz, CDCl₃) δ 7.39(d, 2H), 7.10(d, 3H), 6.85(d, 1H), 4.95(m, 1H), 4.82(m, 1H), 4.74(br, 1H), 3.81(d, 3H), 3.29(m, 1H), 2.93~2.66(m, 7H), 2.50(d, 2H), 2.11(br, 1H), 1.90(m, 1H), 1.88(br, 1H), 1.71(br, 1H), 1.62(br, 1H), 1.44(br, 1H), 1.30(m, 3H), 1.00(m, 3H), 0.98(d, 2H), 0.75(m, 2H)
- [1508]
- [1509] **Example 318. (S)-quinuclidin-3-yl**
(5-(4-ethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
- [1510] ¹H-NMR (400MHz, CDCl₃) δ 7.42(d, 2H), 7.09(s, 1H), 6.93(d, 2H), 6.81(d, 1H), 4.94(m, 2H), 4.81(m, 1H), 4.09(m, 2H), 3.80(d, 3H), 3.28(m, 1H), 2.90~2.671(m, 7H), 2.11(br, 1H), 1.90(m, 1H), 1.88(br, 1H), 1.71(br, 1H), 1.62(br, 1H), 1.43(t, 4H), 1.26(m, 3H), 0.97(m, 3H)
- [1511]
- [1512] **Example 319. (S)-quinuclidin-3-yl**
(6-methoxy-2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate
- [1513] ¹H-NMR (400MHz, CDCl₃) δ 7.42(d, 2H), 7.09(s, 1H), 6.94(d, 2H), 6.82(d, 1H), 4.94(m, 2H), 4.81(m, 1H), 3.95(m, 2H), 3.80(d, 3H), 3.28(m, 1H), 2.90~2.67(m, 7H), 2.11(br, 1H), 1.90(m, 1H), 1.88(br, 1H), 1.83(m, 2H), 1.71(br, 1H), 1.62(br, 1H), 1.43(br, 1H), 1.26(m, 3H), 1.07(t, 3H), 0.97(m, 3H)
- [1514]
- [1515] **Example 320. (S)-quinuclidin-3-yl**
(5-(4-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate
- [1516] ¹H-NMR (400MHz, CDCl₃) δ 7.42(d, 2H), 7.09(s, 1H), 6.90(d, 2H), 6.85(d, 1H), 4.93(m, 2H), 4.81(m, 1H), 4.59(m, 1H), 3.80(d, 3H), 3.28(m, 1H), 2.90~2.72(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.37(d, 6H), 1.28(m, 3H), 0.97(m, 3H)

[1517]

[1518] **Example 321.(S)-quinuclidin-3-yl**

(5-(3,5-dimethyl-4-propoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1519] ¹H-NMR (400MHz, CDCl₃) δ 7.13(s, 2H), 7.07(s, 1H), 6.82(d, 1H), 4.93(m, 2H), 4.81(m, 1H), 3.78(m, 5H), 3.27(m, 1H), 2.90~2.69(m, 7H), 2.31(s, 6H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.69(m, 2H), 1.60(br, 1H), 1.43(br, 1H), 1.28(m, 3H), 1.09(t, 3H), 0.93(m, 3H)

[1520]

[1521] **Example 322.(S)-quinuclidin-3-yl**

(5-(3-chloro-4-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1522] ¹H-NMR (400MHz, CDCl₃) δ 7.52(s, 1H), 7.33(d, 1H), 7.07(s, 1H), 6.96(d, 1H), 6.83(d, 1H), 4.93(m, 2H), 4.81(m, 1H), 4.58(m, 1H), 3.78(m, 3H), 3.27(m, 1H), 2.90~2.70(m, 7H), 2.10(br, 1H), 1.86(br, 1H), 1.71(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.40(d, 6H), 1.28(m, 3H), 0.96(m, 3H)

[1523]

[1524] **Example 323.(S)-quinuclidin-3-yl**

(5-(2-fluoro-4-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1525] ¹H-NMR (400MHz, CDCl₃) δ 7.24(m, 1H), 7.03(s, 1H), 6.87(d, 1H), 6.75~6.67(m, 2H), 4.96(m, 2H), 4.81(m, 1H), 3.80(s, 3H), 3.78(m, 3H), 3.27(m, 1H), 2.90~2.70(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.58(br, 1H), 1.41(br, 1H), 1.28(m, 3H), 0.97(m, 3H)

[1526]

[1527] **Example 324.(S)-quinuclidin-3-yl**

(5-(4-butoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1528] ¹H-NMR (400MHz, CDCl₃) δ 7.42(d, 2H), 7.09(s, 1H), 6.93(d, 2H), 6.83(d, 1H), 4.93(m, 2H), 4.81(m, 1H), 3.98(m, 2H), 3.79(m, 3H), 3.27(m, 1H), 2.90~2.71(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.71(m, 2H), 1.69(br, 1H), 1.59(br, 1H), 1.52(m, 2H), 1.43(br, 1H), 1.27(m, 3H), 0.99(m, 6H)

[1529]

[1530] **Example 325.(S)-quinuclidin-3-yl**

(5-(4-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1531] ¹H-NMR (400MHz, CDCl₃) δ 7.42(d, 2H), 7.09(s, 1H), 6.93(d, 2H), 6.83(d, 1H), 4.93(m, 2H), 4.81(m, 1H), 3.79(m, 5H), 3.27(m, 1H), 2.90~2.71(m, 7H), 2.10(m, 2H),

1.85(br, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.43(br, 1H), 1.27(m, 3H), 0.99(m, 6H)

[1532]

[1533] **Example 326.(S)-quinuclidin-3-yl**

(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1534] ¹H-NMR (400MHz, CDCl₃) δ 8.24(s, 1H), 7.74(d, 1H), 7.07(s, 1H), 6.86(d, 1H), 6.80(d, 1H), 4.93(m, 2H), 4.81(m, 1H), 4.15(m, 2H), 3.79(m, 3H), 3.27(m, 1H), 2.90~2.71(m, 7H), 2.10(m, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.43(br, 1H), 1.27(m, 3H), 0.97(m, 3H), 0.62(m, 2H), 0.38(m, 2H)

[1535]

[1536] **Example 327.(S)-quinuclidin-3-yl**

(5-(5-chloro-2-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1537] ¹H-NMR (400MHz, CDCl₃) δ 7.25(s, 1H) 7.19(m, 1H), 7.00(s, 1H), 6.89~6.82(m, 2H), 4.93(m, 2H), 4.81(m, 1H), 3.79(m, 6H), 3.29(m, 1H), 2.92~2.65(m, 7H), 2.10(m, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.43(br, 1H), 1.29(m, 3H), 0.98(m, 3H)

[1538]

[1539] **Example 328.(S)-quinuclidin-3-yl**

(5-(4-butylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1540] ¹H-NMR (400MHz, CDCl₃) δ 7.40(d, 2H) 7.20(d, 2H), 7.10(s, 1H), 6.84(d, 1H), 4.95(s, 2H), 4.80(br, 1H), 3.78(d, 3H), 3.25(m, 1H), 2.92~2.65(m, 7H), 2.64(m, 2H), 2.10(m, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.60(m, 2H), 1.59(br, 1H), 1.43(m, 3H), 1.29(m, 3H), 0.98(m, 3H), 0.92(t, 3H)

[1541]

[1542] **Example 329. (S)-quinuclidin-3-yl**

(6-methoxy-5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1543] ¹H-NMR (400MHz, CDCl₃) δ 7.14(s, 2H) 7.07(s, 1H), 6.82(d, 1H), 4.94(s, 2H), 4.80(br, 1H), 3.78(d, 3H), 3.76(s, 3H), 3.25(m, 1H), 2.92~2.65(m, 7H), 2.32(s, 6H), 2.10(m, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.40(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1544]

[1545] **Example 330.(S)-quinuclidin-3-yl**

(5-(4-ethoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1546] ¹H-NMR (400MHz, CDCl₃) δ 7.14(s, 2H) 7.07(s, 1H), 6.83(d, 1H), 4.94(s, 2H), 4.80(br, 1H), 3.89(m, 2H), 3.78(d, 3H), 3.25(m, 1H), 2.92~2.65(m, 7H), 2.31(s, 6H), 2.10(m, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.43(t, 4H), 1.28(m, 3H),

0.98(m, 3H)

[1547]

[1548] **Example 331.(S)-quinuclidin-3-yl**

(5-(4-butoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1549] ¹H-NMR (400MHz, CDCl₃) δ 7.13(s, 2H), 7.07(s, 1H), 6.83(d, 1H), 4.93(m, 2H), 4.80(br, 1H), 3.80(m, 3H), 3.25(m, 1H), 2.92~2.71(m, 7H), 2.69(m, 2H), 2.31(s, 6H), 2.10(m, 1H), 1.85(br, 1H), 1.77(m, 2H), 1.69(br, 1H), 1.60(m, 2H), 1.59(m, 3H), 1.43(br, 1H), 1.29(m, 3H), 0.98(m, 6H)

[1550]

[1551] **Example 332.(S)-quinuclidin-3-yl**

(6-methoxy-5-(2-methoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1552] ¹H-NMR (400MHz, CDCl₃) δ 8.15(d, 1H), 7.11(s, 1H), 7.03(d, 1H), 6.89(s, 1H), 6.85(d, 1H), 4.93(m, 2H), 4.80(br, 1H), 3.97(s, 3H), 3.79(d, 3H), 3.25(m, 1H), 2.92~2.71(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.43(br, 1H), 1.29(m, 3H), 0.98(m, 6H)

[1553]

[1554] **Example 333. (S)-quinuclidin-3-yl**

(5-(3-fluorophenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1555] ¹H-NMR (400MHz, CDCl₃) δ 7.34(m, 1H), 7.25(m, 2H), 7.10(s, 1H), 7.02(m, 1H), 6.86(m, 1H), 4.95(s, 2H), 4.80(br, 1H), 3.81(m, 3H), 3.25(m, 1H), 2.90~2.71(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1556]

[1557] **Example 334.(S)-quinuclidin-3-yl**

(5-(3-ethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹

¹H-NMR (400MHz, CDCl₃) δ 7.33(s, 3H), 7.17(m, 1H), 7.16(s, 1H), 6.86(m, 1H), 4.95(m, 2H), 4.80(br, 1H), 3.80(m, 3H), 3.25(m, 1H), 2.90~2.80(m, 7H), 2.70(m, 2H), 2.10(br, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 6H), 0.98(m, 3H)

[1558]

[1559] **Example 335.(S)-quinuclidin-3-yl**

(5-(3-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1560] ¹H-NMR (400MHz, CDCl₃) δ 7.32~7.27(m, 3H), 7.11(m, 2H), 6.85(m, 1H), 4.95(m, 2H), 4.80(br, 1H), 3.79(m, 3H), 3.25(m, 1H), 2.90~2.72(m, 7H), 2.53(d, 2H), 2.10(br,

1H), 1.90(m, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H), 0.90(d, 6H)

[1561]

[1562] **Example 336.(S)-quinuclidin-3-yl**

(5-(3-isopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1563] ¹H-NMR (400MHz, CDCl₃) δ 7.33(m, 3H), 7.20(m, 1H), 7.12(s, 1H), 6.85(m, 1H), 4.95(m, 2H), 4.80(br, 1H), 3.80(m, 3H), 3.25(m, 1H), 2.95(m, 1H), 2.90~2.72(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 9H), 0.98(m, 3H)

[1564]

[1565] **Example 337.(S)-quinuclidin-3-yl (5-(3-(tert -**

butyl)phenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1566] ¹H-NMR (400MHz, CDCl₃) δ 7.52(s, 1H), 7.33(m, 3H), 7.12(s, 1H), 6.86(m, 1H), 4.95(m, 2H), 4.80(br, 1H), 3.80(m, 3H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.37(s, 9H), 1.28(m, 3H), 0.98(m, 3H)

[1567]

[1568] **Example 338.(S)-quinuclidin-3-yl**

(6-methoxy-5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1569] ¹H-NMR (400MHz, CDCl₃) δ 7.31(m, 1H), 7.11~7.06(m, 3H), 6.87(m, 2H), 4.95(m, 2H), 4.80(br, 1H), 3.84(s, 3H), 3.80(m, 3H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1570]

[1571] **Example 339.(S)-quinuclidin-3-yl**

(5-(3-ethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.30(m, 1H), 7.11(s, 1H), 7.07(m, 2H), 6.85(m, 2H), 4.95(m, 2H), 4.80(br, 1H), 4.08(m, 2H), 3.79(m, 3H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.43(t, 3H), 1.28(m, 3H), 0.98(m, 3H)

[1572]

[1573] **Example 340.(S)-quinuclidin-3-yl**

(6-methoxy-2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1574] ¹H-NMR (400MHz, CDCl₃) δ 7.28(m, 1H), 7.11(s, 1H), 7.06(m, 2H), 6.86(m, 2H), 4.95(m, 2H), 4.80(br, 1H), 3.96(m, 2H), 3.79(m, 3H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.80(m, 2H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H),

1.28(m, 3H), 0.98(m, 6H)

[1575]

[1576] **Example 341.(S)-quinuclidin-3-yl**

(5-(3-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1577] ¹H-NMR (400MHz, CDCl₃) δ 7.28(m, 1H), 7.11(s, 1H), 7.05(m, 2H), 6.85(d, 2H), 4.95(m, 2H), 4.80(br, 1H), 4.59(m, 1H), 3.80(m, 3H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.35(d, 6H), 1.28(m, 3H), 0.98(m, 3H)

[1578]

[1579] **Example 342.(S)-quinuclidin-3-yl**

(5-(3-butoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.28(m, 1H), 7.10(s, 1H), 7.05(m, 2H), 6.86(d, 2H), 4.95(m, 2H), 4.80(br, 1H), 3.98(m, 2H), 3.80(m, 3H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.78(m, 2H), 1.70(br, 1H), 1.59(br, 1H), 1.55(m, 2H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 6H)

[1580]

[1581] **Example 343.(S)-quinuclidin-3-yl**

(5-(3-isobutoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1582] ¹H-NMR (400MHz, CDCl₃) δ 7.28(m, 1H), 7.11(s, 1H), 7.05(m, 2H), 6.85(d, 2H), 4.95(m, 2H), 4.80(br, 1H), 3.80(m, 3H), 3.75(d, 2H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(m, 2H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 9H)

[1583]

[1584] **Example 344.(S)-quinuclidin-3-yl**

(5-(2,5-dimethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1585] ¹H-NMR (400MHz, CDCl₃) δ 7.03(s, 1H), 7.03~6.80(m, 4H), 4.95(s, 2H), 4.80(br, 1H), 3.78(m, 6H), 3.73(s, 3H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1586]

[1587] **Example 345.(S)-quinuclidin-3-yl**

(5-(3,5-dimethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1588] ¹H-NMR (400MHz, CDCl₃) δ 7.11(s, 1H), 6.85(m, 1H), 6.65(s, 2H), 6.45(s, 1H), 4.95(s, 2H), 4.80(br, 1H), 3.80(m, 9H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1589]

[1590] **Example 346. (S)-quinuclidin-3-yl**

(5-(2-chloro-4-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1591] ¹H-NMR (400MHz, CDCl₃) δ 7.17(d, 1H), 7.00(s, 1H), 6.96(s, 1H), 6.84(m, 2H), 4.95(s, 2H), 4.80(br, 1H), 3.82(s, 3H), 3.75(m, 3H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1592]

[1593] **Example 347.(S)-quinuclidin-3-yl**

(5-(4-ethoxy-3-fluorophenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1594] ¹H-NMR (400MHz, CDCl₃) δ 7.30(m 1H), 7.18(d, 1H), 7.08(s, 1H), 6.98(t, 1H), 6.84(d, 1H), 4.95(s, 2H), 4.80(br, 1H), 4.14(m, 2H), 3.79(m, 3H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.47(t, 3H), 1.45(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1595]

[1596] **Example 348. (S)-quinuclidin-3-yl**

(5-(4-isopropoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1597] ¹H-NMR (400MHz, CDCl₃) δ 7.13(s, 2H), 7.08(s, 1H), 6.82(d, 1H), 4.95(s, 2H), 4.80(br, 1H), 4.22(m, 1H), 3.78(m, 3H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.30(s, 6H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.45(br, 1H), 1.30(d, 6H), 1.28(m, 3H), 0.98(m, 3H)

[1598]

[1599] **Examples 349 to 388**

[1600] The titled compounds of Examples 349 to 388 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (5-bromo-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate prepared in Preparation 7; and the corresponding substituted-boronic acids, respectively.

[1601]

[1602] **Example 349.(S)-quinuclidin-3-yl**

(5-(4-ethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1603] ¹H-NMR (400MHz, CDCl₃) δ 7.44(d, 2H), 7.27(d, 2H), 7.20(d, 1H), 7.03~6.97(m, 1H), 4.93(m, 2H), 4.79(br, 1H), 3.28(m, 1H), 2.90~2.71(m, 7H), 2.69(m, 2H), 2.11(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.59(br, 1H), 1.43(br, 1H), 1.32(m, 6H), 0.97(m, 3H)

[1604]

[1605] **Example 350.(S)-quinuclidin-3-yl**

(6-fluoro-2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1606] ¹H-NMR (400MHz, CDCl₃) δ 7.44(d, 2H), 7.27(m, 2H), 7.00(m, 1H), 7.03~6.97(m, 1H), 4.92(m, 2H), 4.79(br, 1H), 3.28(m, 1H), 2.90~2.71(m, 7H), 2.63(m, 2H), 2.11(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.68(m, 2H), 1.60(br, 1H), 1.43(br, 1H), 1.32(m, 6H), 0.97(m, 3H)

[1607]

Example 351.(S)-quinuclidin-3-yl**(6-fluoro-5-(4-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1609] ¹H-NMR (400MHz, CDCl₃) δ 7.44(d, 2H), 7.27(m, 2H), 7.00(m, 1H), 7.03~6.97(m, 1H), 4.92(m, 2H), 4.79(br, 1H), 3.28(m, 1H), 2.96(m, 1H), 2.90~2.72(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.28(m, 9H), 0.97(m, 3H)

[1610]

Example 352. (S)-quinuclidin-3-yl**(6-fluoro-5-(4-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1612] ¹H-NMR (400MHz, CDCl₃) δ 7.44(d, 2H), 7.22(d, 3H), 7.03~6.97(m, 1H), 4.92(m, 2H), 4.79(br, 1H), 3.28(m, 1H), 2.90~2.72(m, 7H), 2.52(d, 2H), 2.11(br, 1H), 1.94(m, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.30(m, 3H), 0.98(m, 3H), 0.94(d, 6H)

[1613]

Example 353. (S)-quinuclidin-3-yl (5-(4-(tert -**butyl)phenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1615] ¹H-NMR (400MHz, CDCl₃) δ 7.46(s, 4H), 7.21(d, 1H), 7.03~6.97(m, 1H), 4.99~4.90(m, 2H), 4.79(br, 1H), 3.29(m, 1H), 2.90~2.69(m, 7H), 2.11(br, 1H), 1.94(m, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.33(s, 9H), 1.30(m, 3H), 0.98(m, 3H)

[1616]

Example 354.(S)-quinuclidin-3-yl**(5-(4-cyclopropylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1618] ¹H-NMR (400MHz, CDCl₃) δ 7.42(d, 2H), 7.20(d, 1H), 7.13(d, 2H), 7.02~6.99(m, 1H), 4.98~4.88(m, 2H), 4.79(br, 1H), 3.28(m, 1H), 2.88~2.68(m, 7H), 2.11(br, 1H), 1.95(m, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.29(m, 3H), 1.00(m, 2H), 0.98(m, 3H), 0.75(m, 2H)

[1619]

Example 355. (S)-quinuclidin-3-yl**(6-fluoro-5-(4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1621] ¹H-NMR (400MHz, CDCl₃) δ 7.46(d, 2H), 7.19(d, 1H), 6.99(m, 3H), 4.98(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 3.96(s, 3H), 3.28(m, 1H), 2.88~2.68(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.29(m, 3H), 0.98(m, 3H)

[1622]

[1623] **Example 356. (S)-quinuclidin-3-yl**

(5-(4-ethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1624] ¹H-NMR (400MHz, CDCl₃) δ 7.44(d, 2H), 7.18(d, 1H), 6.98(m, 3H), 4.98(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 4.11(m, 2H), 3.28(m, 1H), 2.88~2.68(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.45(t, 3H), 1.44(br, 1H), 1.29(m, 3H), 0.98(m, 3H)

[1625]

[1626] **Example 357. (S)-quinuclidin-3-yl**

(6-fluoro-2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1627] ¹H-NMR (400MHz, CDCl₃) δ 7.44(d, 2H), 7.18(d, 1H), 6.98(m, 3H), 4.98(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 3.97(t, 2H), 3.28(m, 1H), 2.88~2.68(m, 7H), 2.11(br, 1H), 1.85(m, 3H), 1.72(br, 1H), 1.60(br, 1H), 1.45(t, 3H), 1.44(br, 1H), 1.29(m, 3H), 1.05(t, 3H), 0.98(m, 3H)

[1628]

[1629] **Example 358. (S)-quinuclidin-3-yl**

(6-fluoro-5-(4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1630] ¹H-NMR (400MHz, CDCl₃) δ 7.43(d, 2H), 7.18(d, 1H), 7.02(m, 1H), 6.94(d, 2H), 4.98(m, 1H), 4.88(m, 1H), 4.79(br, 1H), 4.58(m, 1H), 3.28(m, 1H), 2.88~2.68(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.44(br, 1H), 1.31(d, 6H), 1.29(m, 3H), 0.98(m, 3H)

[1631]

[1632] **Example 359. (S)-quinuclidin-3-yl**

(5-(3-chloro-4-isopropoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1633] ¹H-NMR (400MHz, CDCl₃) δ 7.54(s, 1H), 7.37(d, 1H), 7.18(d, 1H), 7.02(m, 2H), 4.98(m, 2H), 4.79(br, 1H), 4.57(m, 1H), 3.28(m, 1H), 2.88~2.68(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.44(br, 1H), 1.42(d, 6H), 1.28(m, 3H), 0.98(m, 3H)

[1634]

[1635] **Example 360. (S)-quinuclidin-3-yl**

(6-fluoro-5-(2-fluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1636] ¹H-NMR (400MHz, CDCl₃) δ 7.28(m, 1H), 7.14(d, 1H), 7.00(m, 1H), 6.75(m, 2H), 4.98(m, 2H), 4.79(br, 1H), 3.84(s, 3H), 3.28(m, 1H), 2.88~2.68(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.29(m, 3H), 0.98(m, 3H)

[1637]

[1638] **Example 361. (S)-quinuclidin-3-yl
(5-(4-butoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate**

[1639] ¹H-NMR (400MHz, CDCl₃) δ 7.44(d, 1H), 7.18(d, 1H), 6.98(m, 3H), 4.98(m, 2H), 4.79(br, 1H), 4.01(t, 2H), 3.28(m, 1H), 2.88~2.68(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.81(m, 2H), 1.72(br, 1H), 1.60(br, 1H), 1.51(m, 2H), 1.43(br, 1H), 1.29(m, 3H), 0.98(m, 6H)

[1640]

[1641] **Example 362.(S)-quinuclidin-3-yl
(6-fluoro-5-(4-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbama
te**

[1642] ¹H-NMR (400MHz, CDCl₃) δ 7.44(d, 2H), 7.18(d, 1H), 6.97(m, 3H), 4.98(m, 2H), 4.79(br, 1H), 3.77(d, 2H), 3.28(m, 1H), 2.88~2.68(m, 7H), 2.11(m, 3H), 1.85(br, 1H), 1.81(m, 2H), 1.72(br, 1H), 1.60(br, 1H), 1.51(m, 2H), 1.43(br, 1H), 1.29(m, 3H), 1.05(d, 6H), 0.98(m, 6H)

[1643]

[1644] **Example 363.(S)-quinuclidin-3-yl
(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-in
den-1-yl)carbamate**

[1645] ¹H-NMR (400MHz, CDCl₃) δ 8.27(s, 1H), 7.74(d, 1H), 7.16(d, 1H), 7.00(m, 1H), 6.83(d, 1H), 4.98(m, 1H), 4.90(m, 1H), 4.79(br, 1H), 4.18(d, 2H), 3.28(m, 1H), 2.88~2.68(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.29(m, 4H), 0.98(m, 3H), 0.64(m, 2H), 0.37(m, 2H)

[1646]

[1647] **Example 364.(S)-quinuclidin-3-yl
(5-(5-chloro-2-methoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)c
arbamate**

[1648] ¹H-NMR (400MHz, CDCl₃) δ 7.31(m, 2H), 7.09(d, 1H), 6.97(m, 1H), 6.89(d, 1H), 4.98(m, 1H), 4.90(m, 1H), 4.79(br, 1H), 3.78(s, 3H), 3.28(m, 1H), 2.88~2.68(m, 7H), 2.11(br, 1H), 1.85(br, 1H), 1.72(br, 1H), 1.60(br, 1H), 1.43(br, 1H), 1.29(m, 4H), 0.98(m, 3H), 0.64(m, 2H), 0.37(m, 2H)

[1649]

[1650] **Example 365.(S)-quinuclidin-3-yl
(5-(4-butylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹H
-NMR (400MHz, CDCl₃) δ 7.42(d, 2H) 7.25(m, 3H), 6.97(m, 1H), 4.95(s, 1H),**

4.85(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.92~2.65(m, 7H), 2.64(m, 2H), 2.10(m, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.60(m, 2H), 1.59(br, 1H), 1.43(m, 3H), 1.29(m, 3H), 0.98(m, 6H)

[1651]

[1652] **Example 366.(S)-quinuclidin-3-yl**

(6-fluoro-5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1653] ¹H-NMR (400MHz, CDCl₃) δ 7.17(s, 4H), 7.98(m, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.77(s, 3H), 3.25(m, 1H), 2.92~2.65(m, 7H), 2.34(s, 6H), 2.10(br, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.58(br, 1H), 1.40(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1654]

[1655] **Example 367.(S)-quinuclidin-3-yl**

(5-(4-ethoxy-3,5-dimethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1656] ¹H-NMR (400MHz, CDCl₃) δ 7.17(s, 4H), 6.98(m, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.88(d, 3H), 3.25(m, 1H), 2.92~2.65(m, 7H), 2.32(s, 6H), 2.10(br, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.44(t, 4H), 1.28(m, 3H), 0.98(m, 3H)

[1657]

[1658] **Example 368.(S)-quinuclidin-3-yl**

(5-(4-butoxy-3,5-dimethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1659] ¹H-NMR (400MHz, CDCl₃) δ 7.18(s, 4H), 6.98(m, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.80(m, 2H), 3.25(m, 1H), 2.92~2.71(m, 7H), 2.31(s, 6H), 2.10(m, 1H), 1.85(br, 1H), 1.77(m, 2H), 1.69(br, 1H), 1.60(m, 2H), 1.59(m, 3H), 1.43(br, 1H), 1.29(m, 3H), 0.98(m, 6H)

[1660]

[1661] **Example 369.(S)-quinuclidin-3-yl**

(6-fluoro-5-(2-methoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1662] ¹H-NMR (400MHz, CDCl₃) δ 8.19(d, 1H), 7.23(m, 1H), 7.03(m, 1H), 6.89(s, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.97(s, 3H), 3.25(m, 1H), 2.92~2.71(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.43(br, 1H), 1.29(m, 3H), 0.98(m, 3H)

[1663]

[1664] **Example 370.(S)-quinuclidin-3-yl**

(6-fluoro-5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.38(m, 1H), 7.36~7.19(m, 3H), 7.05(m, 2H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.90~2.71(m, 7H), 2.10(br, 1H), 1.85(br,

1H), 1.69(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1665]

[1666] **Example 371.(S)-quinuclidin-3-yl**

(5-(3-ethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹H-NMR (400MHz, CDCl₃) δ 7.34(m, 3H), 7.20(m, 2H), 7.00(m, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.90~2.70(m, 7H), 2.68(m, 2H), 2.10(br, 1H), 1.85(br, 1H), 1.69(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 6H), 0.98(m, 3H)

[1667]

[1668] **Example 372.(S)-quinuclidin-3-yl**

(6-fluoro-5-(3-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹H-NMR (400MHz, CDCl₃) δ 7.34(m, 2H), 7.27(m, 1H), 7.21(m, 1H), 7.15(m, 1H), 6.99(m, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.90~2.72(m, 7H), 2.52(d, 2H), 2.10(br, 1H), 1.90(m, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H), 0.90(d, 6H)

[1669]

[1670] **Example 373.(S)-quinuclidin-3-yl**

(6-fluoro-5-(3-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹H-NMR (400MHz, CDCl₃) δ 7.37~7.34(m, 3H), 7.22(m, 2H), 6.99(m, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.25(m, 1H), 2.95(m, 1H), 2.90~2.72(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 9H), 0.98(m, 3H)

[1671]

[1672] **Example 374.(S)-quinuclidin-3-yl (5-(3-(tert -**

butyl)phenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹H-NMR (400MHz, CDCl₃) δ 7.53(s, 1H), 7.41(m, 1H), 7.35(m, 1H), 7.22(d, 1H), 7.01(m, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.80(m, 3H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.37(s, 9H), 1.28(m, 3H), 0.98(m, 3H)

[1673]

[1674] **Example 375.(S)-quinuclidin-3-yl**

(6-fluoro-5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹H-NMR (400MHz, CDCl₃) δ 7.35(m, 1H), 7.22(m, 1H), 7.11(m, 1H), 7.09(s, 1H), 7.01(m, 1H), 6.91(d, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.85(s, 3H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1675]

[1676] **Example 376.(S)-quinuclidin-3-yl**

(5-(3-ethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate¹H-NMR (400MHz, CDCl₃) δ 7.35(m, 1H), 7.22(m, 1H), 7.11(m, 1H), 7.09(s, 1H),

7.01(m, 1H), 6.89(d, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 4.09(m, 2H),
3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H),
1.46(br, 1H), 1.45(t, 3H), 1.28(m, 3H), 0.98(m, 3H)

[1677]

[1678] **Example 377.(S)-quinuclidin-3-yl**

(6-fluoro-2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.33(m, 1H), 7.22(d, 1H), 7.11(m, 1H), 7.09(s, 1H),
7.01(m, 1H), 6.90(d, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.96(m, 2H),
3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.80(m, 2H), 1.70(br, 1H),
1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 1.15(t, 3H), 0.98(m, 3H)

[1679]

[1680] **Example 378.(S)-quinuclidin-3-yl**

(6-fluoro-5-(3-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1681] ¹H-NMR (400MHz, CDCl₃) δ 7.32(m, 1H), 7.22(d, 1H), 7.11(m, 1H), 7.09(s, 1H),
7.01(m, 1H), 6.87(d, 1H), 4.95(m, 2H), 4.80(br, 1H), 4.57(m, 1H), 3.25(m, 1H),
2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H),
1.35(d, 6H), 1.28(m, 3H), 0.98(m, 3H)

[1682]

[1683] **Example 379.(S)-quinuclidin-3-yl**

(5-(3-butoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1684] ¹H-NMR (400MHz, CDCl₃) δ 7.34(m, 1H), 7.22(d, 1H), 7.10~7.01(m, 3H), 6.89(d,
1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 4.00(m, 2H), 3.25(m, 1H), 2.90~2.73(m,
7H), 2.10(br, 1H), 1.85(br, 1H), 1.78(m, 2H), 1.70(br, 1H), 1.59(br, 1H), 1.53(m, 2H),
1.46(br, 1H), 1.28(m, 3H), 0.98(m, 6H)

[1685]

[1686] **Example 380.(S)-quinuclidin-3-yl**

(6-fluoro-5-(3-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

¹H-NMR (400MHz, CDCl₃) δ 7.33(m, 1H), 7.22(d, 1H), 7.11~6.91(m, 3H), 6.89(d,
1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.76(d, 2H), 3.25(m, 1H), 2.90~2.73(m,
7H), 2.10(m, 2H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H),
1.05(d, 6H), 0.97(m, 3H)

[1687]

[1688] **Example 381.(S)-quinuclidin-3-yl**

(5-(2,4-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1689] ¹H-NMR (400MHz, CDCl₃) δ 7.16(d 1H), 7.09(d, 1H), 6.97(m, 1H), 6.56(m, 2H),
4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.85(s, 3H), 3.79(s, 3H), 3.25(m, 1H),

2.92~2.71(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1690]

[1691] **Example 382.(S)-quinuclidin-3-yl**

(5-(2,5-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1692] ¹H-NMR (400MHz, CDCl₃) δ 7.12(d, 1H), 7.01(m, 1H), 6.96(m, 2H), 6.87(s, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.79(s, 3H), 3.76(s, 3H), 3.25(m, 1H), 2.93~2.72(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1693]

[1694] **Example 383.(S)-quinuclidin-3-yl**

(5-(2,6-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1695] ¹H-NMR (400MHz, CDCl₃) δ 7.33(m, 1H), 7.05(d, 1H), 6.98(m, 1H), 6.65(d, 2H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.75(s, 6H), 3.25(m, 1H), 2.93~2.72(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1696]

[1697] **Example 384.(S)-quinuclidin-3-yl**

(5-(3,5-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1698] ¹H-NMR (400MHz, CDCl₃) δ 7.20(d, 1H), 7.02(m, 1H), 6.65(s, 2H), 6.48(s, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.83(s, 6H), 3.25(m, 1H), 2.89~2.72(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1699]

[1700] **Example 385.(S)-quinuclidin-3-yl**

(5-(3,4-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1701] ¹H-NMR (400MHz, CDCl₃) δ 7.20(d, 1H), 7.08~6.92(m, 3H), 6.93(d, 1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.93(s, 6H), 3.25(m, 1H), 2.93~2.72(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1702]

[1703] **Example 386.(S)-quinuclidin-3-yl**

(5-(2-chloro-4-methoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1704] ¹H-NMR (400MHz, CDCl₃) δ 7.21(d, 1H), 7.06(d, 1H), 7.03~7.00(m, 2H), 6.86(d,

1H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 3.84(s, 3H), 3.25(m, 1H), 2.90~2.72(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.46(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1705]

[1706] **Example 387.(S)-quinuclidin-3-yl**

(5-(4-ethoxy-3-fluorophenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1707] ¹H-NMR (400MHz, CDCl₃) δ 7.29(m, 1H), 7.23(m, 1H), 7.17(d, 1H), 7.01(m, 2H), 4.95(s, 1H), 4.85(m, 1H), 4.80(br, 1H), 4.15(m, 2H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.47(t, 3H), 1.45(br, 1H), 1.28(m, 3H), 0.98(m, 3H)

[1708]

[1709] **Example 388.(S)-quinuclidin-3-yl**

(6-fluoro-5-(4-isopropoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1710] ¹H-NMR (400MHz, CDCl₃) δ 7.19~7.00(m, 3H), 6.97(m, 1H), 4.95(m, 1H), 4.85(m, 1H), 4.80(br, 1H), 4.21(m, 1H), 3.25(m, 1H), 2.90~2.73(m, 7H), 2.31(s, 6H), 2.10(br, 1H), 1.85(br, 1H), 1.70(br, 1H), 1.59(br, 1H), 1.45(br, 1H), 1.30(d, 6H), 1.28(m, 3H), 0.98(m, 3H)

[1711]

[1712] **Examples 389 to 398**

[1713] The titled compounds of Examples 389 to 398 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (5'-bromo-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate prepared in Preparation 8; and the corresponding substituted-phenylboronic acids, respectively.

[1714]

[1715] **Example 389. (S)-quinuclidin-3-yl**

(5'-(4-fluorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate

[1716] ¹H-NMR (400MHz, CDCl₃) δ 7.54(m, 2H), 7.42(m, 2H), 7.38(s, 1H), 7.13(t, 2H), 5.02(m, 1H), 4.93(m, 1H), 4.74(m, 1H), 3.25(m, 1H), 3.10(m, 1H), 2.91~2.72(m, 6H), 2.09(m, 1H), 1.82(m, 1H), 1.70(br, 1H), 1.60(m, 1H), 1.43(br, 1H), 0.92(m, 2H), 0.81(m, 1H), 0.59(m, 1H)

[1717]

[1718] **Example 390.(S)-quinuclidin-3-yl**

(5'-(4-chlorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate

[1719] ¹H-NMR (400MHz, CDCl₃) δ 7.55(d, 2H), 7.47(m, 5H), 5.02(m, 1H), 4.91(m, 1H), 4.77(m, 1H), 3.25(m, 1H), 3.10(m, 1H), 2.91~2.72(m, 6H), 2.09(m, 1H), 1.82(m, 1H), 1.70(br, 1H), 1.60(m, 1H), 1.43(br, 1H), 0.92(m, 2H), 0.81(m, 1H), 0.59(m, 1H)

[1720]

[1721] **Example 391.(S)-quinuclidin-3-yl**

(5'-(4-(trifluoromethyl)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl) carbamate

[1722] ¹H-NMR (400MHz, CDCl₃) δ 7.69(s, 4H), 7.47(m, 3H), 5.04(m, 1H), 4.95(m, 1H), 4.77(m, 1H), 3.25(m, 1H), 3.10(m, 1H), 2.91~2.72(m, 6H), 2.09(m, 1H), 1.82(m, 1H), 1.70(br, 1H), 1.60(m, 1H), 1.43(br, 1H), 0.91(m, 2H), 0.81(m, 1H), 0.59(m, 1H)

[1723]

[1724] **Example 392.(S)-quinuclidin-3-yl**

(5'-(4-(trifluoromethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl) carbamate

[1725] ¹H-NMR (400MHz, CDCl₃) δ 7.58(d, 2H), 7.46(m, 2H), 7.40(s, 1H), 7.29(d, 2H), 5.03(m, 1H), 4.94(m, 1H), 4.76(m, 1H), 3.25(m, 1H), 3.09(m, 1H), 2.95~2.76(m, 6H), 2.09(m, 1H), 1.82(m, 1H), 1.72(br, 1H), 1.62(m, 1H), 1.43(br, 1H), 0.92(m, 2H), 0.81(m, 1H), 0.59(m, 1H)

[1726]

[1727] **Example 393.(S)-quinuclidin-3-yl**

(5'-(3-chlorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl) carbamate

[1728] ¹H-NMR (400MHz, CDCl₃) δ 7.56(s, 1H), 7.44(m, 2H), 7.37(m, 1H), 7.33(m, 1H), 5.02(m, 1H), 4.91(m, 1H), 4.77(m, 1H), 3.25(m, 1H), 2.91~2.72(m, 7H), 2.09(m, 1H), 1.80(m, 1H), 1.70(br, 1H), 1.60(m, 1H), 1.43(br, 1H), 0.91(m, 2H), 0.80(m, 1H), 0.59(m, 1H)

[1729]

[1730] **Example 394.(S)-quinuclidin-3-yl**

(5'-(3-(trifluoromethyl)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl) carbamate

[1731] ¹H-NMR (400MHz, CDCl₃) δ 7.56(s, 1H), 7.44(m, 2H), 7.37(m, 1H), 7.33(m, 1H), 5.02(m, 1H), 4.91(m, 1H), 4.77(m, 1H), 3.25(m, 1H), 2.91~2.72(m, 7H), 2.09(m, 1H), 1.80(m, 1H), 1.70(br, 1H), 1.60(m, 1H), 1.43(br, 1H), 0.91(m, 2H), 0.80(m, 1H), 0.59(m, 1H)

[1732]

[1733] **Example 395.(S)-quinuclidin-3-yl**

(5'-(4-(2-methoxyethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl) carbamate

[1734] ¹H-NMR (400MHz, CDCl₃) δ 7.51(d, 2H), 7.41(m, 3H), 7.01(d, 2H), 5.02(m, 1H), 4.90(m, 1H), 4.75(m, 1H), 4.18(m, 2H), 3.80(m, 2H), 3.48(s, 3H), 3.25(m, 1H), 3.08(m, 1H), 2.91~2.72(m, 5H), 2.09(m, 1H), 1.85(br, 1H), 1.80(m, 1H), 1.70(br, 1H), 1.60(m, 1H), 1.43(br, 1H), 0.91(m, 2H), 0.81(m, 1H), 0.59(m, 1H)

[1735]

[1736] **Example 396. (S)-quinuclidin-3-yl**

(5'-(3-(2-methoxyethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate

[1737] ¹H-NMR (400MHz, CDCl₃) δ 7.46(m, 2H), 7.45(s, 1H), 7.35(t, 1H), 7.18(m, 2H), 6.93(d, 1H), 5.04(m, 1H), 4.91(m, 1H), 4.75(m, 1H), 4.19(m, 2H), 3.79(m, 2H), 3.48(s, 3H), 3.25(m, 1H), 3.08(m, 1H), 2.91~2.72(m, 5H), 2.09(m, 1H), 1.85(br, 1H), 1.80(m, 1H), 1.70(br, 1H), 1.60(m, 1H), 1.43(br, 1H), 0.91(m, 2H), 0.81(m, 1H), 0.59(m, 1H)

[1738]

[1739] **Example 397.(S)-quinuclidin-3-yl**

(5'-(4-(methoxymethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate

[1740] ¹H-NMR (400MHz, CDCl₃) δ 7.51(d, 2H), 7.43(d, 2H), 7.39(s, 1H), 7.11(d, 2H), 5.22(s, 2H), 5.02(m, 1H), 4.92(m, 1H), 4.75(m, 1H), 3.52(s, 3H), 3.25(m, 1H), 3.08(m, 1H), 2.91~2.72(m, 5H), 2.09(m, 1H), 1.85(br, 1H), 1.80(m, 1H), 1.70(br, 1H), 1.60(m, 1H), 1.43(br, 1H), 0.91(m, 2H), 0.79(m, 1H), 0.59(m, 1H)

[1741]

[1742] **Example 398.(S)-quinuclidin-3-yl**

(5'-(3-(methoxymethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate

[1743] ¹H-NMR (400MHz, CDCl₃) δ 7.46(m, 2H), 7.45(s, 1H), 7.35(t, 1H), 7.18(m, 2H), 6.93(d, 1H), 5.22(s, 2H), 5.02(m, 1H), 4.92(m, 1H), 4.75(m, 1H), 3.51(s, 3H), 3.25(m, 1H), 3.08(m, 1H), 2.91~2.72(m, 5H), 2.09(m, 1H), 1.85(br, 1H), 1.80(m, 1H), 1.70(br, 1H), 1.60(m, 1H), 1.43(br, 1H), 0.91(m, 2H), 0.80(m, 1H), 0.59(m, 1H)

[1744]

[1745] **Examples 399 to 403**

[1746] The titled compounds of Examples 399 to 403 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate prepared in Preparation 9; and the corresponding substituted-phenylboronic acids, respectively.

[1747]

[1748] **Example 399. (S)-quinuclidin-3-yl**

(5-(3-chlorophenyl)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1749] ¹H NMR (400MHz, CD₃OD) δ 7.62~7.49(m, 2H), 7.48~7.29(m, 5H), 5.23(d, 1H), 4.80(brs, 1H), 4.14~4.08(m, 1H), 3.29~3.24(m, 1H), 2.92~2.72(m, 5H), 2.43~2.37(m, 1H), 2.12~2.05(m, 1H), 2.00~1.93(m, 1H), 1.88~1.75(m, 2H), 1.70~1.63(m, 1H), 1.54~1.43(m, 4H), 1.26(brs, 3H)

[1750]

[1751] **Example 400. (S)-quinuclidin-3-yl**

(5-(2-chlorophenyl)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

[1752] ¹H NMR (400MHz, CD₃OD) δ 7.52~7.45(m, 1H), 7.38~7.22(m, 6H), 5.29~5.21(m, 1H), 4.94~4.90(m, 7H), 4.86~4.77(m, 1H), 4.15~4.07(m, 1H), 3.31~3.22(m, 1H), 2.93~2.71(m, 4H), 2.46~2.37(m, 1H), 2.14~2.05(m, 1H), 2.01~1.93(m, 1H), 1.90~1.74(m, 2H), 1.73~1.61(m, 1H), 1.57~1.48(m, 1H), 1.48~1.40(m, 3H), 1.28~1.24(m, 3H)

[1753]

[1754] **Example 401. (S)-quinuclidin-3-yl**

(3,3-dimethyl-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1755] ¹H NMR (400MHz, CD₃OD) δ 7.89~7.84(m, 2H), 7.66~7.63(m, 2H), 7.53~7.46(m, 2H), 7.35(dd, 1H), 5.26(t, 1H), 4.83~4.78(m, 1H), 3.30~3.26(m, 1H), 2.92~2.73(m, 5H), 2.42(ddd, 1H), 2.14~2.06(m, 1H), 1.96(dd, 1H), 1.89~1.76(m, 2H), 1.71~1.65(m, 1H), 1.55~1.46(m, 4H), 1.30~1.27(m, 3H)

[1756]

[1757] **Example 402. (S)-quinuclidin-3-yl**

(3,3-dimethyl-5-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1758] ¹H NMR (400MHz, CD₃OD) δ 7.62(d, 1H), 7.56~7.43(m, 4H), 7.36~7.24(m, 2H), 5.24(brs, 1H), 4.85~4.78(m, 1H), 3.29~3.19(m, 1H), 2.92~2.72(m, 5H), 2.41(dd, 1H), 2.10(d, 1H), 2.03~1.94(m, 1H), 1.88~1.76(m, 2H), 1.71~1.64(m, 1H), 1.54~1.44(m, 4H), 1.28(brs, 3H)

[1759]

[1760] **Example 403. (S)-quinuclidin-3-yl**

(3,3-dimethyl-5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate

[1761] ¹H NMR(400MHz, CD₃OD) δ 7.50~7.38(m, 4H), 7.34~7.28(m, 3H), 5.26(t, 1H), 4.83~4.78(m, 1H), 3.29~3.26(m, 1H), 2.92~2.73(m, 5H), 2.42(dt, 1H), 2.10(dd, 1H), 2.00~1.96(m, 1H), 1.88~1.77(m, 2H), 1.70~1.66(m, 1H), 1.52(brs, 1H), 1.43(s, 3H), 1.26(s, 3H)

[1762]

[1763] **Examples 404 and 405**

[1764] The titled compounds of Examples 404 and 405 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (6-bromo-dihydrobenzofuran-3-yl)carbamate prepared in Preparation 10; and the corresponding substituted-phenylboronic acids, respectively.

[1765]

[1766] **Example 404. (S)-quinuclidin-3-yl**

(6-(3-(trifluoromethyl)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate

[1767] ¹H-NMR (400MHz, CDCl₃) δ 7.78(s, 1H), 7.30~7.11(d, 1H), 7.62~7.60(d, 1H), 7.56~7.52(t, 1H), 7.45~7.41(t, 1H), 7.17~7.14(m, 1H), 7.06(s, 1H), 5.42(m, 2H), 4.76~4.72(m, 2H), 4.44~4.41(m, 1H), 3.25~3.19(m, 1H), 2.82~2.69(m, 5H), 2.03~2.00(m, 1H), 1.77~1.65(m, 2H), 1.59~1.57(m, 1H), 1.45~1.30(m, 1H)

[1768]

Example 405. (S)-quinuclidin-3-yl**(6-(3-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate**

[1770] ¹H-NMR (400MHz, CDCl₃) δ 7.48~7.38(m, 4H), 7.21~7.20(d, 1H), 7.15~7.12(m, 1H), 7.04(s, 1H), 5.43~5.38(m, 2H), 4.76~4.71(m, 2H), 4.44~4.41(m, 1H), 3.25~3.19(m, 1H), 2.82~2.66(m, 5H), 2.03~2.01(m, 1H), 1.77~1.65(m, 2H), 1.59~1.55(m, 1H), 1.39(m, 1H)

[1771]

Example 406. (S)-quinuclidin-3-yl**(5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate**

[1773] The titled compound was prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (5-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate prepared in Preparation 11; and 3-fluorophenylboronic acid.

[1774] ¹H-NMR (400MHz, CDCl₃) δ 7.52~7.44(m, 2H), 7.38~7.27(m, 2H), 7.23~7.21(d, 1H), 7.02~6.98(t, 1H), 6.85~6.83(d, 1H), 5.22~5.19(m, 1H), 5.09~5.07(m, 1H), 4.76~4.74(m, 1H), 3.26~3.20(m, 1H), 2.82~2.64(m, 5H), 1.77~1.68(m, 2H), 1.66~1.53(m, 4H), 1.46~1.39(m, 4H), 1.27(m, 1H)

[1775]

Examples 407 to 411

[1777] The titled compounds of Examples 407 to 411 were prepared in accordance with the same procedures as in Example 1, using (S)-quinuclidin-3-yl (6-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate prepared in Preparation 12; and the corresponding substituted-phenylboronic acids, respectively.

[1778]

Example 407. (S)-quinuclidin-3-yl**(6-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate**

[1780] ¹H-NMR (400MHz, CDCl₃) δ 7.39~7.31(m, 3H), 7.27~7.22(t, 1H), 7.12~7.09(t, 1H), 7.06~7.02(t, 1H), 6.95(s, 1H), 5.36~5.30(m, 1H), 5.06~5.04(d, 1H), 4.76~4.74(m, 1H), 3.24~3.19(m, 1H), 2.81~2.69(m, 5H), 1.76~1.67(m, 2H), 1.54~1.49(m, 4H), 1.45~1.43(m, 4H), 1.40~1.26(m, 1H)

[1781]

Example 408. (S)-quinuclidin-3-yl

(6-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate

[1783] ¹H-NMR (400MHz, CDCl₃) δ 7.53(s, 1H), 7.43~7.31(m, 4H), 7.1~7.09(m, 1H), 6.95(s, 1H), 5.18~5.14(m, 1H), 5.07~5.05(m, 1H), 4.77~4.75(m, 1H), 3.26~3.21(m, 1H), 2.89~2.65(m, 5H), 1.77~1.73(m, 2H), 1.69~1.68(m, 4H), 1.56~1.44(m, 4H), 1.40(m, 1H)

[1784]

Example 409. (S)-quinuclidin-3-yl**(2,2-dimethyl-6-(3-(trifluoromethyl)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate**

[1786] ¹H-NMR (400MHz, CDCl₃) δ 7.79(s, 1H), 7.73~7.71(d, 1H), 7.62~7.60(d, 1H), 7.57~7.53(t, 1H), 7.41~7.37(t, 1H), 7.15~7.12(t, 1H), 6.98(s, 1H), 5.23~5.19(t, 1H), 5.08~5.06(d, 1H), 4.77~4.75(m, 1H), 3.26~3.21(m, 1H), 2.89~2.65(m, 5H), 1.78~1.69(m, 2H), 1.57~1.53(m, 3H), 1.46~1.40(m, 4H), 1.40~1.27(m, 1H)

[1787]

Example 410. (S)-quinuclidin-3-yl**(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate**

[1789] ¹H-NMR (400MHz, CDCl₃) δ 7.47~7.43(m, 2H), 7.39~7.35(m, 2H), 7.22~7.20(d, 1H), 7.13~7.09(t, 1H), 6.96(s, 1H), 5.19~5.14(t, 1H), 5.08~5.06(d, 1H), 4.76~4.75(m, 1H), 3.27~3.21(m, 1H), 2.84~2.66(m, 5H), 1.77~1.68(m, 2H), 1.56~1.53(m, 4H), 1.46~1.40(m, 4H), 1.39~1.27(m, 1H)

[1790]

Example 411. (S)-quinuclidin-3-yl**(6-(3-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate**

[1792] ¹H-NMR (400MHz, CDCl₃) δ 7.35~7.27(m, 2H), 7.23~7.22(m, 2H), 7.19~7.17(m, 1H), 7.03(m, 1H), 6.97(s, 1H), 5.21~5.18(m, 3H), 5.05~5.00(m, 1H), 4.74~4.73(m, 1H), 3.49(s, 3H), 3.23~3.18(m, 1H), 2.80~2.66(m, 5H), 2.04(m, 1H), 1.76~1.67(m, 2H), 1.56~1.38(m, 8H)

[1793]

[1794] Experimental Example 1: Evaluation of inhibitory activities against GCS

[1795] The inhibitory activities of the compounds of the present invention against GCS were evaluated, as follows, according to the method described in the known literature (Hayashi Y et al., A sensitive and reproducible assay to measure the activity of glucosylceramide synthase and lactosylceramide synthase using HPLC and fluorescent substrates, *Analytical Biochemistry* 345 (2005) 181-186). Ibiglustat, known as a GCS inhibitor, was used as a control.

[1796] (1) Materials

- [1797] A549 cells (ATCC, CCL-185)
- [1798] NBD C6-ceramide (Thermo Fisher, N1154)
- [1799] UDP-glucose (Sigma, U4625)
- [1800] Potassium chloride (Sigma, P9333)
- [1801] UltraPure™ 0.5 M EDTA (Invitrogen, 15575-038)
- [1802] BCA protein assay kit (Thermo Fisher, 23227)
- [1803] Ibiglustat (Shanghai Systeam Biochem Co., ltd, Genz-682452)
- [1804] HEPES (sigma, H3375)
- [1805] Protease/phosphatase inhibitor cocktail (CST, 5872s)
- [1806] DMEM (GIBCO, 11995-065)
- [1807] FBS (GIBCO, 16000-044)
- [1808] Antibiotic-Antimycotic (100X) (GIBCO, 15240-112)
- [1809] 200 mM L-glutamine (GIBCO, 25030081)
- [1810] PBS (GIBCO, 10010-023)
- [1811] 0.25% Trypsin-EDTA (GIBCO, 25200-056)
- [1812] Dimethyl sulfoxide (Sigma, 34869)
- [1813] 2-propanol, HPLC grade (Burdick & Jackson, AH323-4)
- [1814] Hexane, HPLC grade (Burdick & Jackson, AH216-4)
- [1815] Chloroform (Sigma, C2432)
- [1816] Methanol (Merck, 1.06009.1011)
- [1817] (2) Protocol
- [1818] <1> Preparation of cell lysates
- [1819] A549 cells (ATCC, CCL-185) were cultured in a DMEM medium supplemented with 10% fetal bovine serum (FBS), 1x antibiotic-antimycotic, and 1x L-glutamine, in an incubator at 37°C and 5% CO₂. After the cells attached to the culture dish were washed with phosphate buffered saline (PBS), the cells were scraped off with a cell scraper and then centrifuged (4000 rpm, 3 min, 4°C) to collect the cells in a 50 ml tube. The cell pellets were suspended in a lysis buffer (50 mM HEPES, pH 7.3, containing 1x the protease/phosphatase inhibitor cocktail), lysed by sonication, and then the lysate was centrifuged (13000 rpm, 10 min, 4°C). The obtained supernatant was used for the quantitative analysis of proteins. The amount of proteins was measured using the BCA protein assay kit, using bovine serum albumin as a standard.
- [1820] <2> GCS enzyme reaction
- [1821] Enzymatic reactions were initiated by sequentially adding the following reaction materials to a 96 deep-well plate. Thereafter, the enzymatic reactions were performed at 37°C for 90 minutes.

[1822]

Enzyme reaction mix (Total 50ul)

1	Stock Con.	Final Con.	Volume (ul)
Cpd. Mix	Cpd. 500~0.003uM (DMSO)	10000~0.056nM	1
	Total		1

2	Stock Con.	Final Con.	Volume (ul)
Sub Mix	20mM UDP-Glc	500uM	1.25
	25mM EDTA	1mM	2
	500uM NBD-Cer/BSA	5uM	0.5
	D.W		35.25
	Total		39

3	Stock Con.	Final Con.	Volume (ul)
Enzyme Mix	3.135ug/ul A549 cell lysate	0.627ug/ul(31.35ug)	10
	Total		10

[1823] <3> Lipid extraction

[1824] The enzymatic reactions were stopped by adding 100 μ l of chloroform/methanol (2:1, v/v). After vortexing for 15 seconds, each mixture was centrifuged (4000 rpm, 10 min, 18°C). The lower layer (50 μ l) was transferred to a new 96 deep-well plate and dried with a reduced concentrator.

[1825] <4> HPLC analysis

[1826] Lipids were dissolved in 100 μ l of isopropyl alcohol/n-hexane/H₂O (55:44:1, v/v/v) and then transferred to a glass vial for HPLC (Agilent, 8004-HP-H/i3u). The sample (100 μ l) was automatically loaded onto a normal-phase column (Intersil SIL 150A-5, 4.6x250mm, GL Sciences, Japan) and then eluted at a flow rate of 2.0 ml/min with isopropyl alcohol/n-hexane/H₂O (55:44:1, v/v/v). The fluorescence thereof was measured with a fluorescence detector (Agilent, 1260 FLD Spectra), using 470 nm and 530 nm as excitation and emission wavelengths, respectively.

[1827] <5> Data analysis

[1828] Data analysis was performed by the following equations.

[1829] % Area (Sample) = Area (GlcCer) / [Area (Cer) + Area (GlcCer)] X 100

[1830] % GCS activity = [Area (Sample) - Area (ibiglustat)] / [Area (DMSO) - Area (ibiglustat)] X 100

[1831] The obtained % GCS activity data was analyzed with the software GraphPad Prism (Ver 5.01) to calculate the IC₅₀ values. The results are shown in Tables 1 to 4 below.

[1832] Table 1

[1833]

Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)
1	9.8	41	16.9	81	2.8
2	17.2	42	23.6	82	2.5
3	21.7	43	33.4	83	7.5
4	11.0	44	18.6	84	7.3
5	3.8	45	33.3	85	3.1
6	1.7	46	8.9	86	3.6
7	1.1	47	37.5	87	9.4
8	1.2	48	58.2	88	2.9
9	2.4	49	9.3	89	8.5
10	2.9	50	9.7	90	11.0
11	22.2	51	7.1	91	2.3
12	14.8	52	14.9	92	16.1
13	9.5	53	8.1	93	1.4
14	8.9	54	20.65	94	9.5
15	11.8	55	32.42	95	11.2
16	12.7	56	32.1	96	6.9
17	3.7	57	2.5	97	3.0
18	5.3	58	2.8	98	2.8
19	12.7	59	5.44	99	6.0
20	16.0	60	16.9	100	2.1
21	12.3	61	12.7	101	1.9
22	15.1	62	13.13	102	4.6
23	10.2	63	7.55	103	1.7
24	1.6	64	3.9	104	1.9
25	65.7	65	5.5	105	1.8
26	48.1	66	30.9	106	1.2
27	55.3	67	12.3	107	1.1
28	79.2	68	15.2	108	2.3
29	38.0	69	108.8	109	3.6
30	34.0	70	20.1	110	6.0
31	41.5	71	13.0	111	3.5
32	71.2	72	10.7	112	2.5
33	25.8	73	22.5	113	6.4
34	13.7	74	24.1	114	3.8
35	20.29	75	14.9	115	3.6
36	14.28	76	5.9	116	1.8
37	33.9	77	2.9	117	3.5
38	33.9	78	2.1	118	14.2
39	26.9	79	2.6	119	10.9
40	40.4	80	3.0	120	4.2

[1834] Table 2

[1835]

Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)
121	0.7	161	1.6	201	3.9
122	6.8	162	7.0	202	6.1
123	0.9	163	0.6	203	1.2
124	3.1	164	0.6	204	8.3
125	17.0	165	13.7	205	1.0
126	14.0	166	1.6	206	0.6
127	5.9	167	0.5	207	6.2
128	2.8	168	2.7	208	3.7
129	5.1	169	1.9	209	3.0
130	1.3	170	6.1	210	0.6
131	2.1	171	2.5	211	1.2
132	3.7	172	1.8	212	1.2
133	4.3	173	7.2	213	2.0
134	6.8	174	4.5	214	1.7
135	1.4	175	2.3	215	1.4
136	0.7	176	1.7	216	0.7
137	2.9	177	3.2	217	2.4
138	1.3	178	3.2	218	0.6
139	10.0	179	4.3	219	2.9
140	1.0	180	1.4	220	1.2
141	3.0	181	0.3	221	1.5
142	1.5	182	2.1	222	2.9
143	4.5	183	2.8	223	0.9
144	1.0	184	6.5	224	2.9
145	4.6	185	0.5	225	2.9
146	3.3	186	9.5	226	6.3
147	1.9	187	4.5	227	2.2
148	1.4	188	8.4	228	3.8
149	1.6	189	2.2	229	4.4
150	0.7	190	2.1	230	1.2
151	2.2	191	9.3	231	0.5
152	1.7	192	3.7	232	0.8
153	2.8	193	2.0	233	1.2
154	1.7	194	10.1	234	0.6
155	1.1	195	6.4	235	0.9
156	2.6	196	0.9	236	3.4
157	0.6	197	1.7	237	5.2
158	3.4	198	1.2	238	2.4
159	4.3	199	0.7	239	7.6
160	2.0	200	0.6	240	3.5

[1836] Table 3

[1837]

Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)
241	1.3	281	0.6	321	4.3
242	5.9	282	0.7	322	4.4
243	1.4	283	1.3	323	5.4
244	1.8	284	0.8	324	0.8
245	3.0	285	0.5	325	0.8
246	3.9	286	0.4	326	0.7
247	11.9	287	0.7	327	1.8
248	3.0	288	1.2	328	0.4
249	9.0	289	0.8	329	4.9
250	4.8	290	1.4	330	5.1
251	1.1	291	1.7	331	3.7
252	7.4	292	1.6	332	5.1
253	3.4	293	2.0	333	1.7
254	7.0	294	4.0	334	0.1
255	6.2	295	2.7	335	4.3
256	1.9	296	1.2	336	4.0
257	2.1	297	0.7	337	8.9
258	5.9	298	6.6	338	1.3
259	2.8	299	2.2	339	2.1
260	1.0	300	1.4	340	1.3
261	3.1	301	1.2	341	3.2
262	1.5	302	1.4	342	1.2
263	2.6	303	4.4	343	2.3
264	3.6	304	3.5	344	2.1
265	0.7	305	4.1	345	3.8
266	0.7	306	0.8	346	2.4
267	2.8	307	1.5	347	2.6
268	0.7	308	0.3	348	6.7
269	5.2	309	0.6	349	0.8
270	1.1	310	0.7	350	0.4
271	5.1	311	2.4	351	0.5
272	9.9	312	2.2	352	0.7
273	5.2	313	1.3	353	1.2
274	2.7	314	0.9	354	0.3
275	5.1	315	0.9	355	1.1
276	1.3	316	1.9	356	0.5
277	0.8	317	2.0	357	0.3
278	0.6	318	2.3	358	0.3
279	0.8	319	1.0	359	2.4
280	0.4	320	0.9	360	0.7

[1838] Table 4

[1839]

Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)
361	0.1	381	1.6	401	73
362	0.2	382	0.5	402	74.5
363	0.1	383	1.9	403	155.2
364	0.1	384	1.3	404	5.3
365	0.3	385	6.9	405	7.1
366	5.3	386	0.2	406	31.1
367	4.3	387	1.8	407	4.8
368	6.2	388	11.5	408	3.0
369	2.8	389	19.0	409	3.3
370	1.8	390	18.6	410	3.0
371	2.6	391	21.4	411	10.9
372	3.9	392	10.2		
373	3.9	393	4.8		
374	7.7	394	5.6		
375	0.9	395	2.4		
376	2.6	396	2.7		
377	1.4	397	0.8		
378	1.7	398	0.9		
379	0.6	399	103.7		
380	1.7	400	65.6		

[1840] From the results of Tables 1 to 4, it can be seen that the compounds of the present invention exhibit excellent inhibitory activity against GCS.

[1841]

[1842] Experimental Example 2: Evaluation of inhibitory activities against GM1 production

[1843] GM1, which is the final product of sphingolipid metabolism, is expressed on the cell membrane and thus the detection thereof is easy. In addition, the amount of GM1 represents the conversion of ceramide to glucosylceramide. Therefore, the inhibitory activities of the compounds of the present invention against GM1 production were evaluated, as follows, according to the method described in the known literature (Dijkhuis et al., Gangliosides do not affect ABC transporter function in human neuroblastoma cells. *The Journal of Lipid Research* 47 (2006). 1187-1195). Ibiglustat, known as a GCS inhibitor, was used as a control.

[1844] (1) Materials

[1845] Jurkat cells, Clone E6-1 (ATCC, TIB-152)

[1846] Cholera toxin subunit B (CTB), FITC (Sigma, C1655)

[1847] Ibiglustat (Shanghai Systeam Biochem Co., Ltd, Genz-682452)

[1848] DMSO (Sigma, D2650)

[1849] Fixation buffer (BD, 554655)

[1850] RPMI 1640 (Gibco, A1049101)

[1851] FBS (Gibco, 16000-044)

[1852] Antibiotic-Antimycotic (100X) (Gibco, 15240-122)

- [1853] FACS Sheath Fluid (BD, 342003)
- [1854] Jurkat cells were cultured in RPMI 1640 medium supplemented with 10% FBS and 1X Antibiotic-Antimycotic. A washing solution was prepared by adding 10 ml of FBS to 490 ml of FACS Sheath Fluid. The CTB-FITC solution was prepared by diluting the CTB-FITC stock solution (10 mg/ml) with the washing solution to a final concentration of 2 µg/ml.
- [1855] (2) Protocol
- [1856] A cell suspension (1×10^5 cells/ml) was prepared with the culture medium (RPMI 1640 medium supplemented with 10% FBS and 1X Antibiotic-Antimycotic). The cell suspension (200 µl) was added to each well of a 96-well plate (20,000 cells/well) and then the compounds were treated thereto in a final concentration of 0.05 to 3000 nM (3 fold, 11 points) per well. Each mixture was incubated in a CO₂ incubator at 37°C for 72 hours. After centrifuging at 1500 rpm for 3 minutes to remove the medium, the cells were resuspended in 200 µl of the washing solution per well. After centrifuging at 1500 rpm for 3 minutes to remove the washing solution, the cells were resuspended in 200 µl of the 2 µg/ml CTB-FITC solution. The obtained suspension was incubated at 4°C for 60 minutes, while not being exposed to light. After centrifuging at 1500 rpm for 3 minutes to remove the CTB-FITC solution, the cells were washed with 200 µl of the washing solution. The washing process was additionally repeated twice. The washed plate was centrifuged at 1500 rpm for 3 minutes to remove the washing solution and then the cells were completely resuspended in 200 µl of the fixation buffer. IC₅₀ was determined from the values obtained by quantifying FITC fluorescences with Guava™ easyCyte 5HT (Merck Milipore, 0500-4005).
- [1857] Data analysis was performed by the following equations.
- [1858] % MFI (median fluorescence intensity) = (fluorescence value of drug-treated group / fluorescence value of DMSO-treated group) X 100
- [1859] % Cells = (cell concentration in the well / cell concentration in the DMSO-treated group) X 100
- [1860] % MFI and % cell data were analyzed with the software GraphPad Prism (Ver 5.01) to calculate IC₅₀ values. The results are shown in Tables 5 to 8 below.
- [1861] Table 5

[1862]

Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)
1	139.2	48	65.7	88	11.1
2	201.8	49	61.4	89	50.0
3	142.5	50	52.3	90	37.9
4	95.8	51	30.2	91	25.1
5	70.2	52	82.3	92	43.9
6	39.4	53	80.0	93	10.5
7	36.8	54	161	94	23.6
8	27.4	55	172.8	95	49.7
9	93.1	56	209.9	96	16.2
10	65.5	57	49.9	97	9.3
11	123.0	58	87.8	98	7.5
12	73.0	59	164.5	99	22.2
13	41.7	60	111.7	100	21.5
14	54.3	61	39.6	101	8.7
15	34.4	62	103	102	17.4
16	56.1	63	116.7	103	19.5
17	27.6	64	74.7	104	16.9
18	31.6	65	56.2	105	15.2
19	20.3	66	127.7	106	5.8
20	125.9	67	144.0	107	6.3
21	126.6	68	91.8	108	7.6
22	89.6	69	399.8	109	7.8
23	63.7	70	70.9	110	15.1
24	17.4	71	64.3	111	32.0
25	105.9	72	58.2	112	35.6
26	67.2	73	26.0	113	54.8
27	35.7	74	13.0	114	33.7
28	52.0	75	8.3	115	38.3
29	63.0	76	3.7	116	16.7
30	106.8	77	6.3	117	41.8
31	65.5	78	3.5	118	38.4
32	120.2	79	3.9	119	38.3
37	55.2	80	4.1	120	28.4
38	62.0	81	12.2	121	4.7
39	51.9	82	3.2	122	50.8
43	182.8	83	3.7	123	9.3
44	35.2	84	4.9	124	22.3
45	57.3	85	11.6	125	9.5
46	19.2	86	13.8	126	50.5
47	26.6	87	42.8	127	18.2

[1863] Table 6

[1864]

Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)
128	18.4	168	9.6	208	67.4
129	36.8	169	9.8	209	32.1
130	10.0	170	13.0	210	7.5
131	10.6	171	17.0	211	13.2
132	29.2	172	48.5	212	19.1
133	22.6	173	34.8	213	39.8
134	43.2	174	40.2	214	64.2
135	8.1	175	42.8	215	14.9
136	1.7	176	27.6	216	28.7
137	12.1	177	22.9	217	72.1
138	9.1	178	26.9	218	6.7
139	74.4	179	41.0	219	30.4
140	10.5	180	28.1	220	17.6
141	39.9	181	5.5	221	16.9
142	20.5	182	20.9	222	25.6
143	25.2	183	18.6	223	5.2
144	6.2	184	40.0	224	18.8
145	23.0	185	11.1	225	21.3
146	14.1	186	82.6	226	57.0
147	14.0	187	31.7	227	10.2
148	30.0	188	46.2	228	48.6
149	27.6	189	23.0	229	56.2
150	6.8	190	13.3	230	30.8
151	37.9	191	123.4	231	24.3
152	32.5	192	25.8	232	12.5
153	41.4	193	15.3	233	23.3
154	27.4	194	47.6	234	13.6
155	8.4	195	36.1	235	6.5
156	46.7	196	23.2	236	32.4
157	2.8	197	8.7	237	29.2
158	17.1	198	11.7	238	13.2
159	12.7	199	5.5	239	48.9
160	22.7	200	3.7	240	51.3
161	10.8	201	38.2	241	51.3
162	38.8	202	26.3	242	64.4
163	12.2	203	8.2	243	21.4
164	6.5	204	57.2	244	38.0
165	15.6	205	7.6	245	23.0
166	26.3	206	14.0	246	14.7
167	3.8	207	58.6	247	41.0

[1865] Table 7

[1866]

Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)
248	14.9	288	11.2	328	11.4
249	37.0	289	7.4	329	65.8
250	33.0	290	12.3	330	52.7
251	7.2	291	13.5	331	22.6
252	43.9	292	7.8	332	158.4
253	37.2	293	8.7	333	45
254	45.2	294	10.4	334	20.9
255	35.8	295	35.0	335	50.4
256	24.6	296	15.6	336	48
257	27.4	297	3.0	337	65
258	17.4	298	63.2	338	53.7
259	10.2	299	25.3	339	62.5
260	14.4	300	23.0	340	43.8
261	51.5	301	9.6	341	61.9
262	34.4	302	4.0	342	21.6
263	34.9	303	27.2	343	45.7
264	14.4	304	23.5	344	51
265	6.7	305	9.8	345	45.7
266	4.7	306	27.5	346	38.3
267	83.1	307	30.2	347	46.8
268	2.5	308	5.5	348	44.1
269	6.5	309	11.2	349	10.3
270	2.3	310	16.3	350	4.5
271	30.6	311	27.0	351	7.4
272	49.3	312	13.1	352	5.7
273	13.4	313	7.3	353	12.7
274	10.3	314	7.7	354	5.9
275	25.0	315	11.3	355	62.8
276	33.2	316	13.3	356	21.6
277	2.7	317	10.3	357	5.3
278	6.0	318	20.0	358	7.7
279	7.3	319	7.7	359	33.1
280	1.6	320	8.5	360	39.0
281	5.0	321	31.9	361	2.1
282	5.6	322	24.4	362	2.5
283	17.2	323	78.9	363	8.7
284	8.5	324	5.8	364	17.2
285	3.7	325	2.1	365	2.4
286	4.1	326	10.8	366	79.4
287	4.1	327	16.8	367	68.2

[1867] Table 8

[1868]


Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)
368	22.9	388	93.1	408	15.8
369	171.7	389	76.5	409	14.9
370	39.3	390	44.1	410	13.0
371	24.8	391	55.3	411	79.3
372	46.2	392	41.9		
373	31.2	393	54.9		
374	26.5	394	48.8		
375	23	395	30.9		
376	85.9	396	39.6		
377	35.5	397	17.4		
378	87.5	398	36.6		
379	15.8	399	43.59		
380	36.5	400	107.5		
381	59.9	401	15.13		
382	31.3	402	19.5		
383	123.1	403	85.31		
384	83.2	404	25.9		
385	331.6	405	44.7		
386	29.5	406	119.7		
387	48.2	407	44.4		

[1869] From the results of Tables 5 to 8, it can be seen that the compounds of the present invention exhibit excellent inhibitory activity against GM1 production.

Claims

[Claim 1]

A compound of Formula 1 or pharmaceutically acceptable salt thereof:
<Formula 1>



wherein,

L is -O-, -CO-, -CR₁R₂-, or -NR₃-,

Y and Z are, independently each other, -CR₁R₂-; -NR₃-; -O-; or -S-,

R₁ and R₂ are, independently each other, hydrogen; halogen; C₁~C₆ alkyl; C₁~C₆ alkyl having a nitrogen, oxygen, or sulfur atom; C₃~C₁₀ cycloalkyl; 3- to 12-membered heterocyclic; or C₁~C₆ alkoxy; or R₁ and R₂ form C₃~C₁₀ cycloalkyl together with the carbon atom to which they are attached,

R₃ is hydrogen; C₁~C₆ alkyl; C₁~C₆ alkyl having a nitrogen, oxygen, or sulfur atom; C₃~C₁₀ cycloalkyl; 3- to 12-membered heterocyclic; or C₁~C₆ alkoxy,

X is hydrogen; halogen; C₁~C₆ alkyl; C₁~C₆ alkyl substituted with 1 to 3 halogens; C₁~C₆ alkyl having a nitrogen, oxygen, or sulfur atom; C₁~C₆ alkoxy; or C₁~C₆ alkoxy substituted with 1 to 3 halogens,

W is a bond, -CH₂-, -O-, -NH-, -CH₂CH₂-, -CH=CH-, or -C≡C-,

A ring is 6- to 12-membered aryl; 5- to 12-membered heteroaryl; C₃~C₁₀ cycloalkyl; or 3- to 12-membered heterocyclic, and

X₁, X₂, X₃, and X₄ are, independently each other, hydrogen; cyano; halogen; C₁~C₆ alkyl; C₁~C₆ alkoxy-C₁~C₆ alkyl; C₁~C₆ alkyl substituted with 1 to 3 halogens; C₃~C₁₀ cycloalkyl; 3- to 12-membered heterocyclic; C₁~C₆ alkoxy; C₁~C₆ alkoxy substituted with 1 to 3 halogens; C₁~C₆ alkoxy-C₁~C₆ alkoxy; morpholinyl-C₁~C₆ alkoxy; mono- or di-C₁~C₆ alkylamino-C₁~C₆ alkoxy; C₃~C₁₀ cycloalkyl-C₁~C₆ alkoxy; C₁~C₆ alkylthio; amino; mono- or di-C₁~C₆ alkylamino; C₁~C₆ alkylcarbonyl; hydroxy; or nitro.

[Claim 2]

The compound or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein L is -O-.

[Claim 3]

The compound or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein Y and Z are, independently each other, -O- or -CR₁

R₂-.

- [Claim 4] The compound or pharmaceutically acceptable salt thereof as claimed in claim 3, wherein R₁ and R₂ are, independently each other, hydrogen or C₁~C₆ alkyl; or R₁ and R₂ form C₃~C₁₀ cycloalkyl together with the carbon atom to which they are attached.
- [Claim 5] The compound or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein Y is -O-; and Z is -CR₁R₂-.
- [Claim 6] The compound or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein X is hydrogen, halogen, or C₁~C₆ alkoxy.
- [Claim 7] The compound or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein W is a bond or -CH=CH-.
- [Claim 8] The compound or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein the A ring is 6- to 12-membered aryl.
- [Claim 9] The compound or pharmaceutically acceptable salt thereof as claimed in claim 8, wherein the A ring is phenyl, naphthalenyl, or biphenyl.
- [Claim 10] The compound or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein the A ring is 5- to 12-membered heteroaryl.
- [Claim 11] The compound or pharmaceutically acceptable salt thereof as claimed in claim 10, wherein the A ring is benzodioxolyl, pyridinyl, thiophenyl, quinolinyl, isoquinolinyl, benzofuranyl, benzo[b]thiophenyl, quinoxalinyl, or furanyl.
- [Claim 12] The compound or pharmaceutically acceptable salt thereof of claim 1, wherein the A ring is 3- to 12-membered heterocyclic.
- [Claim 13] The compound or pharmaceutically acceptable salt thereof as claimed in claim 12, wherein the A ring is 2,3-dihydrobenzodioxinyl, 2,3-dihydrobenzofuranyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, chromanyl, or 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl.
- [Claim 14] The compound or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein X₁, X₂, X₃, and X₄ are, independently each other, hydrogen; cyano; halogen; C₁~C₆ alkyl; C₁~C₆ alkoxy-C₁~C₆ alkyl; C₁~C₆ alkyl substituted with 1 to 3 halogens; C₃~C₁₀ cycloalkyl; morpholinyl; C₁~C₆ alkoxy; C₁~C₆ alkoxy substituted with 1 to 3 halogens; C₁~C₆ alkoxy-C₁~C₆ alkoxy; morpholinyl-C₁~C₆ alkoxy; mono- or di-C₁~C₆ alkylamino-C₁~C₆ alkoxy; C₃~C₁₀ cycloalkyl-C₁~C₆ alkoxy; C₁~C₆ alkylthio; mono- or di-C₁~C₆ alkylamino; or C₁~C₆ alkylcarbonyl.
- [Claim 15] The compound or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein
L is -O-,

Y and Z are, independently each other, -O- or -CR₁R₂-,

R₁ and R₂ are, independently each other, hydrogen or C₁~C₆ alkyl; or R₁ and R₂ form C₃~C₁₀ cycloalkyl together with the carbon atom to which they are attached,

X is hydrogen, halogen, or C₁~C₆ alkoxy,

W is a bond or -CH=CH-,

A ring is 6- to 12-membered aryl, 5- to 12-membered heteroaryl, or 3- to 12-membered heterocyclic, and

X₁, X₂, X₃, and X₄ are, independently each other, hydrogen; cyano; halogen; C₁~C₆ alkyl; C₁~C₆ alkoxy-C₁~C₆ alkyl; C₁~C₆ alkyl substituted with 1 to 3 halogens; C₃~C₁₀ cycloalkyl; morpholinyl; C₁~C₆ alkoxy; C₁~C₆ alkoxy substituted with 1 to 3 halogens; C₁~C₆ alkoxy-C₁~C₆ alkoxy; morpholinyl-C₁~C₆ alkoxy; mono- or di-C₁~C₆ alkylamino-C₁~C₆ alkoxy; C₃~C₁₀ cycloalkyl-C₁~C₆ alkoxy; C₁~C₆ alkylthio; mono- or di-C₁~C₆ alkylamino; or C₁~C₆ alkylcarbonyl.

[Claim 16] The compound or pharmaceutically acceptable salt thereof as claimed in claim 15, wherein Y is -O-; and Z is -CR₁R₂-.

[Claim 17] The compound or pharmaceutically acceptable salt thereof as claimed in claim 15, wherein the A ring is phenyl, naphthalenyl, or biphenyl.

[Claim 18] The compound or pharmaceutically acceptable salt thereof as claimed in claim 15, wherein the A ring is benzodioxolyl, pyridinyl, thiophenyl, quinolinyl, isoquinolinyl, benzofuranyl, benzo[b]thiophenyl, quinoxalinyl, or furanyl.

[Claim 19] The compound or pharmaceutically acceptable salt thereof as claimed in claim 15, wherein the A ring is 2,3-dihydrobenzodioxinyl, 2,3-dihydrobenzofuranyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, chromanyl, or 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl.

[Claim 20] The compound or pharmaceutically acceptable salt thereof as claimed in claim 1, which is selected from the group consisting of:
 (S)-quinuclidin-3-yl
 (5-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl

(5-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl (5-(*p*-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-(difluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,3-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(6-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(4-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(3-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(2-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(2-chlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(4-(difluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl (6-(*p*-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(3,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(3,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(2,5-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(2,3-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(2,4-difluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl

(6-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(2,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(3,4-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(3,5-dichlorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(4-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-6-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(6-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-6-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(6-(2-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-(2-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate

e;

(S)-quinuclidin-3-yl

(2,2-dimethyl-6-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl (2,2-dimethyl-6-(*p*-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(6-(4-(difluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(6-(3,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(6-(2,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(6-(2,3-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(6-(2,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(6-(3,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(2,2-dimethyl-6-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(2,2-dimethyl-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(6-(3,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(6-(3,4-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(6-(2,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

mate;

(S)-quinuclidin-3-yl

(6-(4-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(4-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(2,2-dimethyl-5-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(2,2-dimethyl-5-(4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(2,2-dimethyl-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(2,2-dimethyl-5-(2-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(2,2-dimethyl-5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl (2,2-dimethyl-5-(*p*-tolyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(4-(difluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(3,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2,4-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(3,5-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2,3-difluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(3,4-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(3,5-dichlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(2,2-dimethyl-5-(2,3,4-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(2,2-dimethyl-5-(2,4,5-trifluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(4-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2-(methoxymethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-(dimethylamino)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (2,2-dimethyl-5-(3-(methylthio)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl (5-(3-(*tert* -

butyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,3-dihydrobenzofuran-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-5-(3-(2-morpholinoethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-(2-fluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-5-(4-(2,2,2-trifluoroethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-5-(4-(2-morpholinoethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-5-(2-(trifluoromethyl)pyridin-4-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,5-dichloropyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-5-(4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2-chloro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-chloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl

(5-(2-chloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2-chloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-chloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,3-dichloro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-chloro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2-fluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-(dimethylamino)-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(chroman-6-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-cyclopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-(dimethylamino)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-ethoxy-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-methoxy-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl

(5-(4-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (2,2-dimethyl-5-(thiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (2,2-dimethyl-5-(4-methylthiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-(2-(dimethylamino)ethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(isoquinolin-8-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(isoquinolin-5-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(isoquinolin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (2,2-dimethyl-5-(quinolin-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl (5-(4-(*tert*-butyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (2,2-dimethyl-5-(4-morpholinophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-(methoxymethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl

(5-(4-(2,2-difluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-5-(3-methyl-4-morpholinophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-fluoro-4-morpholinophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-chloro-4-morpholinophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-(difluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-5-(quinolin-8-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(benzofuran-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(benzofuran-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,4-dichloro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl

(2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-butylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,3-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,4-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,5-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,6-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3,5-dimethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-ethoxy-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,5-difluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2-fluoro-5-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3,5-dimethyl-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-ethoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2-ethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

ate;

(S)-quinuclidin-3-yl

(5-(2-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-chloro-5-(trifluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(4-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(4-methoxy-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl (5-(4-(*tert*-butoxymethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-chloro-3-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-chloro-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2,6-dimethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(benzo[b]thiophen-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl (5-(2-(*tert*-

butoxy)pyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(6-methoxy-5-(trifluoromethyl)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(6-methoxynaphthalen-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-([1,1'-biphenyl]-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (2,2-dimethyl-5-(quinoxalin-6-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(furan-2-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-isopropoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(6-isopropoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-(2-fluoroethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2-ethoxy-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2-methoxy-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2-butoxy-5-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl

(5-(4-butoxy-3-chlorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;
(S)-quinuclidin-3-yl
(5-(2,4-dipropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;
(S)-quinuclidin-3-yl
(5-(3-chloro-4-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;
(S)-quinuclidin-3-yl
(5-(3-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;
(S)-quinuclidin-3-yl
(5-(4-ethoxy-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;
(S)-quinuclidin-3-yl
(5-(3-chloro-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;
(S)-quinuclidin-3-yl
(5-(5-fluoro-2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;
(S)-quinuclidin-3-yl
(5-(3-fluoro-4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;
(S)-quinuclidin-3-yl
(5-(5-chloro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;
(S)-quinuclidin-3-yl
(5-(2-fluoro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;
(S)-quinuclidin-3-yl
(5-(5-chloro-2-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;
(S)-quinuclidin-3-yl
(5-(5-fluoro-2-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;
(S)-quinuclidin-3-yl
(5-(2-fluoro-6-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;

(S)-quinuclidin-3-yl
(5-(3-fluoro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(3-fluoro-4-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(5-chloro-2-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(3-butoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-fluoro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(5-fluoro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(2-chloro-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(3-fluoro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(2-chloro-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(3-methoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(2-chloro-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(4-fluoro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(3,4-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

mate;

(S)-quinuclidin-3-yl

(5-(4-fluoro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;

(S)-quinuclidin-3-yl

(5-(2-fluoro-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-fluoro-5-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-fluoro-3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(5-isopropyl-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-fluoro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;

(S)-quinuclidin-3-yl

(5-(5-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(2,2-dimethyl-5-(5-methylfuran-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(3-fluoro-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-chloro-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl) carbamate;

(S)-quinuclidin-3-yl

(5-(benzo[b]thiophen-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(4-fluoro-2-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl (5-(3-(*tert* -

butyl)-5-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-chloro-5-ethoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(4-chloro-3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-fluoro-3-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(5-cyano-2-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(3-ethoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(3-fluoro-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(2,2-dimethyl-5-(3-methyl-4-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(2,2-dimethyl-5-(3-(methylthio)-5-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(3-fluoro-4-(trifluoromethoxy)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-ethoxy-4-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-methoxy-5-(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2,4-bis(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(5-(3-chloro-2-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(3-methoxy-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(4-fluoro-3-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(2-ethoxy-5-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(3-fluoro-5-propoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(3,5-bis(trifluoromethyl)phenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(3-chloro-4-methylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(2,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-chloro-4-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)
carbamate;
(S)-quinuclidin-3-yl
(5-(6-ethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2-ethoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2-isopropoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-5-(6-propoxypyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)ca

rbamate;
 (S)-quinuclidin-3-yl
 (5-(6-butoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(6-(2-methoxyethoxy)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(6-isobutoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-butoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2,4-dimethoxypyridin-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2-acetylthiophen-3-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-((E)-3-fluorostyryl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-((E)-4-ethylstyryl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-((E)-2-cyclohexylvinyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (2,2-diethyl-5-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (2,2-diethyl-5-(4-ethylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (2,2-diethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl (5-(4-(*tert* -

butyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-butylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-cyclopropylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-diethyl-5-(4-isopropylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-diethyl-5-(4-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-ethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-diethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-diethyl-5-(4-isopropoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-diethyl-5-(4-isobutylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-diethyl-5-(3-fluorophenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-diethyl-5-(3-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-ethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-diethyl-5-(3-isopropoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-diethyl-5-(3-ethylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-diethyl-5-(3-isopropylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl (5-(3-(*tert*-butyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2,3-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2,4-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2,5-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3,4-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3,5-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2,6-dimethoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-(difluoromethyl)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-(dimethylamino)phenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-ethoxy-3,5-dimethylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3,5-dimethyl-4-propoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-butoxy-3,5-dimethylphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (2,2-diethyl-5-(thiophen-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl

(2,2-diethyl-5-(furan-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(6-(cyclopropylmethoxy)pyridin-3-yl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (2,2-diethyl-5-(2-fluoro-4-methoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-chloro-4-isopropoxyphenyl)-2,2-diethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-ethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (6-methoxy-2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-isopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl (5-(4-(*tert*-butyl)phenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-cyclopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-ethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (6-methoxy-2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl

(5-(4-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(3,5-dimethyl-4-propoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(3-chloro-4-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(2-fluoro-4-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(4-butoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(4-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(5-chloro-2-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(4-butylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(6-methoxy-5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(4-ethoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(5-(4-butoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl

(6-methoxy-5-(2-methoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(5-(3-fluorophenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-ethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-isobutylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-isopropylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl (5-(3-(*tert*-butyl)phenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-methoxy-5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-ethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-methoxy-2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-isopropoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-butoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-isobutoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(2,5-dimethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3,5-dimethoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

en-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2-chloro-4-methoxyphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-ethoxy-3-fluorophenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-isopropoxy-3,5-dimethylphenyl)-6-methoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-ethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (6-fluoro-2,2-dimethyl-5-(4-propylphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (6-fluoro-5-(4-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (6-fluoro-5-(4-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl (5-(4-(*tert*-butyl)phenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-cyclopropylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (6-fluoro-5-(4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-ethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (6-fluoro-2,2-dimethyl-5-(4-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl

(6-fluoro-5-(4-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(3-chloro-4-isopropoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-fluoro-5-(2-fluoro-4-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-butoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-fluoro-5-(4-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(6-(cyclopropylmethoxy)pyridin-3-yl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(5-chloro-2-methoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-butylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-fluoro-5-(4-methoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-ethoxy-3,5-dimethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(5-(4-butoxy-3,5-dimethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-fluoro-5-(2-methoxypyridin-4-yl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
(S)-quinuclidin-3-yl
(6-fluoro-5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(5-(3-ethylphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(6-fluoro-5-(3-isobutylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(6-fluoro-5-(3-isopropylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl (5-(3-(*tert*-butyl)phenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(6-fluoro-5-(3-methoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(5-(3-ethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(6-fluoro-2,2-dimethyl-5-(3-propoxyphenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(6-fluoro-5-(3-isopropoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(5-(3-butoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(6-fluoro-5-(3-isobutoxyphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(5-(2,4-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(5-(2,5-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;

(S)-quinuclidin-3-yl
(5-(2,6-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden

-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3,5-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3,4-dimethoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2-chloro-4-methoxyphenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(4-ethoxy-3-fluorophenyl)-6-fluoro-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (6-fluoro-5-(4-isopropoxy-3,5-dimethylphenyl)-2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5'-(4-fluorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5'-(4-chlorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5'-(4-(trifluoromethyl)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5'-(4-(trifluoromethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5'-(3-chlorophenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5'-(3-(trifluoromethyl)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5'-(4-(2-methoxyethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
 (S)-quinuclidin-3-yl

(5'-(3-(2-methoxyethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5'-(4-(methoxymethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5'-(3-(methoxymethoxy)phenyl)-1',3'-dihydrospiro[cyclopropane-1,2'-inden]-1'-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(3-chlorophenyl)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (5-(2-chlorophenyl)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (3,3-dimethyl-5-(3-(trifluoromethyl)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (3,3-dimethyl-5-(3-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (3,3-dimethyl-5-(2-(trifluoromethoxy)phenyl)-2,3-dihydro-1H-inden-1-yl)carbamate;
 (S)-quinuclidin-3-yl
 (6-(3-(trifluoromethyl)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate;
 (S)-quinuclidin-3-yl
 (6-(3-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate;
 ;
 (S)-quinuclidin-3-yl
 (5-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate;
 (S)-quinuclidin-3-yl
 (6-(3-fluorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate;
 (S)-quinuclidin-3-yl
 (6-(3-chlorophenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate;
 (S)-quinuclidin-3-yl

(2,2-dimethyl-6-(3-(trifluoromethyl)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate;
(S)-quinuclidin-3-yl
(2,2-dimethyl-6-(3-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-3-yl)carbamate; and
(S)-quinuclidin-3-yl
(6-(3-(2-methoxyethoxy)phenyl)-2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)carbamate.

- [Claim 21] A pharmaceutical composition for inhibiting glucosylceramide synthase comprising the compound or pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 20 as an active ingredient.
- [Claim 22] A pharmaceutical composition as claimed in claim 21, for preventing or treating Gaucher disease, Fabry disease, Tay-Sachs disease, or Parkinson's disease.
- [Claim 23] A method for inhibiting glucosylceramide synthase in a mammal, which comprises administering a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 20 to the mammal in need thereof.